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1.1	  INTRACELLULAR	  PROTEOLYTIC	  SYSTEMS	  
In	   all	   cells,	   the	   production	   and	   degradation	   of	   proteins,	   commonly	   known	   as	   protein	  
turnover,	   is	   a	   constant	   and	   crucial	   process	   for	   survival,	   tissue	   renewal	   and	   repair.	   Protein	  
breakdown	  also	   represents	  a	  quality	   control	  mechanism,	  by	  eliminating	  damaged	  or	  abnormally	  
folded	   proteins	   (Chondrogianni	   et	   al.,	   2012b).	   Additionally,	   continual	   protein	   degradation	  
represents	   the	   main	   source	   of	   epitopes	   that	   are	   presented	   to	   T	   cells	   on	   class	   I	   and	   II	   major	  
histocompatibility	  complex	  (MHC	  I	  and	  MHC	  II).	  In	  mammalian	  cells,	  numerous	  proteolytic	  systems	  
take	   part	   in	   protein	   catabolism,	   the	  most	   important	   are	   lysosomes,	   caspases,	   calpains	   and	   the	  
ubiquitin-­‐proteasome	  system	  (UPS).	  
Lysosomes	   are	   membrane-­‐enclosed	   organelles	   that	   contain	   an	   array	   of	   degradative	  
enzymes,	  a	  large	  variety	  of	  hydrolases	  and	  protease	  (e.g.	  cathepsins)	  capable	  of	  breaking	  down	  all	  
types	   of	   biological	   polymers:	   proteins,	   nucleic	   acids,	   carbohydrates	   and	   lipids.	   Lysosomes	  
represent	  the	  digestive	  system	  of	  the	  cell,	  which	  degrade	  material	  taken	  up	  from	  outside	  the	  cell	  
by	  endocytosis	  and	  phagocytosis	  as	  well	  as	  obsolete	  components	  of	  cell	  itself	  by	  autophagy	  (Wong	  
et	  al.,	  2010;	  Ciechanover	  et	  al.,	  2013).	  As	  several	  pathways	  terminate	  in	  the	  lysosome,	  lysosomal	  
dysfunction	   has	   a	   profound	   impact	   on	   cell	   homeostasis,	   resulting	   in	   manifold	   pathological	  
conditions,	  including	  infectious	  diseases,	  neurodegeneration	  and	  aging	  (Boya,	  2012).	  
Caspases	  are	  a	  family	  of	  cysteine	  proteases	  that	  play	  essential	  roles	  in	  apoptosis,	  necrosis,	  
inflammation	  and	  tissues	  remodeling.	  Each	  caspase	  is	  a	  cysteine	  aspartase,	  synthesized	  as	  inactive	  
precursor	   termed	   procaspase.	   Based	   on	   kinetic	   data,	   substrate	   specificity	   and	   procaspase	  
structure,	  caspases	  have	  been	  conceptually	  divided	  into	  initiators	  and	  effectors.	  Initiator	  caspases	  
(e.g.,	   CASP2,	   CASP8,	   CASP9,	   and	   CASP10)	   activate	   effector	   caspases	   in	   response	   to	   specific	   cell	  
death	  signals;	  on	  the	  contrary	  effector	  caspases	  (e.g.,	  CASP3,	  CASP6,	  CASP7)	  cleave	  various	  cellular	  
proteins	  to	  trigger	  the	  apoptotic	  process.	  Dysregulation	  of	  caspases	  are	  hallmarks	  of	  many	  human	  
diseases,	   including	  cancer,	  autoimmunity,	  neurodegenerative	  disorders	  and	   increasing	  evidences	  




Calpains	   are	   calcium-­‐activated	   cystein	   proteases	   playing	   a	   role	   in	   various	   intracellular	  
signal	   transduction	   pathways	   mediated	   by	   Ca2+.	   The	   calpain	   system	   originally	   includes	   three	  
proteins:	   two	   Ca2+-­‐dependent	   proteases,	   mu-­‐calpain	   and	   m-­‐calpain	   and	   a	   third	   polypeptide	  
calpastatin,	  which	   is	   able	   to	   inhibit	   the	   two	   calpains.	   Calpains	   cleave	   target	   proteins	   at	   specific	  
sites,	   generating	   large	   polypeptides	   with	   different	   physiological	   properties.	   The	   calpains	  
participate	   in	   a	   variety	   of	   cellular	   processes,	   including	   remodeling	   of	   cytoskeletal/membrane	  
attachments,	   different	   signal	   transduction	   pathways	   and	   apoptosis.	   Deregulated	   calpain	   activity	  
following	   loss	   of	   Ca2+	   homeostasis	   results	   in	   tissue	   damage	   in	   response	   to	   events	   such	   as	  
myocardial	  infarcts,	  stroke,	  and	  brain	  trauma	  (Goll	  et	  al.,	  2003).	  
	  
1.2	  UPS	  
The	  UPS	   is	   the	  primary	  selective	  degradation	  system	  in	  the	  nucleus,	  cytoplasm	  as	  well	  as	  
endoplasmic	   reticulum	   (ER)	   of	   eukaryotic	   cells,	   required	   for	   the	   turnover	   of	   myriad	   soluble	  
proteins.	  The	  UPS	  plays	  two	  crucial	  roles:	  first	  of	  all	  in	  the	  maintenance	  of	  cellular	  homeostasis	  as	  
it	   is	  responsible	  for	  the	  clearance	  of	  abnormal,	  denatured	  or	  damaged	  proteins,	  and	  secondly	   in	  
the	   control	   of	   numerous	   processes,	   including	   cell-­‐cycle	   progression,	   signal	   transduction,	  
transcriptional	   regulation	   and	   endocytosis,	   by	   the	   regulated	   degradation	   of	   short-­‐lived	   proteins	  
(Hershko	  et	  al.,	  1998;	  Chondrogianni	  et	  al.,	  2010).	  	  
Proteins	   to	  be	  degraded	  via	  UPS	  are	   firstly	   tagged	  by	  the	  covalent	  attachment	  of	  protein	  
modifiers,	  where	   the	  most	   important	   is	   represented	   by	   ubiquitin,	   a	   highly	   conserved	   76	   amino	  
acid	   residues	   polypeptide.	   The	   conjugation	   process	   is	   a	   three-­‐step	   cascade	   mechanism	   which	  
involved	   several	   multiprotein	   complexes.	   Initially,	   the	   E1	   ubiquitin-­‐activating	   enzyme	   activates	  
ubiquitin	   in	   an	   ATP-­‐dependent	   manner,	   then	   one	   of	   several	   E2	   enzymes	   (known	   as	   ubiquitin-­‐
carrier	  proteins	  or	  ubiquitin-­‐conjugating	  enzymes)	  transfers	  the	  activated	  ubiquitin	  from	  E1	  to	  the	  
substrate	   that	   is	   specifically	   bound	   to	   a	  member	   of	   the	   E3	   ubiquitin-­‐protein	   ligases,	   which	   can	  
catalyze	  the	  transfer	  of	  the	  ubiquitin	  with	  a	  direct	  (RING	  domain	  family)	  or	  indirect	  (HECT	  domain	  
family)	  reaction.	  Thus,	  the	  carboxyl-­‐terminal	  portion	  of	  the	  ubiquitin	  is	  linked	  to	  an	  ε-­‐NH2	  group	  of	  
an	  internal	  lysine	  (Lys)	  residue	  in	  the	  target	  substrate.	  These	  repeated	  steps	  leading	  to	  produce	  a	  
poly-­‐ubiquitin	   (polyUb)	   chain	   that	   serves	   as	   a	   recognition	   marker	   to	   the	   downstream	   26S	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proteasome	  complex,	  the	  catalytic	  unit	  of	  the	  UPS.	  Proteasomal	  degradation	  has	  been	  shown	  to	  
be	  mediated	  mainly	  by	  poly-­‐ubiquitination	  on	  Lys48	  of	  ubiquitin,	  but	  other	  Lys	  (K63,	  K6,	  K11,	  K27,	  K29	  
and	   K33)	   have	   also	   been	   described	   (Saeki	   et	   al.,	   2009;	   Xu	   et	   al.,	   2009).	   Furthermore	   it	   was	  
suggested	  that	  at	  least	  four	  Ub	  moieties	  are	  necessary	  for	  an	  efficient	  recognition	  and	  processing	  
by	   the	   26S	   proteasomes;	   however	   recent	   investigations	   show	   that	   the	   proteasomal	   proteolytic	  
signal	   is	   far	   more	   complex	   and	   differentiated.	   Indeed,	   different	   kind	   of	   target	   protein	  
modifications	   have	   been	   described	   including:	   i)	   homogeneous	   and	   heterogeneous	   Ub	   chains,	  
where	  heterogeneous	  chains	  can	  be	  linear	  or	  single/multiply	  branched;	  ii)	  modification	  by	  a	  single	  
Ub	  moiety	  or	  multiple	  single	  Ub	  moieties;	  iii)	  Ub	  modification	  of	  ‘non-­‐canonical’	  internal	  residues	  
(Ser,	  Cys,	  Thr)	  in	  the	  target	  substrate;	  iv)	  Ub	  modification	  of	  the	  N-­‐terminal	  residue	  of	  the	  target	  
substrate;	   v)	  modification	   by	  Ub-­‐like	   proteins	   (UbL)	   as	   single	  molecule	   or	   chain	   and	   also	  mixed	  
chain	  made	  of	  UbL	  and	  Ub.	  
The	  ubiquitin-­‐conjugated	  substrate	  is	  finally	  degraded	  to	  short	  peptides	  (4-­‐25	  amino	  acids)	  
by	  the	  26S	  proteasomes,	  concomitantly	  with	  release	  and	  recycle	  of	  free	  ubiquitin	  (Ciechanover	  et	  
al.,	  2014).	  Considering	  the	  variety	  of	  cellular	  processes	  in	  which	  the	  UPS	  is	  involved,	  its	  aberrations	  
are	   implicated	   in	   the	   pathogenesis	   of	   several	   diseases,	   including	   neurodegenerative	   diseases,	  
malignancies,	  immune	  and	  inflammatory	  disorders.	  
	  
1.2.1	  PROTEASOME:	  STRUCTURE	  AND	  ASSEMBLY	  	  
The	  26S	  proteasome	   is	   a	  highly	   conserved	   subcellular	   structure	  with	  multiple	  proteolytic	  
activities	  and	  represents	  the	  machinery	  of	  UPS	  (Brooks	  et	  al.,	  2000;	  Chondrogianni	  et	  al.,	  2012a),	  
localized	  in	  the	  cytoplasm,	  nucleus	  as	  well	  as	  on	  the	  ER.	  Its	  structure	  consists	  of	  two	  distinct	  sub-­‐
complexes:	  the	  20S	  core	  proteasome	  and	  the	  regulatory	  19S	  (or	  PA700)	  complex,	  that	  binds	  either	  
to	  one	  or	  both	  ends	  of	  the	  20S	  core	  (Stadtmueller	  et	  al.,	  2011)	  (fig.	  1).	  




Figure	  1.	  Structure	  of	  20S	  and	  26S	  proteasome	  (www.bostonbiochem.com).	  
	  
The	  20S	  constitutive	  proteasome,	  a	  700	  kDa	  multisubunit	  enzyme,	  is	  a	  barrel-­‐shape	  stack	  
of	   four	  heptameric	   rings	  where	   two	  outer	  α-­‐subunits	   rings	   (α1-­‐7)	  embrace	   two	  central	  head-­‐to-­‐
head	  oriented	  rings	  containing	  β-­‐subunits	  (β1-­‐7).	  The	  α	  subunits	  are	  involved	  in	  the	  control	  of	  the	  
gate	  opening	  and	  bind	  regulatory	  complexes,	  whereas	  three	  of	  the	  β	  subunits	  (β1,	  β2,	  β5)	  harbor	  
the	  active	  sites	  responsible	  for	  the	  proteasome	  hydrolyzing	  activities,	  which	  cleave	  peptide	  bound	  
on	   the	   carboxyl	   site	   after,	   acidic	   (caspase-­‐like	   activity),	   basic	   (trypsin-­‐like	   activity),	   and	  
hydrophobic	   (chymotrypsin-­‐like	   activity)	   amino	   acids,	   respectively	   (Goldberg	   et	   al.,	   2007).	   The	  
catalytically	   active	   residue	   is	   a	   single	   threonine	   located	   at	   the	   amino	   termini	   of	   the	   three	   β	  
subunits,	   and	   characterizes	   the	   proteasome	   as	   a	   member	   of	   the	   family	   of	   AMINO-­‐TERMINAL	  
NUCLEOPHILE	  (NTN)	  HYDROLASES (Kloetzel,	  2001).	  
The	  Proteasome	  biogenesis	  takes	  place	  at	  the	  ER	  and	  it	  is	  an	  accurately	  ordered	  multistep	  
event,	   mediated	   by	   at	   least	   five	   conserved	   extrinsic	   chaperones	   named	   PAC1-­‐4	   (proteasome	  
assembling	   chaperones)	   and	   UMP1/POMP	   (chaperone	   proteasome	   maturation	   protein)	   in	  
mammals.	  The	  assembly	  of	  the	  20S	  core	  starts	  with	  the	  α-­‐ring	  formation	  and,	  although	  the	  precise	  
mechanism	  is	  unknown,	  it	  is	  suggested	  that	  PAC3-­‐PAC4	  are	  required,	  while	  the	  role	  of	  PAC1-­‐PAC2	  
is	  to	  prevent	  dimerization	  of	  α-­‐rings.	  After	  the	  assembly	  of	  the	  α-­‐ring	  is	  completed,	  β-­‐subunits	  are	  
incorporated	  onto	  the	  α-­‐ring,	   initially	  as	  precursors-­‐subunits,	  giving	  rise	  to	  half	  proteasome.	  The	  
combination	   of	   two	   half-­‐proteasomes	   produces	   pre-­‐holoproteasomes;	   the	   maturation	   steps	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involve	  the	  cleavage	  of	  the	  N-­‐terminal	  propeptide	  from	  the	  three	  pairs	  of	  β	  catalytic	  subunits,	  thus	  
exposing	  the	  catalytic	  threonine	  active	  residue.	  This	  process	  is	  assisted	  both	  by	  propeptides	  and	  C-­‐
terminal	  tails	  of	  β-­‐subunits	  as	  well	  as	  by	  the	  assembly	  chaperones.	  Furthermore,	  each	  β	  subunit	  is	  
recruited	   onto	   the	   α-­‐ring	   in	   a	   defined	   order	   of	   β2,	   β3,	   β4,	   β5,	   β6,	   β1	   and	   β7,	   as	   revealed	   in	  
knockdown	   experiments	   of	   single	   β	   subunits	   in	  mammalian	   cells.	   The	   formation	   of	  mature	   20S	  
proteasomes	  is	  followed	  by	  the	  degradation	  of	  chaperons	  (Hirano	  et	  al.,	  2006;	  Fricke	  et	  al.,	  2007;	  
Sahara	  et	  al.,	  2013).	  
	  
1.2.2	  PROTEASOMES	  REGULATORS	  	  
In	  order	   to	  prevent	  uncontrolled	  proteolitic	  degradation	  whitin	   cells,	   different	   regulators	  
are	   able	   to	   monitor	   both	   recognition	   and	   degradation	   of	   proteasome	   substrates.	   The	   most	  
important	  regulator	  is	  the	  19S	  (or	  PA700)	  proteasomes	  regulator	  (approximately	  1	  MDa),	  which	  is	  
composed	  by	  two	  multisubunit	  sub-­‐complexes,	  the	  lid	  and	  the	  base.	  
The	  lid	  is	  made	  of	  seven	  non-­‐ATPase	  subunits	  (Rpn	  3-­‐9)	  and	  it	  is	  involved	  in	  the	  recognition	  
and	   de-­‐ubiquitination	   of	   ubiquitin-­‐conjugated	   substrates,	   before	   their	   translocation	   and	  
degradation,	  as	  well	  as	  ubiquitin	  recycling	  (Verma	  et	  al.,	  2002).	  The	  base	  directly	  contacts	  the	  α-­‐
rings	  of	   the	  20S	  complex,	  contains	  six	  homologous	  ATPases	   (Rpt	  1-­‐6)	  which	  perform	  chaperone-­‐
like	   activities	   and	   three	   non-­‐ATPase	   subunits	   (Rpn	   1,	   2,	   10).	   The	   base	   allows	   target	   proteins	   to	  
access	  the	  proteolytic	  channel,	  by	  unfolding	  substrates	  and	  opening	  the	  gate	  of	  the	  catalytic	  core.	  
The	  19S	  regulator	  might	  bind	  both	  the	  α-­‐rings	  of	  the	  20S	  core,	  forming	  a	  large	  particle	  named	  26S	  
proteasome.	  
There	  are	  also	  additional	  regulators	  of	  the	  proteasome,	  among	  which	  the	  11S	  complex	  (or	  
PA28)	  is	  the	  best	  characterized	  (Stadmueller	  et	  al.,	  2011).	  Three	  different	  isoforms	  of	  11S	  activator	  
are	   known:	   PA28α,	   PA28β,	   PA28γ	   (Rechsteiner	   et	   al.,	   2005).	   PA28α	  and	  PA28β	   subunits	   can	  be	  
induced	  by	  interferon-­‐γ	  and	  have	  been	  implicated	  in	  the	  production	  of	  MHC	  class	  I	  epitopes.	  It	  has	  
been	   also	   proposed	   that	   PA28αβ	   could	   affect	   the	   quality	   of	   antigenic	   peptides	   produced	   by	  
proteasome,	   by	   inducing	   changes	   in	   the	   structural	   conformation	   of	   the	   catalytic	   core	   (Kloetzel,	  
2001).	  
On	  the	  contrary,	  PA28γ	  is	  not	  induced	  by	  interferon-­‐γ	  and	  it	  has	  been	  implicated	  mainly	  in	  
the	  degradation	  of	  nuclear	  proteins	   like	   certain	   inhibitors	  of	   cyclin-­‐dependent	   kinase	   (p21,	  p16,	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p19).	   These	   activators	   have	   been	   described	   as	   involved	   in	   ubiquitin-­‐independent	   degradation	  
pathways.	   Moreover,	   as	   they	   do	   not	   show	   ATPase	   activity,	   it	   has	   been	   suggested	   that	   their	  
substrates	   might	   be	   small	   peptides	   or	   proteins	   with	   unstructured	   regions,	   where	   an	   unfolding	  
activity	  is	  not	  required.	  
The	  co-­‐expression	  of	  19S	  and	  11S	  complexes	  within	  the	  same	  cell	  might	  give	  rise	  to	  hybrid	  
proteasomes,	  that	  are	  20S	  core	  proteasomes	  with	  both	  regulators	  at	  the	  two	  ends	  (11S-­‐20S-­‐19S).	  
The	   exact	   function	   of	   hybrid	   proteasomes	   is	   still	   unknown,	   but	   likely	   the	   target	   substrate	   is	  
recognized	   and	   bound	   by	   the	   19S	   regulator,	  while	   the	   11S	  might	   favor	   the	   release	   of	   products	  
after	  proteasome	  hydrolysis	  (Tanahashi	  et	  al.,	  2000)	  or	  it	  could	  change	  its	  proteolytic	  specificities,	  
causing	  a	  different	  set	  of	  peptide	  products	  (Jung	  et	  al.,	  2012).	  
It	   has	   been	   also	   recognized	   that	   certain	   proteins	   can	   be	   degraded	   by	   the	   20S	   core	  
proteasome	  in	  an	  ATP-­‐independent	  manner.	  This	  is	  the	  case	  of	  ornithine	  decarboxylase,	  unfolded	  
and	  defective	  ribosomal	  proteins	  (DRiPs),	  damaged	  and/or	  oxidized	  proteins,	  which	  are	  produced	  
as	  consequence	  of	  oxidative	  stress,	  diseases	  and	  aging	  (Pickering	  et	  al.,	  2012b).	  Indeed,	  oxidative	  
damage	   frequently	   leads	   to	   oxidation	   of	   aminoacid	   side	   chain	   and	   the	   introduction	   of	   carbonyl	  
group,	   as	   well	   as	   conformational	   changes	   of	   proteins	   resulting	   in	   exposition	   of	   hydrophobic	  
domains,	   which	   do	   not	   normally	   interact	   with	   aqueous	   environment.	   It	   is	   believed	   that	   these	  
abnormally	  exposed	  residues	  act	  as	  recognition	  sites	  for	  the	  20S	  proteasomes	  and	  they	  are	  able	  to	  
induce	   conformational	   changes	   of	   α	   subunits,	   leading	   to	   the	   opening	   of	   the	   gate	   and	   protein	  
degradation.	  
Additionally,	  these	  groups	  of	  proteins	  represent	  an	  important	  source	  of	  antigenic	  peptides,	  
which	  are	  loaded	  on	  MHC	  class	  I	  complex	  and	  presented	  on	  cellular	  surface	  for	  the	  recognition	  by	  
CD8+	   T-­‐lymphocytes.	   Several	   lines	   of	   evidences	   suggest	   that	   a	   variant	   of	   the	   constitutive	   20S	  
proteasomes,	   named	   immunoproteasome	   (i-­‐proteasome),	   is	   primarily	   involved	   in	   this	   process	  
(Kloetzel,	   2001;	   Strehl	   et	   al.,	   2005),	   as	   discussed	   more	   in	   detail	   in	   the	   next	   chapter.	   Of	   note,	  
another	   proteasomes	   isoform	   named	   thymoproteasome	   exists,	   where	   a	   β5t	   replace	   the	   β5	  
catalytic	  subunit	  of	  constitutive	  proteasome,	  and	  it	  plays	  a	  role	  in	  the	  positive	  selection	  of	  CD8+	  T-­‐
cells	  (Takahama	  et	  al.,	  2012),	  but	  further	  dissertations	  on	  its	  patho-­‐physiological	  role	  are	  beyond	  
the	  aim	  of	  this	  thesis.	  




1.3.1	  STRUCTURE	  AND	  TISSUE	  DISTRIBUTION	  
As	  a	  consequence	  of	  pro-­‐inflammatory	  stimuli,	  such	  as	  exposure	  to	  Tumor	  Necrosis	  Factor-­‐
α	  (TNF-­‐α),	   Interferon	  γ	  (IFN-­‐γ)	  or	  Lipopolysaccharide	  (LPS),	  the	  constitutive	  catalytic	  subunits	  β1,	  
β2	  and	  β5	  are	  replaced	  by	  inducible	  β-­‐counterparts,	  named	  β1i	  (or	  low	  molecular	  mass	  peptide	  2,	  
LMP2),	   β2i	   (or	  multicatalytic	   endopeptidase	   complex-­‐like	   1,	  MECL-­‐1)	   and	   β5i	   (or	   low	  molecular	  
mass	  peptide	  7,	  LMP7)	  respectively.	  Under	  these	  conditions,	  proteasome	  has	  to	  be	  synthesized	  ex	  
novo,	  leading	  to	  the	  formation	  of	  immunoproteasome.	  
The	   two	  genes	   that	  encode	  β1i	   and	  β5i	   subunits	  are	  mapped	   in	   the	  MHC	  class	   II	   region,	  
located	   on	   chromosome	   6	   in	   humans,	   and	   they	   are	   clustered	  with	   the	   TAP-­‐1	   and	   TAP-­‐2	   genes	  
(transporter	  associated	  with	  antigen	  processing),	  while	  gene	  encoding	  the	  third	  inducible	  catalytic	  
subunit	  β2i	  is	  found	  on	  chromosome	  16	  (Zhou	  et	  al.,	  1993).	  Like	  β1i	  and	  β5i,	  the	  expression	  of	  TAP	  
proteins	   is	  also	  up-­‐regulated	  by	  IFN-­‐γ	  (Yang	  et	  al.,	  1992).	   Indeed,	  their	  promoter	  region	  contains	  
binding	  sites	  for	  multiple	  transcription	  factors,	  including	  the	  interferon	  consensus	  sequence-­‐2	  and	  
the	  gamma	  interferon	  activated	  sequence,	  which	  bind	  the	  dimer	  signal	  transducers	  and	  activators	  
of	   transcription-­‐1	   (Stat-­‐1)	  and	  the	   interferon	  regulatory	   factor-­‐1	   (IRF-­‐1)	   (Chatterjee	  et	  al.,	  2000),	  
the	   major	   transcription	   factors	   involved	   in	   IFN-­‐γ	   signal	   transduction.	   Additionally,	   cAMP	  
responsive	  elements	  and	  regions	  of	  consensus	  sequence	  for	  NF-­‐kB	  binding	  are	  also	  present,	  thus	  
suggesting	  that	  additional	  cytokine-­‐independent	  regulation	  mechanisms	  are	  possible.	  
Taking	   into	   consideration	   that	  only	   the	  X-­‐ray	   structure	  of	  murine	   i-­‐proteasome	  has	  been	  
solved	  (Huber	  et	  al.,	  2012),	  bioinformatic	  analyses	  showed	  that	  human	  constitutive	  and	  inducible	  
proteasome	  subunits	  are	  characterized	  by	  an	  high	  conservation	  of	  the	  amino	  acids	  in	  the	  binding	  
pocket	  of	   substrates,	   except	   for	   β1i,	   that	   contains	   two	  prominent	   substitutions	   that	   reduce	   the	  
size	  of	   the	  binding	  pocket	  and	  change	  the	  overall	  charge	  of	   the	   local	  environment	   from	  positive	  
(β1)	   to	   neutral.	   These	   changes	   could	   in	   part	   explain	   the	   drastic	   reduction	   in	   the	   caspase-­‐like	  
activity	  of	  the	   i-­‐proteasome;	   indeed	  the	  cleavage	  after	  acidic	  residues,	  which	   is	  accomplished	  by	  
the	   β1	   constitutive	   subunit,	   is	   nearly	   abolished	  with	   the	   β1i	   (Toes	   et	   al.,	   2001).	   Additionally,	   i-­‐
proteasome	  shows	  an	   increase	  of	  the	  chymotrypsin-­‐like	  activity,	  which	  promotes	  the	  generation	  
of	  MHC	  class	  I	  peptides	  containing	  hydrophobic	  C-­‐terminal	  anchors,	  thus	  favoring	  the	  production	  
of	   antigenic	   peptides.	   However,	   it	   is	   necessary	   to	   underline	   that	   the	   various	   catalytic	   subunits	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confer	   to	   i-­‐proteasome	  different	   cleavage	  preferences	   and	  degradation	   rates,	  which	   in	   part	   are	  
determined	   by	   amino	   acids	   that	   constitute	   the	   binding	   pocket,	   but	   also	   from	   the	   amino	   acidic	  
composition	  of	  the	  substrate	  (Groll	  et	  al.,	  1997;	  Groll	  et	  al.,	  2002).	  Moreover,	  as	  above	  described	  
for	   constitutive	  20S	  proteasomes,	   the	   i-­‐proteasome	  can	  bind	  both	   the	  19S	  and	  PA28	   regulatory	  




Figure	  2.	  Inducible	  subunits	  form	  the	  20S	  immunoproteasome	  (i20S).	  The	  mature	  i20S	  then	  binds	  to	  either	  PA700	  (19S	  
proteasome),	  or	  PA28αβ	  (11S	  proteasome),	  or	  a	  combination	  of	  both	  proteasome	  activators	  at	  its	  two	  ends	  to	  form	  
three	  different	  types	  of	  immunoproteasome	  (Angeles	  et	  al.,	  2012).	  
	  
Interestingly	   the	  constitutive	  and	   inducible	  β	  subunits	  often	  coexist	   in	  cells,	  giving	  rise	  to	  
intermediate	   types	  or	   subtypes	  proteasomes	   (Vigneron	  et	   al.,	   2012).	   This	   ability	  of	   the	   cells	   to	  
produce	   various	   subtypes	   of	   proteasomes	   with	   different	   catalytic	   properties	   and	   substrate	  
preference	   has	   several	   advantages.	   Firstly,	   this	   plasticity	   allows	   the	   cell	   to	   respond	   to	  
environmental	   condition	   changes	   and	   to	   adjust	   the	   proteolytic	   capacity	   to	   new	   challenges.	  
Secondly,	   the	   presence	   of	   different	   subtypes	   increases	   the	   repertoire	   of	   substrates	   that	   can	   be	  
degraded	  and	  of	  peptides	  eventually	  generated.	  
I-­‐proteasomes	  were	  firstly	  identified	  in	  vivo	  in	  cells	  and	  organs	  of	  the	  immune	  system,	  such	  
as	   T	   cells,	   B	   cells,	  monocytes,	  macrophages,	   dendritic	   cells,	   or	  medullary	   thymic	   epithelial	   cells	  
(Kniepert	  et	  al.,	  2013).	  In	  line	  with	  its	  role	  in	  shaping	  the	  MHC	  class	  I-­‐restricted	  peptide	  repertoire,	  
it	  has	  been	  shown	  that	  the	  spleen	  has	  the	  highest	  i-­‐proteasome	  expression	  and	  activity	  than	  any	  
other	  tissue	  in	  rats	  (Noda	  et	  al.,	  2000).	  Additionally,	  it	  was	  long	  assumed	  that	  most	  of	  the	  tissues	  
of	  non-­‐hematopoietic	  origin	  and	  organs	  without	  immunological	  functions	  were	  normally	  devoid	  of	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i-­‐proteasome.	  However,	  over	  the	  past	  few	  years,	  an	  increasing	  number	  of	  studies	  have	  re-­‐defined	  
i-­‐proteasome	   expression	   in	   a	  wide	   array	   of	   non	   immunological	   cells	   and	   organs	   (Ebstein	   et	   al.,	  
2012).	   Indeed,	   the	  β5i	   inducible	  catalytic	  subunit	   is	  constitutively	  expressed	   in	  normal	   tissues	  as	  
colon,	   liver,	   umbilical	   vein,	   placenta	   including	   small	   intestinal	   epithelial	   cells.	   In	   addition,	   a	   fully	  
mature	   i-­‐proteasome,	   containing	   the	   all	   three	   inducible	   catalytic	   subunits,	   can	  be	  purified	   from	  
human	  kidney.	  Noteworthy,	  in	  both	  colon	  and	  liver,	  β5i	  is	  accompanied	  by	  the	  up-­‐regulation	  of	  the	  
two	  other	  inducible	  subunits	  β1i	  and	  MECL-­‐1	  during	  the	  course	  of	  pathologies,	   including	  Crohn’s	  
disease	   (Visekruna	   et	   al.,	   2006)	   and	   cirrhosis	   (Vasuri	   et	   al.,	   2010),	   probably	   as	   result	   of	   an	  
alteration	   of	   the	   local	   inflammatory	   environment.	   Most	   surprisingly,	   i-­‐proteasome	   has	   been	  
reported	   to	   be	   expressed	   in	   uninjured	   immune	   privileged	   tissues,	   such	   as	   the	   retina	  
(photoreceptors	  and	  neurons	   in	  the	  outer	   layer	  of	  the	  retina)	   (Ferrington	  et	  al.,	  2008)	  and	  brain	  
(synapse	   and	   Purkinje	   cells)	   (Mishto	   et	   al.,	   2006a;	   Diaz-­‐Hernandez	   et	   al.,	   2003).	   Additionally,	  
earlier	  studies	  in	  humans	  have	  suggested	  that	  i-­‐proteasomes	  are	  absent	  in	  neurons	  under	  normal	  
conditions,	  but	  they	  can	  be	  induced	  during	  neurodegenerative	  diseases	  such	  as	  Alzheimer	  (Mishto	  
et	   al.,	   2006a),	   Multiple	   Sclerosis	   (Mishto	   et	   al.,	   2010)	   and	   Huntington	   (Diaz-­‐Hernandes	   et	   al.,	  
2003).	  
The	  nature	  of	  the	  stimuli	  leading	  to	  the	  basal	  and	  persistent	  expression	  of	  one	  or	  more	  of	  
the	  three	  inducible	  catalytic	  subunits	  even	  under	  healthy	  conditions	  remains	  unclear.	  None	  of	  cell	  
types	   above	  mentioned	   is	   a	   strong	  producer	  of	   IFN-­‐γ,	   thereby	  excluding	   the	  possibility	   that	   the	  
formation	   of	   i-­‐proteasome	   is	   driven	   by	   permanent	   autocrine	   stimulation.	   The	   prolonged	  
expression	  of	   β1i,	   β5i	   and	  MECL-­‐1	   subunits	   in	   these	   tissues	  might	   rely	   on	   the	   secretion	  of	   pro-­‐
inflammatory	  cytokines	  by	  neighboring	  cells	  such	  as	  resident	  macrophages	  and	  infiltrating	  T	  cells	  
or	  NK	  cells,	  which	  secrete	  high	  levels	  of	  IFN-­‐γ	  during	  pathological	  condition,	  but	  it	  is	  quite	  unlike	  in	  
uninjured	   environment.	   Therefore,	   it	   is	   also	   possible	   that	   the	   constitutive	   expression	   of	   i-­‐
proteasome	   subunits	   in	   these	   non-­‐immune	   tissues	   may	   reflect	   a	   permanent	   activation	   of	  
intracellular	  signaling	  pathways	  (Ebstein	  et	  al.,	  2012),	  which	  deserve	  further	  investigations.	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1.3.2	  FUNCTIONS:	  ROLE	  IN	  MHC	  CLASS	  I	  ANTIGEN	  PROCESSING	  VS	  NON	  IMMUNE	  FUNCTIONS	  
Proteasomes	  efficiently	  play	  the	  first	  step	  in	  MHC	  class	  I-­‐restricted	  antigen	  presentation	  by	  
providing	   the	   correct	   C-­‐terminus	   of	   antigenic	   peptides,	   which	   are	   generated	   mainly	   by	   the	  
chymotrypsin-­‐like	  activity	  of	  the	  β5	  constitutive	  catalytic	  subunit	  and	  enhanced	  in	  presence	  of	  β5i	  
and	   β1i	   inducible	   catalytic	   subunits.	   However,	   studies	   on	   Knock-­‐out	   mice	   for	   i-­‐proteasome	  
subunits	   did	   not	   show	   an	   evident	   phenotype.	   Indeed,	   mice	   deficient	   in	   β5i	   have	   exhibited	   a	  
modest	  reduction	  in	  the	  surface	  expression	  of	  MHC	  class	  I	  molecules	  and	  reduced	  levels	  of	  CD8+	  T	  
cells	  (Fehling	  et	  al.,	  1994),	  while	  deficiency	  in	  β1i	  seems	  to	  determine	  a	  decrease	  in	  the	  number	  of	  
CD8+	  T	  cells	  and	  a	  reduced	  response	  to	  different	  epitopes	  (Basler	  et	  al.,	  2006).	  Even	  triple-­‐deficient	  
mice	   (knock-­‐out	   for	   all	   three	   inducible	   catalytic	   subunits)	   were	   viable,	   fertile	   and	  
immunocompetent	   (Kincaid	   et	   al.,	   2011),	   suggesting	   that	   although	   there	   were	   differences	   in	  
knock-­‐out	  mice	  regarding	  antigen	  processing	  and	  in	  the	  response	  toward	  specific	  antigens,	  there	  
was	  no	  evidence	  for	  a	  global	  deficit	  in	  immune	  function.	  
Interestingly	   recent	   findings	   suggest	   that,	   beyond	   the	   antigen	   presentation,	   the	   i-­‐
proteasome	  is	  involved	  in	  the	  regulation	  of	  different	  biological	  processes,	  such	  as	  oxidative	  stress	  
and	  cell	  cycle	  progression,	  as	  well	  as	  cytokine	  production	  (Ebstein	  et	  al.,	  2012).	  Different	  studies	  
suggested	   a	   role	   of	   the	   i-­‐proteasome	   in	   maintaining	   cellular	   homeostasis	   during	   IFN-­‐mediated	  
oxidative	  stress,	  by	  removal	  oxidized	  proteins	  and	  preventing	  the	  accumulation	  of	  harmful	  protein	  
aggregates	  (Seifert	  et	  al.,	  2010,	  Pickering	  et	  al.,	  2012a).	  Accordingly,	   i-­‐proteasome	  is	  significantly	  
up-­‐regulated	  in	  the	  central	  nervous	  system	  in	  response	  to	  acute	  injury	  (Hussong	  et	  al.,	  2010)	  and	  
in	   cultured	   cells	   exposed	   to	   oxidative	   stress	   (Ding	   et	   al.,	   2003).	   Increased	   levels	   of	   oxidized	  
proteins	  in	  the	  brain	  and	  liver	  of	  β1i	  knock-­‐out	  mice	  (Ding	  et	  al.,	  2006)	  and	  a	  greater	  sensitivity	  to	  
oxidative	  stress	  exhibited	  by	  retinal	  pigmented	  epithelial	  cells	  of	  double	  knock-­‐out	  mice	  in	  β5i	  and	  
MECL-­‐1	   subunits,	   support	   a	   role	   of	   i-­‐proteasome	   in	   protecting	   against	   oxidative	   damage	  
(Ferrington	  et	  al.,	  2008).	  In	  murine	  embryonic	  stem	  cells,	  the	  removal	  of	  oxidized	  proteins	  occurs	  
during	   cell	   maturation	   phase	   and	   Hernebring	   and	   co-­‐workers	   showed	   that	   this	   phase	   of	  
differentiation	   is	   accompanied	   by	   the	   induction	   of	   genes	   encoding	   for	   the	   PA28αβ	   proteasome	  
activator,	   subunits	  of	   the	   i-­‐proteasome	  and	  TNF-­‐α,	  with	   the	  assembly	  of	  mature	   forms	  of	  PA28-­‐
20S	  and	  an	  increase	  of	  proteasome	  activity	  (Hernebring	  et	  al.,	  2013).	  It	  has	  also	  been	  reported,	  in	  
human	   embryonic	   stem	   cells,	   an	   enhanced	   expression	   of	   genes	   encoding	   for	   the	   inducible	  
subunits	   of	   the	   20S,	   which	   are	   down-­‐regulated	   during	   differentiation,	   suggesting	   a	   role	   of	   i-­‐
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proteasome	   in	   the	   degradation	   of	   cell	   cycle	   regulators	   and/or	   differentiation	   inducing	   factors	  
(Atkinson	   et	   al.,	   2012).	   The	   link	   between	   i-­‐proteasome	   and	   differentiation	   was	   also	   found	   in	  
patients	  with	  a	  missense	  mutation	   in	  β5i	  gene,	  who	  suffered	   from	  auto-­‐inflammatory	   response,	  
characterized	   by	   impaired	   adipocyte	   differentiation	   and	   increased	   level	   of	   IL-­‐6	   (Kitamura	   et	   al.,	  
2011).	  This	  latter	  study	  also	  added	  new	  insights	  on	  the	  involvement	  of	  i-­‐proteasome	  in	  regulation	  
of	  pro-­‐inflammatory	  cytokines	  during	  cellular	  stress	  response,	  by	  acting	  on	  key	  signaling	  pathways,	  
the	  most	  important	  of	  which	  is	  represented	  by	  NF-­‐kB	  (Maldonado	  et	  al.,	  2013).	  
	  
1.4	  CIRCULATING	  PROTEASOMES	  	  
Although	  proteasomes	  are	  intracellular	  enzymes,	  they	  have	  been	  detected	  in	  extracellular	  
spaces	   and	   fluids,	   e.g.	   extracellular	   alveolar	   space,	   blood	   serum	   and	   plasma	   as	   well	   as	  
cerebrospinal	   fluid,	   and	   they	   were	   defined	   extracellular	   or	   circulating	   proteasomes	   (c-­‐
proteasomes).	   Taking	   into	   account	   that	   intact	   and	   proteolytically	   active	   c-­‐proteasomes	   are	  
detectable	   even	   in	   healthy	   subjects,	   their	   incidence	   and	   relevance	   has	   been	   studied	   in	   several	  
pathological	   conditions	   (Sixt	   et	   al.,	   2008).	  Wada	  and	   colleagues	   (Wada	  et	   al.,	   1993)	   for	   the	   first	  
time	  have	  measured	  c-­‐proteasomes	  concentration	  in	  serum	  samples	  of	  patients	  with	  hematologic	  
malignancies	  and	  it	  was	  positively	  correlated	  to	  the	  tumor	  burden.	  Interdependency	  between	  the	  
stage	   of	   malignancy	   and	   the	   level	   of	   c-­‐proteasomes	   was	   also	   detected	   in	   patients	   with	   solid	  
tumors	   and	   cancer-­‐predisposing	   diseases	   (e.g.	   liver	   cirrhosis)	   as	   well	   as	   in	   several	   autoimmune	  
diseases	  (e.g.	  systemic	  lupus	  erythematosus,	  rheumatoid	  arthritis,	  multiple	  sclerosis)	  (Egerer	  et	  al.,	  
2002).	   In	  general	   these	  studies	  suggest	  that	  the	  amount	  of	  c-­‐proteasomes	  might	  be	  a	  marker	  of	  
disease	  activity,	  for	  which	  the	  improvement	  in	  the	  clinical	  course	  usually	  embraces	  a	  reduction	  of	  
c-­‐proteasomes	   levels.	   Additionally,	   c-­‐proteasomes	   concentration	   has	   been	   proposed	   as	  
independent	  prognostic	  factor	  for	  survival	   in	  multiple	  myeloma	  (Jakob	  et	  al.,	  2007).	  Noteworthy,	  
to	   date,	   changes	   in	   the	   levels	   of	   c-­‐	   proteasomes	   during	   human	   aging	   have	   not	   yet	   been	  
investigated.	  
The	  origin	  of	  the	  circulating	  proteasomes	  is	  still	  a	  matter	  of	  debate.	  Zoeger	  and	  co-­‐workers	  
(Zoeger	   et	   al.,	   2006)	   have	   excluded	   that	   c-­‐proteasomes	   may	   have	   origin	   from	   the	   major	   cell	  
population	   of	   the	   blood	   (erythrocytes,	   monocytes,	   polymorphonuclear	   cells,	   B	   cells,	   T-­‐
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lymphocytes	  and	  platelets).	   Indeed,	  c-­‐proteasomes	  isolated	  from	  plasma	  of	  healthy	  subjects	  and	  
patients	  with	  autoimmune	  disease	  exhibited	  different	  profiles	  from	  those	  of	  blood	  cells.	  It	  has	  also	  
been	   proposed	   that	   c-­‐proteasomes	  might	   be	   released	   into	   the	   blood	   plasma	   from	   apoptotic	   or	  
damaged	   cells,	   but	   this	   hypothesis	   explains	   only	   the	   elevated	   concentrations	   of	   c-­‐proteasomes	  
measured	  in	  patients	  suffering	  from	  diseases	  characterized	  by	  a	  significant	  increased	  of	  cell	  death.	  
In	   fact,	   immunological	   activity,	   rather	   than	   the	   cellular	   damage,	   seems	   to	   be	   the	   cause	   of	  
increased	   of	   c-­‐proteasomes	   levels	   in	   the	   case	   of	   sepsis	   and	   severe	   injury	   (Roth	   et	   al.,	   2005).	  
Surprisingly,	   active	   mechanisms	   of	   release	   of	   proteasomes	   have	   been	   suggested	   by	  
immunoelectron	  microscopy	  analysis,	  which	   revealed	  vesicles	   containing	  proteasomes,	   in	  merge	  
with	   the	   outer	   membrane	   of	   the	   choroid	   plexus	   cells	   (Mueller	   et	   al.,	   2012).	   Furthermore,	  
proteasomes	  have	  also	  been	  detected	  in	  exosomes	  of	  mesenchymal	  stem	  cells,	  this	  suggests	  that	  
cells	  can	  secrete	  proteasome	  via	  the	  exosome	  pathway	  (Lai	  et	  al.,	  2012).	  
	  
1.5	  PROTEASOMES	  AND	  DISEASES	  
Taking	   into	   account	   that	   the	  UPS	   is	   involved	   in	   the	   regulation	  of	  basic	   cellular	  processes	  
including	   cycle	   and	   proliferation	   cell,	   gene	   transcription,	   apoptosis,	   signal	   transduction,	   antigen	  
processing	   (fig.	   3),	   it	   is	   not	   unexpected	   that	   its	   impairment	   might	   lead	   to	   pathological	  
consequences	  (Ferrington	  et	  al.,	  2012;	  Lecker	  et	  al.,	  2006).	  
Actually,	   altered	   proteasomes	   activity	   and	   expression,	   and/or	   accumulation	   of	   ubiquitin-­‐
conjugated	   proteins	   have	   been	   reported	   in	   multiple	   diseases,	   including	   neurodegenerative	  
disorders	  such	  as	  Alzheimer’s	  disease	  (Mishto	  et	  al.,	  2006a),	  Parkinson’s	  disease	  (Um	  et	  al.,	  2010)	  
and	  Huntington’s	   disease	   (Diaz-­‐Hernandez	   et	   al.,	   2003).	   In	   these	   disorders,	   oxidative	   stress	   and	  
inflammation	  play	  a	  pivotal	  role,	  but	  whether	  changes	  in	  proteasomes	  expression	  and	  activity	  can	  
be	   considered	   a	   consequence	   of	   altered	   cellular	   conditions	   or	   part	   of	   mechanisms	   involved	   in	  
disease	  onset,	  is	  still	  a	  matter	  of	  debate.	  
Proteasomes	   also	   play	   a	   role	   in	   cancer	   progression	   since	   they	   are	   involved	   in	   the	  
degradation	  of	  a	  myriad	  of	  proteins	  such	  as	  oncogenes,	  tumor	  suppressors,	  transcription	  factors	  
and	   signaling	  molecules,	   including	   the	   inhibitor	  of	  nuclear	   factor	   κB	   (IκB),	   the	   tumor	   suppressor	  
p53,	   inhibitors	   of	   kinases	   p21	   and	   p27	   and	   of	   the	   proapoptotic	   protein	   Bax,	   among	   others	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(Hershko,	   2005).	   Accordingly,	   in	   the	   last	   decade,	   proteasomes	   have	   been	   considered	   a	   suitable	  
target	   for	   cancer	   therapeutic	   treatment	   and	   to	   this	   purpose	   several	   compounds	   have	   been	  
developed,	  tested	  in	  vitro	  and	  two	  of	  these	  have	  been	  approved	  for	  therapy	  in	  humans	  (Orlowski	  
et	   al.,	   2008).	   The	   first	   one,	   named	   Bortezomib,	  was	   approved	   for	   treating	   of	   relapsed	  multiple	  
myeloma	  and	  of	  mantle	  cell	  lymphoma,	  while	  the	  second	  one,	  named	  Carfilzomib,	  was	  approved	  
for	   use	   in	   patients	  with	  multiple	  myeloma	  who	   received	   at	   least	   two	   prior	   therapies,	   including	  
Bortezomib.	  
Further,	   the	   deregulation	   of	   the	   i-­‐proteasome	   has	   been	   associated	   with	   various	   auto-­‐
inflammatory	   diseases,	   as	   rheumatoid	   arthritis	   (Muchamuel	   et	   al.,	   2009)	   and	  Nakajo-­‐Nishimura	  
syndrome	  (Kitamura	  et	  al.,	  2011).	  
Finally,	  despite	  the	   increased	  concentration	  of	   i-­‐proteasome	  subunits	   found	   in	  patients	  suffering	  
from	   myofibrillar	   myopathy	   and	   inclusion	   body	   myositis	   (Ferrer	   et	   al.,	   2004),	   the	   role	   of	  





Figure	  3.	  Proteasomes	  and	  disease.	  Deregulation	  of	  the	  immunoproteasome	  has	  been	  associated	  with	  various	  clinical	  
disorders,	   including	  cancer,	  autoimmune	  disease,	  neurodegenerative	  disease,	  heart	  disease,	  aging,	  and	   infection,	  as	  
well	  as	  the	  conditions	  of	  oxidative	  stress	  (Angeles	  et	  al.,	  2012).	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1.6	  HUMAN	  AGING	  AND	  PROTEASOMES	  
It	   is	   now	   recognized	   that	   human	   aging	   is	   a	   complex	   phenotype,	   resulting	   from	   the	  
continuous	   adaptation	   of	   the	   body	   to	   unrepaired	  molecular	   and	   cellular	   damages,	   caused	   by	   a	  
variety	   of	   external	   and	   internal	   agents.	   Additionally,	   genetics,	   stochasticity	   and	   environmental	  
elements	  contribute	  at	  different	  degree	  to	  determine	  the	  aging	  phenotype.	  	  
At	   the	  molecular	   level,	   the	  maintenance	  of	  homeostasis	   is	  a	  key	   feature	   that	  determines	  
the	  organism	  lifespan	  and	  it	   is	   influenced	  by	  several	   intracellular	  functions,	   including	  an	  efficient	  
protein	  degradation.	  During	  aging	  the	  accumulation	  of	  damaged	  proteins	  is	  observed	  in	  different	  
cell	   types	   (Mishto	   et	   al.,	   2003,	  Grune	   et	   al.,	   2004).	   In	   particular,	   levels	   of	   oxidized	   proteins	   are	  
reported	   to	   increase	   significantly	   with	   age	   in	   human	   dermal	   fibroblasts,	   keratinocytes,	  
erythrocytes	   and	   brain	   (Petropoulos	   et	   al.,	   2000,	   Levine	   et	   al.,	   2001).	   Such	   an	   age-­‐dependent	  
alteration	  could	  be	   related	   to	  a	  decline	  of	  proteasome	  activities,	   that	  a	  number	  of	   studies	  have	  
observed	   in	   several	   human	   tissues	   (lens,	   lymphocytes	   and	   epidermis	   cells)	   as	   well	   as	   in	   other	  
mammals	  such	  as	  mice,	  rats	  and	  cattle	  (liver,	  spinal	  cord,	  lens,	  heart	  and	  retina)	  (Chondrogianni	  et	  
al.,	  2008).	  Different	  theories	  have	  been	  developed	  to	  explain	  such	  a	  decline.	  It	  has	  been	  proposed	  
that	  the	  decrease	  of	  proteasome	  activity	   is	  a	  result	  of	  the	   inhibiting	  effect	  of	  protein	  aggregates	  
accumulated	  during	  aging	   (Grune	  et	  al.,2004),	  or	  of	  a	   reduced	  rate	  of	  proteasomes	  biosynthesis	  
and	  assembly,	  as	  observed	  in	  peripheral	  blood	  T	  lymphocytes	  and	  in	  epidermis	  cells	  (Ponnappan	  et	  
al.,	   2007,	   Bulteau	   et	   al.,	   2000).	   Accordingly,	   an	   age-­‐associated	   decrease	   in	   proteasome	   content	  
and	   activities	   has	   been	   described	   in	   human	   dermal	   fibroblasts,	   where	   a	   restoration	   of	   normal	  
levels	  of	  proteasome	  reduces	  cellular	  aging	  markers	  (Hwang	  et	  al.,	  2007).	  Additionally,	  it	  has	  been	  
recently	  shown	  that	  naked	  mole-­‐rats,	  a	  species	  of	   long-­‐living	  rodents,	  possess	  an	  high	  activity	  of	  
proteasomes,	  which	  might	  lead	  to	  the	  efficient	  removal	  of	  stress-­‐damaged	  proteins	  and	  contribute	  
to	  reach	  the	  extreme	  lifespan	  of	  the	  organism	  (Rodriguez	  et	  al.,	  2012).	  At	  last,	  proteasome	  activity	  
could	  also	  be	  inhibited	  by	  an	  increased	  number	  of	  post-­‐translational	  modifications	  of	  its	  subunits	  
as	  detected	  in	  human	  epidermis	  cells	  (Bulteau	  et	  al.,	  2000)	  or	  by	  the	  inhibition	  of	  other	  regulatory	  
molecules	   of	   the	   UPS	   (Ferrington	   et	   al.,	   2005).	   Several	   studies	   demonstrated	   that	   all	   of	   these	  
mechanisms	  could	  occur	  during	  aging	  and	  affect	  proteasome	  activity.	   Likely,	   the	   impact	  of	  each	  
single	  mechanism	  on	  proteasome	  function	  could	  vary	  between	  different	  tissues	  and	  cell	  types,	  as	  
well	  as	  among	  multiple	  isoforms	  of	  proteasomes.	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Several	   studies	   have	   been	   published	   on	   the	   expression	   of	   i-­‐proteasome	   subunits	   in	  
different	   tissues	   and	   cell	   types	   during	   aging.	   A	   decline	   of	   i-­‐subunits	   in	   human	   T	   lymphocytes	  
(Ponnappan	   et	   al.,	   2007)	   and	   an	   inability	   of	   senescent	   human	   fibroblasts	   to	   induce	   i-­‐subunits	  
expression	  following	  INF-­‐γ	  treatment	  (Stratford	  et	  al.,	  2006)	  have	  been	  described.	  On	  the	  contrary,	  
an	   increased	   expression	  of	   β1i	   and	  β5i	   i-­‐subunits	   has	   been	  detected	   in	   human	  hippocampus	  of	  
adults,	  as	  well	  as	   in	  brain	  areas	  of	  old	  non-­‐human	  primates,	  without	  age-­‐related	  modification	   in	  
total	  20S	  proteasome	  content.	  A	  role	  for	  the	  immunoproteasomes	  in	  the	  aging	  process	  is	  also	  in	  
agreement	   with	   the	   theory	   of	   inflammaging,	   originally	   proposed	   by	   Franceschi	   and	   co-­‐workers	  
(Franceschi	  et	  al.,	  2000),	  which	  postulates	  that	  aging	   is	  at	   least	   in	  part	  triggered	  by	  an	  increased	  
inflammation.	  Indeed,	  many	  studies	  indicate	  that	  old	  people	  are	  characterized	  by	  increased	  levels	  
of	  inflammatory	  markers	  such	  as	  cytokines,	  chemokines,	  reactive	  oxygen	  species	  (ROS),	  as	  well	  as	  
decreased	   levels	   of	   antioxidant	   enzymes	   such	   as	   superoxide	   dismutase	   (SOD)	   and	   phase	   1	  
detoxifying	  enzymes	  (Franceschi	  et	  al.,	  2007,	  Cevenini	  et	  al.,	  2013).	  According	  to	  this	  theory,	  the	  
persistence	   of	   inflammatory	   stimuli	   over	   time	   represents	   the	   biological	   background	   favoring	  
susceptibility	  to	  age-­‐related	  diseases/disabilities.	  
In	  the	  last	  two	  sections	  we	  will	  focus	  specifically	  on	  liver	  and	  skeletal	  muscle	  aging	  (Grizzi	  et	  
al.,	  2013;	  Sheedfar	  et	  al.,	  2013)	  and	  the	  role	  of	  proteasomes.	  
	  
1.6.1	  HUMAN	  AGING	  AND	  PROTEASOMES:	  THE	  LIVER	  
Aging	  is	  associated	  with	  a	  variety	  of	  morphological	  changes	  in	  the	  liver,	  but	  their	  underlying	  
mechanisms	  are	  still	  unclear.	  The	  liver	  progressively	  shrinks	  by	  20-­‐40%	  during	  the	  course	  of	  human	  
life,	  with	  a	   concomitant	  age-­‐related	  decrease	   in	   its	   volume.	  The	  classic	  gross	  appearance	  of	   the	  
liver	  in	  the	  elderly	  is	  known	  as	  “brown	  atrophy”,	  and	  the	  brown	  color	  is	  due	  to	  an	  accumulation	  of	  
highly	   oxidized	   insoluble	   proteins,	   known	   as	   lipofuscin,	   into	   hepatocytes.	   Other	   sub-­‐cellular	  
changes	  with	  age	  in	  the	  hepatocyte	  involve	  a	  marked	  reduction	  of	  smooth	  endoplasmic	  reticulum	  
surface,	   which	   correlates	   with	   decreased	   hepatic	   microsomal	   protein	   concentrations	   and	  
enzymatic	   activity,	   including	   glucose-­‐6-­‐phosphatase.	   Furthermore,	   the	   human	   liver	   tends	   to	  
develop	  macro	  and	  polyploid	  hepatocytes	  with	  increased	  nuclei	  and	  nucleoli	  during	  aging.	  Elderly	  
secrete	  less	  bile	  acid,	  have	  an	  increased	  biliary	  cholesterol	  levels,	  and	  show	  an	  increased	  oxidative	  
stress	   that	   is	   mainly	   attributable	   to	   a	   reduced	   capacity	   to	   eliminate	   metabolically	   generated	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superoxide	   radicals.	   Aging	   of	   the	   liver	   is	   also	   associated	   with	   impaired	   metabolism	   of	   drugs,	  
adverse	   drug	   interactions,	   and	   susceptibility	   to	   toxins.	   Along	   with	   the	   considerable	   growth	   in	  
Western	  societies	  of	  relatively	  healthy	  elderly	  populations,	  it	  is	  inevitable	  that	  there	  will	  also	  be	  an	  
increase	   in	   the	   number	   of	   elderly	   people	   with	   chronic	   liver	   diseases	   (mainly	   hepatitis	   C	   virus	  
(HCV)-­‐related	  cirrhosis,	  alcoholic	  cirrhosis	  and	  HCC)	  (Grizzi	  et	  al.,	  2013).	  
It	  is	  indubitable	  that	  interest	  in	  the	  role	  of	  aging	  in	  the	  sphere	  of	  hepatology	  has	  increased,	  
especially	  with	  the	  recent	  recognition	  of	  the	  critical	  importance	  of	  age	  in	  determining	  the	  clinical	  
outcome	  in	  (HCV)-­‐related	  chronic	  hepatitis	  and	  the	  influence	  of	  donor	  age	  on	  graft	  survival	  after	  
liver	  transplantation	  (Grizzi	  et	  al.,	  2013).	  Although	  the	  human	  liver	  is	  not	  unscathed	  by	  the	  process	  
of	   aging,	   as	   above	   described,	   its	   changes	   are	   minor	   compared	   with	   other	   organism	   systems.	  
Indeed,	   studies	   in	   humans	   and	   in	   experimental	   model	   suggest	   that,	   in	   comparison	   with	   other	  
organs,	  the	  liver	  ages	  fairly	  well	  (Schmucker	  et	  al.,	  2011).	  
Additionally,	  orthotopic	  liver	  transplants	  where	  the	  age	  of	  the	  donor	  is	  considerably	  higher	  
than	  that	  of	  the	  recipient	  have	  notably	   increased	   in	  the	   last	  years	  and	  clinical	  data	   indicate	  that	  
liver	   graft	   from	   aged	   subjects	   has,	   in	   specific	   conditions,	   function	   and	   duration	   comparable	   to	  
those	  achievable	  with	   liver	   grafts	   from	  young	  donors	   (Cescon	  et	   al.,	   2003;	  Gastaca	  et	   al.,	   2005;	  
Cescon	  et	  al.,	  2008;	  Schmeding	  et	  al.,	  2010).	  This	  evidence	  seems	  to	  indicate	  for	  the	  liver	  a	  peculiar	  
aging	   pattern,	   where	   the	   biological	   age	   does	   not	   correspond	   to	   the	   chronological	   age	   of	   the	  
organ/donor,	   and	   indirectly	   confirms	   its	   capacity	   to	   rejuvenate	   when	   in	   presence	   of	   an	  
appropriate	  microenvironment	  (Conboy	  et	  al.,	  2005).	  The	  molecular	  mechanisms	  involved	  in	  this	  
peculiar	   aging	   pattern	   are	   still	   largely	   unknown,	   but	   efficient	   protein	   degradation	   machineries	  
might	   play	   an	   important	   role	   by	   contributing	   to	   the	   maintenance	   of	   cellular	   homeostasis	  
(Chondrogianni	  et	  al.,	  2010;	  Koga	  et	  al.,	  2011).	  
At	  present,	  despite	  the	  pivotal	  role	  of	  proteasomes	  in	  physiological	  as	  well	  as	  pathological	  
conditions,	  no	  data	  are	  available	  on	  the	  age-­‐related	  modifications	  of	  proteasomes	  in	  human	  liver	  
and	  controversial	  results	  emerged	  in	  rodents.	  In	  truth,	  in	  liver	  of	  aged	  mice	  and	  rats	  all	  or	  some	  of	  
proteasome	  activities	  have	  been	   found	   to	  decrease	   (Shibatani	   et	   al.,	   1996;	  Conconi	   et	   al.	   1996;	  
Breusing	   et	   al.,	   2009;	   Hayashi	   et	   al.,	   1998;	   Rodriguez	   et	   al.,	   2010;	   Rodriguez	   et	   al.,	   2012)	   or	  
decrease	   temporarily	   before	   increasing	   again	   (Keller	   et	   al.,	   2000;	   Petersen	   et	   al.,	   2010)	   or	   be	  
preserved	  (Ding	  et	  al.,	  2006;	  Huber	  et	  al.,	  2009).	  Dasuri	  and	  colleagues	  showed	  as	  aging	  acts	  on	  
proteasome	   remodeling	   in	   the	   liver,	   including	   decrease	   in	   proteasome	   activity,	   increase	   in	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proteasome	  biogenesis,	   alteration	  of	   proteasomes	   subunits	   and	   regulators	   (Dasuri	   et	   al.,	   2009).	  
Moreover,	  very	  recently,	  a	  shift	  toward	  proteasomes	  containing	  inducible	  subunits	  in	  aged	  rat	  liver	  
has	  also	  been	  described	  (Gohlke	  et	  al.,	  2013).	  
These	   data	   underline	   a	   dynamic	   nature	   of	   the	   proteasome	   and	   suggest	   that	   the	  
relationship	  between	  proteasome	  composition/biogenesis	  and	  proteasome	  functionality	  in	  tissues	  
is	  extremely	  complex	  (Dasuri	  et	  al.,	  2009).	  
Studies	   performed	   in	   the	   laboratory	   of	   Professor	   Franceschi,	   in	   collaboration	   with	   the	  
Surgery	   Unit	   of	   Liver	   Transplantation	   and	   multi	   organ	   and	   Pathological	   Anatomy	   ‘’Addarii’’	   of	  
Hospital	  S.	  Orsola	  in	  Bologna,	  showed	  the	  absence	  of	  i-­‐proteasome	  in	  hepatocytes	  during	  fetal	  life,	  
but	   its	  cytoplasmic	   induction	  occurs	  already	  at	   the	  third	  month	  of	  extrauterine	   life	   (Vasuri	  et	  al,	  
2010).	  Whereas	  after	  birth	   the	  most	   important	  phenomenon	   is	   the	  bacterial	   colonization	  of	   the	  
gastrointestinal	   tract,	   this	  event	  could	   trigger	  pro-­‐inflammatory	  stimuli	   responsible	   for	   the	  basal	  
expression	  of	  the	  i-­‐proteasome.	  In	  this	  aspect,	  the	  liver	  is	  different	  from	  other	  organs	  we	  studied,	  
such	   as	   the	   brain,	   where	   the	   i-­‐proteasome	   is	   absent	   in	   healthy	   young	   subjects	   (Mishto	   et	   al.,	  
2010).	  
	  
1.6.2	  HUMAN	  AGING	  AND	  PROTEASOMES:	  THE	  SKELETAL	  MUSCLE	  
During	  aging,	  humans	  and	  other	  mammals	  undergo	  a	  physiological	  process	  named	  skeletal	  
muscle	  wasting,	  characterized	  by	  a	  reduction	  in	  muscle	  mass,	  due	  to	  a	  loss	  of	  net	  protein	  content	  
in	  myofibers.	  Several	  factors	  seem	  to	  be	  involved,	  including	  a	  reduction	  in	  protein	  synthesis	  and	  an	  
increase	   in	   intracellular	   proteolysis,	   due	   to	   activation	   of	   different	   pathways,	   including	   the	   UPS	  
(Sandri,	  2013;	  Murton	  et	  al.,	  2008),	  among	  others.	  
Muscle	  wasting	  occurs	   in	  a	  variety	  of	  physiological	  or	  pathological	  circumstances,	  such	  as	  
inactivity	  or	  muscle	  disuse,	   fasting	  and	  several	  diseases	  as	  cancer,	   renal	   failure	  or	   trauma.	  Since	  
skeletal	  muscle	  is	  the	  major	  protein	  reservoir	  of	  the	  body,	  muscle	  wasting	  has	  beneficial	  effect	  in	  
its	  initial	  stage,	  in	  fact	  it	  provides	  the	  organism	  with	  an	  ample	  pool	  of	  free	  amino	  acids	  that	  can	  be	  
reused	   for	   energy	   production	   or	   protein	   synthesis	   in	   vital	   organs.	   However,	   in	   a	   variety	   of	  
pathologies	  like	  cancer,	  sepsis	  and	  diabetes,	  this	  catabolic	  state	  is	  maintained	  over	  a	  long	  period	  of	  
time	  and	  can	  become	  life-­‐threatening	  (Mitch	  et	  al.,	  1996).	  The	  early	  step	  in	  muscle	  wasting	  seems	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be	  the	  dissociation	  or	  at	  least	  the	  destabilization	  of	  the	  myofibrils,	  a	  process	  in	  which	  not	  UPS	  but	  
other	  proteases	  (such	  as	  calpains,	  caspase	  3	  or	  cathepsin)	  probably	  play	  a	  key	  role	  (Costelli	  et	  al.,	  
2005).	  Instead	  few	  E3	  ligase	  enzymes	  seem	  to	  be	  transcriptionally	  induced	  to	  regulate	  the	  atrophy.	  
The	  first	  to	  be	  identified	  were	  Atrogin-­‐1/MAFbx	  and	  MuRF1	  (De	  Palma	  et	  al.,	  2008),	  two	  E3	  ligases	  
specifically	  expressed	  in	  striated	  and	  smooth	  muscle.	  The	  involvement	  of	  Atrogin-­‐1	  and	  MuRF1	  in	  
atrophy	  has	  been	  reinforced	  by	  experiments	  performed	  in	  knock-­‐out	  mice,	  which	  were	  found	  to	  
be	  resistant	  to	  muscle	  atrophy	  induced	  by	  denervation	  (Nury	  et	  al.,	  2007).	  Another	  ligase	  relevant	  
in	  muscle	  wasting	   is	  CHIP	  (Arndt	  et	  al.,	  2010),	  which	  regulates	  ubiquitination	  and	  the	   lysosomal-­‐
dependent	  degradation	  of	  filamin	  C,	  a	  muscle	  protein	  found	  in	  the	  Z	  line,	  and	  of	  unfolded	  proteins	  
bound	   to	   Hsp70	   or	   Hsp90.	   The	   CHIP	   ubiquitin	   ligase	   markedly	   increases	   in	   the	   aged	   muscle,	  
reflecting	   adaptations	   of	   muscle	   during	   aging	   to	   eliminate	   more	   efficiently	   misfolded	   proteins	  
(Altun	  et	  al.,	  2010).	  
Sarcopenia	  differs	  from	  acute	  disuse	  atrophy	   in	  several	  aspects:	   in	  disuse	  atrophy	  muscle	  
mass	  presents	  a	  reduction	  in	  fibers	  number	  but	  the	  specific	  force	  is	  maintained	  concomitantly	  with	  
fast	   type	   fibers,	   while	   in	   the	   age-­‐related	   sarcopenia	   fibers	   number	   and	   specific	   force	   are	   all	  
reduced	   and	   there	   is	   a	   shift	   towards	   the	   expression	   of	   slow	   type	   fibers	   (Lang	   et	   al.,	   2010).	  
Additionally,	   while	   sarcopenia	   develops	   over	   months	   to	   years	   depending	   on	   the	   species	  
considered,	   the	   rapid	   loss	  of	  muscle	  weight	   (20-­‐50%	   loss)	   induced	  by	   fasting,	  disuse	  and	  during	  
various	  catabolic	  diseases,	  can	  occur	  in	  rodents	  in	  several	  days.	  As	  far	  as	  it	  concerns	  the	  etiology	  of	  
sarcopenia,	   several	   factors	   are	   involved,	   including	   denervation,	   inactivity,	   hormonal	   and	  
nutritional	  changes.	  Further,	  the	  chronic	  inflammatory	  status	  which	  characterizes	  elderly	  subjects	  
(inflammaging)	  (Franceschi	  et	  al.,	  2000,	  2007;	  Cevenini	  et	  al.,	  2013),	  plays	  an	  important	  role	  also	  in	  
age-­‐related	  muscle	  weakness.	  Indeed,	  epidemiological	  studies	  in	  humans	  have	  shown	  that	  there	  is	  
a	   correlation	   between	   high	   levels	   of	   inflammatory	   cytokines,	   low	   levels	   of	   IGF1,	   high	   levels	   of	  
oxidative	   stress,	   decreased	  mitochondrial	   function	   and	  muscle	   weakness.	   In	   particular,	   in	   aged	  
muscle	  an	   increase	   in	  TNF-­‐α,	  which	   is	  one	  of	  the	  major	   inducer	  of	   i-­‐proteasome	  expression,	  was	  
described	  (Kandarian	  et	  al.,	  2006).	  
The	  most	   of	   studies	   on	   intracellular	   protein	   degradation	   by	   UPS	   in	   muscle	   wasting	   and	  
sarcopenia	   are	   focused	   on	   enzymes	   of	   ubiquitination,	   and	   little	   is	   known	   on	   the	   roles	   of	  
proteasomes,	  especially	  in	  humans.	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Dahlmann	   and	   colleagues	   studied	   proteasomes	   composition	   in	   rat	   skeletal	   muscle.	  
Approximately	  95%	  of	  the	  proteasomes	  population	  contained	  the	  β	  constitutive	  subunits	  (subtype	  
I,	  II)	  or	  composed	  by	  an	  intermediate	  subtypes,	  containing	  a	  mixture	  of	  constitutive	  and	  inducible	  
subunits	   (subtypes	   III,	   IV).	   The	   immunoproteasome	   subtype,	   containing	   only	   the	   inducible	  
subunits,	  represented	  a	  minor	  fraction	  (5%)	  of	  the	  total	  proteasomes	  (Dahlmann	  et	  al.,	  2001).	  	  
Ferrington	  and	  co-­‐workers	   investigated	  proteasome	  function	  and	  subunits	  composition	  in	  
type	   I	   fibers	  of	  aged	  rat	   soleus	  muscle	  and	   they	   found	  a	  3-­‐4	   fold	   increase	   in	  content	  of	   the	  20S	  
catalytic	   core	   in	   aged	  muscle	   compared	   to	   young,	   corresponding	   to	   a	   60%	   decrease	   of	   specific	  
activity.	   Additionally,	   an	   age-­‐related	   increase	   of	   β1i	   subunit	   and	   a	   significant	   reduction	   in	   the	  
amount	  of	  PA28	  and	  PA700	  proteasome	  regulators	  was	  described	  (Husom	  et	  al.,	  2004).	  The	  same	  
group	  extended	  these	   investigations	  by	  studying	  proteasome-­‐enriched	  preparations	  and	  purified	  
20S	   proteasomes	   from	   fast-­‐twitch	   skeletal	   muscle	   (type	   II	   fibers)	   in	   young	   and	   aged	   rats,	  
confirming	  these	  results	  (Ferrington	  et	  al.,	  2005).	  A	  possible	  explanation	  for	  the	  lower	  content	  of	  
regulatory	  complexes	  associated	  to	  the	  20S	  core	  could	  be	  the	  increased	  demand	  for	  degradation	  
of	  oxidized	  proteins,	  which	  are	  mainly	  degraded	  by	  20S	  proteasomes.	  
In	   contrast	   to	   these	   findings,	   Altun	   and	   co-­‐workers	   showed	   that	   gastrocnemius	   muscle	  
wasting	  in	  aged	  sarcopenic	  rats	  is	  associated	  with	  enhanced	  activity	  of	  the	  UPS.	  An	  increase	  in	  the	  
protein	   content	   of	   proteasomes	   subunits,	   but	   not	   in	   their	   corresponding	   mRNA,	   was	   also	  
observed,	   suggesting	   an	   enhanced	   translation	   or	   decreased	   rates	   of	   proteasomes	   degradation	  
(Altun	  et	  al.	  2010).	  
To	  our	  knowledge,	  only	  one	  study	  has	  been	  performed	  in	  humans	  by	  analyzing	  proteasome	  
activities	   in	   subjects	   affected	   by	   benign	   abdominal	   disease.	   No	   age-­‐related	   modification	   was	  
observed	  (Bossella	  et	  al.,	  2008).	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2.	  AIM	  OF	  THE	  STUDY	  
As	  discussed	  in	  the	  Introduction,	  aging	  is	  a	  complex	  phenomenon	  that	  affects	  organs	  and	  
tissues	  at	  a	  different	  rate.	  With	  advancing	  age,	  the	  skeletal	  muscle	  undergoes	  a	  progressive	  loss	  of	  
mass	  and	  strength,	  a	  process	  known	  as	  sarcopenia	  that	  eventually	   leads	  to	  a	  decreased	  mobility	  
and	  increased	  risk	  of	  falls	  and	  invalidity.	  On	  the	  other	  side,	  another	  organ	  such	  as	  the	  liver	  that	  is	  
endowed	   with	   a	   peculiar	   regenerative	   capacity	   seems	   to	   be	   only	   marginally	   affected	   by	   aging	  
(Schmucker	   et	   al.,	   2011).	   Accordingly,	   clinical	   data	   indicate	   that	   liver	   transplantation	   from	  aged	  
subjects	   has,	   in	   specific	   conditions,	   function	   and	   duration	   comparable	   to	   those	   achievable	  with	  
grafts	  of	   liver	   from	  young	  donors	   (Cescon	  et	  al.,	  2003;	  Gastaca	  et	  al.,	  2005;	  Cescon	  et	  al.,	  2008;	  
Schmeding	  et	  al.,	  2010).	  The	  molecular	  mechanisms	  involved	  in	  these	  peculiar	  aging	  patterns	  are	  
still	   largely	   unknown,	   but	   it	   is	   conceivable	   that	   protein	   degradation	  machineries	  might	   play	   an	  
important	   role,	   as	   they	   are	   responsible	   for	   the	   maintenance	   of	   cellular	   homeostasis	  
(Chondrogianni	   et	   al.,	   2010;	   Koga	  et	   al.,	   2011).	   Indeed,	   it	   has	  been	   suggested	   that	   alteration	  of	  
proteostasis	   may	   contribute	   to	   the	   onset	   and	   progression	   of	   several	   age-­‐related	   pathological	  
conditions,	  including	  skeletal	  muscle	  wasting	  and	  sarcopenia	  (Ciechanover,	  2013),	  as	  well	  as	  to	  the	  
aging	  phenotypes	  (López-­‐Otín	  et	  al.,	  2013).	  
The	  ubiquitin-­‐proteasome	  system	  (UPS)	  is	  one	  of	  the	  most	  important	  cellular	  pathways	  for	  
intracellular	  degradation	  of	  short-­‐lived	  as	  well	  as	  damaged	  proteins. To	  date,	  studies	  on	  the	  age-­‐
related	  modifications	  of	  proteasomes	   in	   liver	  and	  skeletal	  muscle	  were	  performed	  prevalently	   in	  
rodents,	   with	   controversial	   results,	   while	   only	   preliminary	   observations	   have	   been	   obtained	   in	  
human	  liver	  (Vasuri	  et	  al.,	  2010)	  and	  skeletal	  muscle	  (Bossola	  et	  al.,	  2008).	  In	  this	  scenario,	  the	  aim	  
of	   the	   present	   study	   was	   to	   investigate	   and	   characterize	   in	   humans	   the	   age-­‐related	  
modifications	  of	  proteasomes	  of	  these	  two	  different	  organs.	  To	  do	  this,	  we	  took	  advantage	  of	  a	  
unique	   biobank	   of	   samples	   of	   both	   organs,	   collected	   in	   the	   framework	   of	   two	   larger	   research	  
projects	   (MiUR	   PRIN	   2008	   “Pretransplant	   liver	   biological	   age	   and	   age-­‐mismatch	   between	   donor	  
and	  recipient	  as	  new	  predictors	  of	  transplant	  outcome”	  and	  EU	  FP7	  MYOAGE	  ‘’Understanding	  and	  
Combating	  Age-­‐related	  Muscle	  weakness’’).	  The	  two	  projects	  provided	  us	  respectively:	  i)	  biopsies	  
of	   liver	  used	   for	   transplantation	   from	  donors	  of	   different	   age;	   ii)	   biopsies	  of	  v.	   lateralis	   skeletal	  
muscle	   and	  blood	   serum	   from	  young	   and	  old	   healthy	   volunteers	   as	  well	   as	   patients	  with	   lower	  
limb	  mobility	  impairment	  (LLMI).	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Proteasomes	   subunits	   expression	   and	   composition	   were	   assessed	   by	   qPCR	   and	  
immunoblotting.	  The	  subcellular	  distribution	  of	  different	  proteasomes	  subunits	  was	  analyzed	  by	  
immunohistochemistry.	   Proteasomes	  activities	  were	  assessed	  by	   fluorogenic	  peptides	  assay	  and	  
indirectly,	  by	  measuring	  the	  levels	  of	  oxidized	  and	  polyubitinylated	  proteins.	  Finally,	  we	  measured	  
c-­‐proteasomes	   levels	   in	   sera	   of	   muscle	   donors	   by	   ELISA	   immune-­‐assay	   and	   we	   performed	  
correlation	   analyses	  with	  different	   anthropometric	   and	  biochemical	   parameters	   collected	   in	   the	  
framework	  of	  the	  MYOAGE	  project.	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3.	  MATERIALS	  AND	  METHODS	  	  
3.1	  REAGENTS	  
Suc-­‐Leu-­‐Leu-­‐Val-­‐Tyr-­‐MCA	   (3120-­‐v),	   Z-­‐Leu-­‐Leu-­‐Glu-­‐MCA	   (3179-­‐v)	   and	   free	   MCA	   (3099-­‐v)	  
fluorigenic	  substrates	  were	  from	  Peptide	  Institute	  INC	  (Japan),	  Bz-­‐Val-­‐Gly-­‐Arg-­‐MCA	  (BW	  9375)	  was	  
from	   Biomol	   (Enzo	   Life	   Sciences	   Inc,	   Farmingdale,	   New	   York,	   US).	   Proteasome	   inhibitor	  
epoxomicyn	  (E3652)	  was	  purchased	  from	  Sigma	  (Saint	  Louis,	  Missouri,	  US).	  SynergyTM	  fluorimeter	  
(Bio-­‐Tek	  Instruments,	  Winooski,	  Vermount,	  US)	  was	  used	  to	  detect	  MCA	  fluorescence.	  
Mouse	   monoclonal	   and	   rabbit	   polyclonal	   anti-­‐α4	   (PW8120,	   clone	   MCP34),	   anti-­‐α6	  
(PW8100,	   clone	   MCP20),	   anti-­‐β1	   (PW8140,	   clone	   MCP421),	   anti-­‐β2	   (PW9300,	   clone	   MCP165),	  
anti-­‐β5	  (PW8895),	  anti-­‐β1i	  (PW8840,	  clone	  LMP2-­‐13),	  anti-­‐β2i	  (PW8200),	  anti-­‐β5i	  (PW8845,	  clone	  
LMP7-­‐1),	  anti-­‐PA28α	  (PW8185),	  anti-­‐Rpt2	  (PW8305)	  proteasome	  subunits	  as	  well	  as	  the	  antibody	  
against	  mono	   and	   poly-­‐ubiquitin	   conjugates	   (PW8810,	   clone	   FK2)	   were	   from	   Biomol	   (Enzo	   Life	  
Sciences	  Inc,	  Farmingdale,	  New	  York,	  USA);	  anti-­‐actin	  (sc-­‐8432)	  was	  from	  Santa	  Cruz	  Biotechnology	  
Inc	   (Dallas,	   Texas,	   US)	   and	   anti-­‐PA28β	   (2409)	   was	   from	   Cell	   Signaling	   Technology	   (Boston,	  
Massachusetts,	   US).	   OxyblotTM	   protein	   oxidation	   detection	   kit	   (S7150)	   for	   analysis	   of	   oxidized	  
proteins	   was	   from	   Chemicon	   International	   from	   Pierce	   (#78833;	   Thermo	   Fisher	   Scientific,	  
Walthman,	  MA).	   All	   the	   apparatus	   and	   reagents	   for	   SDS-­‐PAGE	   and	  western	   blotting	   (WB),	   anti-­‐
mouse	  and	  -­‐rabbit	  horseradish	  peroxidise-­‐conjugated	  secondary	  antibodies	  and	  the	  QuantityOne	  
software	  were	   from	  Bio-­‐Rad	   (Hercules,	  CA,	  US).	  ECL	   reagent	   (sc-­‐2048,	  Santa	  Cruz	  Biotechnology	  
Inc),	  Hyperfilm	  ECL	  sheets	  (GEH28906837,	  GE	  Healthcare,	  Chalfont	  St.	  Giles,	  UK)	  and	  Development	  
and	  Fixer	  processing	  (Kodak	  P7042	  and	  P7167,	  Sigma)	  were	  used	  for	  the	  detection	  of	  immunoblot	  
staining.	  
For	   immunohistochemistry,	   EnVision	   Plus	   System	   HRP	   Labelled	   polymer	   (anti-­‐mouse,	  
K4003;	  anti-­‐rabbit	  K4001)	  and	  3',3'	  Diaminobenzidine	  Substrate	  Chromogen	  System	  (K3468)	  from	  
Dako,	  (Glostrup,	  Denmark)	  were	  used.	  
RNeasy	  mini-­‐kit	  (74104,	  QIAGEN,	  Germany)	  was	  used	  to	  extract	  RNA	  from	  skeletal	  muscle	  
cell	  pellets,	  while	  miRNA	  isolation	  kit	  (AM1560,	  Ambion,	  US)	  was	  used	  for	  the	  extraction	  of	  total	  
RNA	   from	   skeletal	  muscle	   tissue.	  UV	   light	   transilluminator	   (Gel	  Doc	  2000,	  Bio-­‐Rad)	  was	  used	   to	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analyze	   extracted	   RNA.	   SuperScript	   III	   Reverse	   Transcriptase	   (18080,	   Invitrogen,	   US),	   random	  
primers	  and	  dNTPs	  were	  used	  for	  cDNA	  synthesis	  from	  total	  RNA	  of	  skeletal	  muscle	  tissue.	  MESA	  
Blue	   qPCR	   MasterMix	   Plus	   for	   SYBR®	   Assay	   No	   ROXsolution	   (RT-­‐SY2X-­‐06+NRWOU,Eurogentec,	  
Belgium)	   was	   used	   for	   the	   quantitative	   expression	   analysis	   of	   proteasome	   subunits	   in	   skeletal	  
muscle	  tissue.	  	  
Primers	   were	   designed	   on	   the	   genomic	   sequence	   present	   in	   the	   Genbank	   database	  
(National	   Center	   for	   Biotechnology	   Information,	   NCBI)	   and	   by	   using	   the	   Primer-­‐BLAST	   tool.	  
Instrument	   Rotor	   Gene-­‐Q	   (R0610137,	   QIAGEN,	   Hilden	   Germany)	   was	   used	   for	   the	   quantitative	  
analysis	  of	  mRNA	  of	  proteasome	  subunits.	  
Immunoplate	  Nunc	  Maxisorp	  (YO-­‐01928-­‐08,	  Thermoscientific,	  US),	  anti-­‐α6	  (PW8100,	  Enzo	  
Lifesciences),	   rabbit	   polyclonal	  Ab	   clone	  K42	   (produced	  at	   the	   Institute	  of	  Biochemistry	  Charité,	  
Berlin	   Germany),	   peroxidase-­‐conjugated	   goat	   anti-­‐rabbit	   IgG	   (111-­‐035-­‐003,	   Jackson	  
ImmunoResearch,	   West	   Grove,	   Chester	   County,	   PA,	   US),	   tetramethylbenzidine	   (T0440,	   Sigma-­‐
Aldrich,	  US)	  were	  used	  to	  perform	  ELISA	  assay.	  All	  the	  other	  solutions	  were	  home	  made.	  
	  
3.2	  HUMAN	  SAMPLE	  BIOBANK	  	  
3.2.1	  STUDY	  OF	  HUMAN	  LIVER	  
Human	  liver	  specimens	  from	  organ	  used	  for	  transplantation	  were	  collected	  in	  the	  context	  
of	   the	  PRIN08	  project	   “Pretransplant	   liver	   biological	   age	   and	   age-­‐mismatch	  between	  donor	   and	  
recipient	  as	  new	  predictors	  of	  transplant	  outcome”	  with	  the	  collaboration	  of	  Professor	  Gian	  Luca	  
Grazi	  .The	  study	  was	  approved	  by	  the	  local	  Ethical	  Committee	  at	  S.	  Orsola-­‐Malpighi	  Hospital	  (2008,	  
June	  26th	  code:	  44/2008/O/Tess).	  Liver	  biopsies	  were	  obtained	  in	  the	  framework	  of	  the	  protocol	  of	  
donor-­‐recipient	  allogenic	  liver	  graft	  performed	  at	  General	  Surgery	  and	  Transplant	  Unit	  (S.	  Orsola-­‐
Malpighi	   Hospital,	   Bologna,	   Italy)	   between	   2008	   and	   2010	   from	   heart-­‐beating	   donors	   before	  
engraftment.	  Fifty-­‐six	  samples	  were	  used	  in	  the	  present	  studies;	  age	  and	  gender	  distribution	  of	  the	  
donors	  are	  summarised	  in	  table	  1.	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Liver	  specimens	  	  
of	  donors	  
	   	   	  





	  ≥70	  years	  
Number	  of	  samples	   9	   31	   16	  
Donor	  gender	   0F-­‐9M	   17F-­‐14M	   6F-­‐10M	  







Table	  1.	  Age	  and	  gender	  distribution	  of	   the	   liver	  biopsies	  collected	   in	   the	  context	  of	  donor-­‐recipient	  allogenic	  graft	  
and	  analyzed	  in	  the	  study.	  M=male	  donors;	  F=female	  donors;	  SD=standard	  deviation.	  
	  
Pre-­‐transplant	  liver	  biopsy	  was	  performed	  in	  young	  donors	  with	  some	  alterations	  in	  serum	  
liver	  function	  test	  or	  in	  presence	  of	  obesity	  and	  other	  metabolic	  diseases,	  as	  well	  as	  virtually	  in	  all	  
elderly	  donors	  (≥70	  years).	  
The	  biopsies	  were	  subdivided	  according	  to	  the	  age	  of	  the	  donor	  in	  three	  groups	  (age	  group	  
1:	  ≤40	  years;	  age	  group	  2:	  41-­‐70	  years;	  age	  group	  3:	  ≥70	  years)	  on	  the	  basis	  of	  previous	  literature	  
(Vo	  et	  al.	  2011).	  
	  
3.2.2	  STUDY	  OF	  HUMAN	  SKELETAL	  MUSCLE	  
The	   samples	   analyzed	  were	   collected	  within	   the	   framework	  of	   the	   FP7	  European	  project	  
‘’MYOAGE-­‐Understanding	  and	  Combating	  Age-­‐related	  Muscle	  weakness’’,	  Coordinator	  Prof.	  Gillian	  
Butler-­‐Browne	  we	  were	  involved	  in.	  
Two	  different	  groups	  of	  subjects	  were	  recruited:	  patients	  with	  limited	  lower	  limb	  mobility	  
impairment	   (LLMI	   patients)	   and	   healthy	   volunteers	   (McPhee	   et	   al.,	   2013).	   The	   study	   was	  
approved	  by	  the	  local	  ethic	  committees	  of	  the	  operative	  units	  (as	  far	  as	  the	  Bologna	  Unit:	  Rizzoli	  
Hospital	  ethical	  committee,	  2010,	  April	  26,	  code	  10823,	  class	  07-­‐03)	  and	  written	  informed	  consent	  
for	  study	  procedures	  was	  obtained	  from	  patients	  and	  volunteers.	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LLMI	  patients	  undergoing	  surgery	  for	  hip	  replacement	  at	  Rizzoli	  Hospital	  in	  Bologna,	  were	  
included.	   Patients	   groups	   were	   matched	   for	   biopsy	   location	   and	   chronological	   age.	   Exclusion	  
criteria	   were:	   chronic	   kidney	   diseases	   or	   liver	   pathologies,	   bleeding	   disorders,	   severe	   diabetes	  
mellitus,	   rheumatic	   disease	   other	   than	   osteoarthritis,	   neuromuscular	   disorders,	   malignancies,	  
systemic	  infections,	  chronic	  steroid	  use,	  psychological	  problems,	  history	  of	  alcohol	  or	  drug	  abuse,	  
evidence	  of	  prior	  surgery	  that	  involves	  the	  hip.	  
Additionally,	  biopsies	  of	  human	  vastus	   lateralis	   (v.	   lateralis)	  muscle	  were	  collected	  during	  
surgery	  (2	  specimens	  of	  450	  mg	  for	  each	  subject),	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  
Numbers	  and	  distribution	  of	  LLMI	  patients	  studied	  are	  reported	  in	  table	  2.	  
	  
Muscle	   specimens	  
of	  LLMI	  patients	  
	   	   	  
Age	  group	   ≤40	  years	   41-­‐70	  years	   ≥70	  years	  
Number	  of	  samples	  	   15	   26	   16	  
Donor	  gender	   6F-­‐9M	   12F-­‐14M	   10F-­‐6M	  
Mean	  age±SD	   32.8	  ±	  4.6	   55.6	  ±	  8.1	   85.2	  ±	  8	  
	  
Table	  2.	  Bioptic	  specimens	  of	  human	  vastus	  lateralis	  muscle	  used	  for	  molecular	  investigations.	  M=male	  donors;	  
F=female	  donors;	  SD=standard	  deviation.	  
	  
The	   healthy	   group,	   was	   composed	   by	   young	   (≤40	   years),	   and	   cognitively	   active	   elderly	  
volunteers	  (≥70	  years)	  without	  clinical	  signs	  of	  muscle	  weakness,	  recruited	  in	  different	  European	  
centers,	  including	  the	  University	  of	  Leiden	  (The	  Netherlands),	  whose	  samples	  were	  analyzed	  in	  the	  
present	  study.	  The	  subjects	  considered	  eligible	  for	  the	  study	  were	  found	  to	  be	  healthy	  on	  the	  basis	  
of	   different	   parameters,	   such	   as	   clinical	   history,	   including	   a	   standard	   questionnaire	   on	   the	  
activities	   of	   daily	   living,	   physical	   examination	   and	   screening	   tests.	   Exclusion	   criteria,	   in	   order	   to	  
select	  healthy	  participants	  and	  minimize	  the	  confounding	  effect	  of	  diseases	  on	  muscle	  mass,	  were	  
as	  follows:	  living	  situation	  dependent	  on	  others,	  inability	  to	  walk	  a	  distance	  of	  250m,	  presence	  of	  
comorbidity	   (neurological	  disorders,	  metabolic	   and	   rheumatic	  diseases),	   coagulation	   syndromes,	  
use	  of	  specific	  drugs	  (immunosuppressive	  drugs,	   insulin,	  anticoagulation),	   immobilization	  for	  one	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week	  during	   last	  three	  months	  and	  orthopedic	  surgery	  during	  the	   last	  two	  years	  or	  still	  cause	  of	  
functional	  limitations.	  Subjects	  young	  and	  old	  involved	  in	  competitive	  sports	  and	  master	  athletes	  
were	  also	  excluded.	  
Small	   biopsies	   from	   v.	   lateralis	   skeletal	  muscle	   (150	  mg	   for	   subject)	  were	   obtained	  with	  




of	  healthy	  subjects	  
	   	  
Age	  group	   ≤40	  years	   ≥70	  years	  
Number	  of	  samples	   5	   9	  
Donor	  gender	   5F	   9F	  
Mean	  age±SD	   21.4	  ±	  4.3	   75.6	  ±	  2.7	  
	  
Table	  3.	  Muscle	  specimens	  of	  healthy	  subjects	  used	  for	  molecular	  investigations.	  M=male	  donors;	  F=female	  donors;	  
SD=standard	  deviation.	  
	  
Additionally,	  satellite	  cells	  were	  isolated	  from	  muscle	  biopsies	  of	  young	  and	  elderly	  healthy	  
subjects	   and	   cultured	   in	   vitro,	   at	   different	   oxygen	   tension	   (5%	   and	   21%)	   at	   the	   University	   of	  
Namur.	  Frozen	  pellets	  of	  myoblasts	  were	  provided	  for	  molecular	  investigations	  (table	  4).	  
	  
Myoblasts	  	  
of	  healthy	  subjects	  
	   	  
Age	  group	   ≤40	  years	   ≥70	  years	  
Number	  of	  samples	   3	   5	  
	  
Table	  4.	  Myoblast	  cell	  cultures	  analyzed.	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Finally,	  peripheral	  blood	  samples	  (40	  ml	  for	  each	  subject)	  from	  LLMI	  patients	  (table	  5)	  and	  
healthy	   subjects	   (table	  6)	  were	  collected	  before	   surgery	  and	   then	  processed	   in	  order	   to	  obtain:	  
plasma,	  serum,	  peripheral	  blood	  mononuclear	  cells	  and	  granulocytes.	  
	  
LLMI	  patients	  	  serum	   	   	   	  
Age	  group	   ≤40	  years	   41-­‐69	  years	   ≥70	  years	  
Number	  of	  samples	   11	   15	   20	  
Donor	  gender	   5F-­‐6M	   5F-­‐10M	   14F-­‐6M	  
Mean	  age±SD	   33.7	  ±	  5.2	   55.8	  ±	  8.3	   84.2	  ±	  7.7	  
	  
Table	  5.	  Serum	  of	  LLMI	  patients	  collected	  and	  analyzed.	  M=male	  donors;	  F=female	  donors;	  SD=standard	  deviation.	  
	  
Healthy	   subjects	  
serum	  
	   	  
Age	  group	   ≤40	  years	   ≥70	  years	  
Number	  of	  samples	   33	   67	  
Donor	  gender	   19F-­‐14M	   31F-­‐36M	  
Mean	  age±SD	   21.6	  ±	  2.8	   74.1	  ±	  3	  
	  
Table	  6.	  Serum	  from	  healthy	  subjects	  collected	  at	  University	  of	  Leiden	  and	  analyzed	  in	  this	  study.	  M=male	  donors;	  
F=female	  donors;	  SD=standard	  deviation.	  
	  
3.3	  HISTOLOGY	  AND	  IMMUNOHISTOCHEMISTRY	  
Liver	   biopsies	   were	   collected	   in	   54	   cases	   for	   routine	   evaluation	   of	   graft	   suitability	   for	  
transplantation	   on	   frozen	   sections,	   following	   the	   pre-­‐transplant	   protocol	   for	   transplant	   safety	  
(Fiorentino	  M,	  et	  al.	   2009).	   In	  2	   cases	  no	   liver	  biopsy	  was	  performed.	  After	  evaluation,	  biopsies	  
were	  formalin	  fixed,	  paraffin	  embedded	  and	  routinely	  processed.	  Slices	  of	  two-­‐µm-­‐thick	  were	  cut	  
and	   stained	   with	   Haematoxylin-­‐Eosin.	   The	   following	   histological	   parameters	   were	   collected:	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occurrence	  of	  portal	  inflammation	  and/or	  lobular	  inflammation,	  fibrosis	  (according	  to	  Ishak	  et	  al.,	  
1995),	   arteriolar	   myointimal	   thickening,	   biliocytes	   regression,	   occurrence	   and	   amount	   of	  
cholestasis,	   polymorphism	   of	   hepatocytes,	   sinusoid	   dilatation,	   percentage	   of	   steatosis	   (both	  
micro-­‐	  and	  macro-­‐vesicular),	  lipofuscin	  accumulation.	  
Immunohistochemistry	   (IHC)	   for	   specific	   antibodies	  versus	   β1,	  β1i,	   β5i,	   and	  PA28α	  proteasomes	  
subunits,	  was	  performed	  in	  54	  cases	  as	  previously	  described	  (Mishto	  et	  al.,	  2011).	  The	  nuclear	  and	  
cytoplasmic	  intensity	  of	  the	  signal	  to	  the	  antibody	  was	  assessed	  semi-­‐quantitatively	  in	  0	  (absent),	  
1+	  (mild/average)	  and	  2+	  (strong),	  as	  previously	  described	  (Vasuri	  et	  al.,	  2010).	  
Biopsies	   of	   skeletal	  muscle	   were	   processed	  with	   the	   same	   experimental	   protocol	   above	  
described.	   The	   obtained	   sections	   were	   analyzed	   for	   specific	   antibodies	   versus	   β1,	   β1i,	   β5i	  
proteasomes	  subunits.	  
	  
3.4	  PREPARATION	  OF	  PROTEIN	  CRUDE	  EXTRACTS	  	  
Protein	  crude	  extracts	  were	  prepared	  as	  previously	  described	  (Schmidt	  et	  al.,	  2006;	  Vasuri	  
et	  al.,	  2010).	  An	  amount	  of	  50	  milligrams	  of	  liver	  frozen	  tissue	  was	  lysed	  in	  TEAD	  buffer	  (Tris-­‐HCl	  
20	   mM	   pH=7.5,	   EDTA	   1mM,	   NaN3	   1mM,	   DTT	   1mM),	   homogenized	   using	   a	   motor-­‐driven	  
homogenizer	   and	   centrifuged	   at	   25000	   g	   for	   1h	   at	   4°C.	   The	   supernatant	   containing	   the	   soluble	  
proteins	  (crude	  extract)	  was	  collected,	  quantified	  by	  Bradford’s	  method	  and	  stored	  at	  -­‐80°C.	  
The	  same	  protocol	  was	  used	  to	  prepare	  crude	  protein	  extracts	   from	  about	  70-­‐100	  mg	  of	  
frozen	  skeletal	  muscle	  biopsies,	  (Dahlmann	  et	  al.,	  2001)	  and	  from	  pellets	  of	  about	  3*106	  myoblast	  
cells.	  
	  
3.5	  20S	  PROTEASOME	  PURIFICATION	  
Purification	   of	   20S	   liver	   proteasomes	   was	   performed	   similar	   as	   described	   elsewhere	  
(Schmidt	  et	   al.,	   2006)	  at	   the	   Institute	  of	  Biochemistry,	  Charitè,	  Berlin.	  Briefly,	   two	  pools	  of	   liver	  
specimens	  from	  adult	   (n=4;	  mean	  age	  48±4.5	  years)	  and	  old	  (n=3;	  mean	  age	  85±3.5	  years)	  male	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donors	   were	   homogenized	   in	   TEAD	   buffer,	   as	   above	   described	   and	   the	   not	   dissolved	   material	  
pelleted	  by	  centrifugation	  for	  20	  minutes	  at	  15000	  g	  and	  4°C.	  Proteins	  in	  the	  supernatant	  fraction	  
were	   loaded	   onto	   a	  DEAE-­‐Toyopearl	   column	   equilibrated	  with	   TEAD	   buffer	   and	   bound	   proteins	  
then	  eluted	  with	  a	  linear	  gradient	  of	  0-­‐0.5	  M	  NaCl/TEAD	  buffer.	  Proteasome	  containing	  fractions	  
were	  pooled	  and	  concentrated	  by	  adding	  (NH4)2SO4	  to	  obtain	  a	  final	  concentration	  of	  75%	  (w/v)	  
respect	   to	   the	   salt.	   Proteins	  were	   spun	   down	   and	   then	   dissolved	   in	   TEAD	  buffer	   before	   loaded	  
onto	  a	  Superose	  6	  gel	  filtration	  column	  for	  chromatography	  in	  TEAD	  buffer	  in	  a	  FPLC	  System	  (GE	  
Healthcare).	  Fractions	  containing	  20S	  proteasome	  were	  pooled	  and	  further	  purified	  by	  subsequent	  
chromatography	   on	   Mono	   Q	   and	   Phenyl-­‐Superose.	   Finally,	   proteasomes	   were	   dialyzed	   against	  
TEAD	  buffer.	  
	  
3.6	  PROTEASOME	  ACTIVITY	  ASSAY	  
Proteasome	  activities	  were	  measured	   in	  crude	  protein	  extracts	  of	   liver	  and	  LLMI	  patients	  
skeletal	  muscle	  and	  in	  purified	  20S	  liver	  proteasome	  by	  using	  the	  fluorogenic	  substrates	  Suc-­‐LLVY-­‐
MCA,	  Bz-­‐VGR-­‐MCA	  and	  Z-­‐LLE-­‐MCA,	  specific	  for	  chymotryptic-­‐,	  tryptic-­‐,	  and	  caspase-­‐like	  activities,	  
as	  already	  described	  (Dahlmann	  et	  al.,	  2000;	  Mishto	  et	  al.	  2006a).	  An	  amount	  of	  10	  µg	  of	  crude	  
protein	   extracts	   of	   liver	   proteins,	   20	   µg	   of	   skeletal	   muscle	   proteins	   respectively	   and	   0,1	   µg	   of	  
purified	  20S	  proteasome	  were	  incubated	  in	  presence	  of	  200µM	  of	  Suc-­‐LLVY-­‐MCA	  and	  Z-­‐LLE-­‐MCA	  
and	  600	  µM	  of	  Bz-­‐VGR-­‐MCA	  in	  TEAD	  buffer,	  at	  37°C	  for	  1h,	   in	  a	  96-­‐well	  plate.	  The	  enzymatically	  
released	   MCA	   was	   measured	   by	   fluorometer	   at	   360	   nm	   excitation	   and	   460	   nm	   emission.	  
Proteasome	  activity	  was	  expressed	  as	  specific	  activity	  (nmol	  of	  free	  MCA/min	  for	  mg	  protein).	  The	  
specificity	  of	   the	   reaction	  was	  assessed	  measuring	   the	   fluorescence	   released	   in	  presence	  of	   the	  
proteasome	  inhibitor	  epoxomycin	  (10	  µM).	  
	  
3.7	  WESTERN	  BLOTTING	  ANALYSIS	  
Western	  blotting	  analysis	  of	  protein	  crude	  extracts	  from	  liver	  and	  skeletal	  muscle	  as	  well	  as	  
purified	   20S	   liver	   proteasomes	   was	   performed	   as	   previously	   described	   (Mishto	   et	   al.,	   2006a;	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Bellavista	  et	  al.,	  2008).	  An	  amount	  of	  40	  μg	  of	  crude	  extracts	  or	  0.5	  μg	  of	  20S	  purified	  proteasomes	  
were	   separated	   in	   a	   16%	  polyacrylamide	   gel	   and	  were	   transferred	   to	   a	  nitrocellulose	   filter.	   The	  
proteasome	   subunits	   were	   detected	   using	   primary	   antibodies	   above	   described,	   overnight	  
incubation	   at	   4°C,	   shaking	   in	   TBS	   solution	  with	   5%	  of	   non-­‐fat	   dry	  milk	   and	  0.01%	  of	   Tween	  20.	  
Densitometry	  analysis	  (INT*mm2)	  of	  the	  band	  corresponding	  to	  each	  subunit	  was	  performed	  using	  
QuantityOne	  Software.	  Each	  experiment	  was	  repeated	  and	  we	  considered	  the	  mean	  of	  results.	  In	  
order	  to	  compare	  samples	  loaded	  in	  different	  gels,	  a	  liver	  and	  a	  skeletal	  muscle	  samples	  were	  used	  
as	  internal	  control	  and	  loaded	  on	  each	  gel	  of	  liver	  and	  muscle	  sets	  respectively.	  Data	  are	  reported	  
as	   relative	  content	  between	   the	   samples	  and	   the	  control’s	  band	  density.	  Protein	   isoloading	  was	  
assessed	  by	  SDS-­‐PAGE	  and	  Coomassie	  dye	  staining.	  
	  
3.8	  OXIDIZED	  PROTEINS	  AND	  POLY-­‐UBIQUITIN	  CONJUGATES	  DETECTION	  
The	   content	   of	   carbonyl	   groups,	   representative	   of	   oxidative	   protein	   modification,	   was	  
determined	  in	  15	  μg	  of	  protein	  crude	  extracts	  from	  liver	  and	  LLMI	  patient	  skeletal	  muscle	  obtained	  
from	  donors	  of	  different	  age	  by	  using	  the	  OxyblotTM	  protein	  oxidation	  detection	  kit	  according	  to	  
manufacturer’s	  instruction,	  SDS-­‐PAGE	  and	  immunoblotting	  analysis.	  
Levels	   of	   poly-­‐ubiquitin	   conjugated	   proteins	   were	   measured	   in	   20	   μg	   of	   protein	   crude	  
extracts	  of	  the	  above	  described	  samples	  by	  SDS-­‐PAGE	  and	  immunoblotting	  analysis	  coupled	  to	  the	  
FK2	  monoclonal	  antibody,	  specific	  for	  K29-­‐,	  K48-­‐,	  and	  K63-­‐	  linked	  conjugates.	  
	  
3.9	  2D-­‐PAGE	  OF	  20S	  PROTEASOMES	  
Purified	   20S	  proteasomes	   from	   liver	   biopsies	  were	  precipitated	  with	   an	   equal	   volume	  of	  
ethanol	   and	   then	   subjected	   to	   two-­‐dimensional	   non-­‐equilibrium	   pH	   polyacrylamide	   gel	  




3.10	  REAL-­‐TIME	  POLYMERASE	  CHAIN	  REACTION	  
To	  analyze	  the	  expression	  of	  a	  subset	  of	  target	  genes	  coding	  for	  proteasomes	  subunits,	  in	  
skeletal	  muscle	  biopsies,	  we	  adopted	  the	  qPCR	  technique.	  We	  extracted	  RNA	  from	  C520	  and	  T2	  
cell	   lines	   as	   positive	   and	   negative	   controls	   for	   immunoproteasome	   respectively.	   C520	   is	   a	  
lymphoblastoid	   cell	   line	   obtained	   from	   EBV-­‐immortalyzed	   B	   lymphocytes,	   expressing	  
predominantly	   immunoproteasome,	  whereas	   the	   T2	   cell	   line	   is	   a	   T-­‐B	   lymphoblast	   hybrid	   (ATCC	  
CRL-­‐1992)	   carrying	  a	  deletion	   in	   the	   region	  of	   chromosome	  6	  encoding	   for	  β1i,	  β5i,	   TAP1,	  TAP2	  
genes	  and	  therefore	  this	  cell	  line	  expresses	  only	  the	  constitutive	  proteasome.	  
	  
3.10.1	  RNA	  EXTRACTION	  FROM	  CELL	  LINES	  	  
We	  extracted	  RNA	   from	  cell	   pellets	  by	  using	  RNeasy	  mini-­‐kit	   (QIAGEN).	  According	   to	   the	  
protocol	   including	   in	   the	  kit,	  we	   firstly	  added	  600ul	  of	  RTL	   lysis	  buffer	   for	  an	  amount	  of	   cells	  of	  
5*106-­‐1*107.	   The	   obtained	   RNA	   was	   stored	   at	   -­‐80°C.	   The	   quality	   of	   products	   was	   assessed	   by	  
electrophoresis	  analysis	  in	  a	  1%	  agarose	  gel,	  to	  verify	  the	  characteristic	  pattern	  of	  rRNAs.	  
	  
3.10.2	  RNA	  EXTRACTION	  FROM	  MUSCLE	  BIOPSIES	  
The	  extraction	  of	   total	  RNA	   from	  biopsies	  of	   skeletal	  muscle	   tissue	  was	  performed	  using	  
the	  miRNA	  isolation	  kit	  (Ambion),	  according	  to	  the	  manufacture	  indications	  reported	  in	  the	  same	  
kit.	  Approximately	  40	  mg	  of	  each	  biopsy	  was	  lysed	  by	  adding	  a	  lysis	  buffer	  in	  a	  volume	  equal	  to	  10	  
times	  the	  weight	  of	  the	  sample	  and	  by	  using	  a	  motor-­‐driven	  homogenizer.	  Products	  of	  extraction	  
were	   treated	   with	   DNase	   enzyme	   to	   remove	   all	   DNA,	   that	   might	   interfere	   with	   subsequent	  
analysis.	  The	  RNA	  was	  stored	  at	  -­‐80°C.	  
	  
3.10.3	  RNA	  QUANTIFICATION	  
	  RNA	   integrity	  was	  assessed	  by	  electrophoresis	  analysis	   in	  a	  1%	  agarose	  gel	  and	  by	  using	  
the	   UV	   light	   transilluminator	   (Bio-­‐Rad).	  We	   evaluated	   the	   presence	   of	   bands	   corresponding	   to	  
ribosomal	  RNA:	  28S,	  18S	  and	  5S.	  The	  RNA	  was	  analyzed	  spectrophotometrically	  to	  determine	   its	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concentration	  and	  to	  highlight	  possible	  contamination	  by	  phenol	  or	  protein.	  The	  proteins,	  which	  
are	  the	  main	  contaminants	  of	  the	  extracts,	  are	  measured	  directly	  at	  280	  nm,	  while	  nucleic	  acids	  at	  
260	   nm.	   The	   A260/A280	   ratio	   was	   used	   to	   estimate	   the	   purity	   of	   the	   RNA,	   typically	   in	   pure	  
preparations	  of	  nucleic	  acids	  this	  ratio	  is	  1.8	  for	  DNA	  and	  2.0	  for	  RNA.	  Instead,	  the	  absorbance	  at	  
230nm	   indicates	   the	   contamination	   of	   the	   sample	   due	   to	   substances	   such	   as	   carbohydrates,	  
phenols,	   aromatic	   compounds	   or	   peptides.	   In	   the	   case	   of	   pure	   samples	   the	   A260/A230	   ratio	  
should	  be	  approximately	  2.2.	  Preparations	  in	  which	  the	  mentioned	  relationships	  differ	  significantly	  
from	  those	  of	  pure	  preparations	  are	  index	  of	  contamination	  and	  this	  makes	  the	  estimation	  of	  the	  
concentration	  of	  obtained	  RNA	  less	  accurate.	  
	  
3.10.4	  cDNA	  SYNTHESIS	  
For	  cDNA	  synthesis,	  750	  ng	  of	  total	  RNA	  were	  inversely	  transcribed	  using	  the	  SuperScript	  III	  
Reverse	  Transcriptase	   (Invitrogen).	  For	  each	  RNA	  sample	  we	  added	  0.5	  μl	  of	   random	  primers	   (3	  
μg/µL),	  1μl	  of	  dNTPs	  (10	  mM	  each)	  and	  sterile	  water	  up	  to	  12.5	  μl.	  The	  mixture	  was	  incubated	  for	  
5'	  at	  65°C	  to	  denature	  the	  RNA	  and	  activate	  the	  primers.	  Subsequently,	  we	  added	  4	  μl	  of	  the	  First-­‐
Strand	  Buffer	  5X,	  1	  μl	  of	  DTT	  0,1	  M,	  0.5	  μl	  of	  the	  SuperScript	  Reverse	  Transcriptase	  (200	  units/μl)	  
and	  sterile	  water	  to	  reach	  20	  µl	  of	  volume.	  The	  thermal	  profile	  of	  synthesis	  was:	  25°C-­‐5',	  50°C-­‐50',	  
72°C-­‐15',	  4°C.	  The	  obtained	  cDNA	  was	  diluted	  1:10	  and	  stored	  at	  -­‐80°C.	  
	  
3.10.5	  qPCR	  
Quantitative	   analysis	   of	   proteasome	   subunits	   was	   performed	   by	   Real-­‐time	   Polymerase	  
Chain	  Reaction	  (PCR	  quantitative	  relative	  analysis).	  The	  gene	  of	  the	  glyceraldehyde-­‐3-­‐phosphate-­‐
dehydrogenase	   (GAPDH)	  was	  used	  as	   a	  housekeeping,	   to	  normalize	   the	   levels	  of	   starting	   cDNA.	  
The	   reaction	   was	   performed	   using	   the	   MESA	   Blue	   qPCR	   MasterMix	   Plus	   for	   SYBR®	   Assay	   No	  
ROXsolution	   (Eurogentec)	  according	   to	   the	  protocol	  of	   the	  company,	   in	  association	  with	  specific	  
primers	  below	  described	  (table	  7).	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Primer	   Length	  	   Tm	   Sequence	  5’à3’	  	  
Gapdh	  For	   24	   60°C	   CATTGCCCTCAACGACCACTTTGT	  	  
Gapdh	  Rev	   26	   60	  °C	   TCTCTCTCTTCCTCTTGTGCTCTTGC	  	  
α6	  For	   20	   53°C	   AATTCTCCATGTTGACAACC	  
α6	  Rev	   20	   55°C	   AGATACAAGACGAGACACAG	  
β1	  For	   20	   59°C	   AGACTGGGAAAGCCGAGAAG	  
β1	  Rev	   20	   57°C	   GCAGAAAATGCGGTCGTGAA	  
Lmp2	  For	   22	   60°C	   CGTTGTGATGGGTTCTGATTCC	  
Lmp2	  Rev	   23	   61°C	   GACAGCTTGTCAAACACTCGGTT	  
Lmp7	  For	   18	   61°C	   GCAGTGGATTCTCGGGCC	  
Lmp7	  Rev	   24	   63°C	   GCCAAGCAGGTAAGGGTTAATCTC	  
Pa28β	  For	   15	   59°C	   GTGCGCCTGAGCGGG	  
Pa28β	  Rev	   23	   61°C	   TCAGCCTCCTGGAAAAGATTCTG	  
α4	  For	   20	   65°C	   CCGCCGGCATGAGCTACGAC	  
α4	  Rev	   21	   66°C	   CGCGGTCGAGCCCTTCTTGAC	  
	  
Table	  7.	  Primers	  used	  in	  qPCR.	  
	  
The	  amplification	  conditions	  used	  in	  the	  standard	  PCR	  reaction	  were	  the	  following:	  a	  step	  
of	  pre-­‐incubation	  at	  95°C	  for	  3',	  followed	  by	  35	  cycles	  of	  denaturation	  at	  93°C	  for	  15",	  annealing	  
step	  at	  60°C	  for	  20"	  and	  an	  extension	  step	  at	  72°C	  for	  1'.	  The	  quality	  of	  products	  was	  verified	  by	  
electrophoresis	  analysis	  in	  a	  2%	  agarose	  gel.	  
Once	   assessed	   the	   specificity	   of	   primers,	   the	   amplification	   of	   transcripts	  was	   performed	  
with	   the	   instrument	  Rotor	  Gene-­‐Q	   (QIAGEN)	  under	   the	   following	  conditions:	  5	  μl	  of	  Master	  Mix	  
2X,	  0.15	  μl	  of	  Forward	  Primer	  (10	  μM),	  0.15	  μl	  of	  Reverse	  Primer	  (10	  μM),	  1	  μl	  of	  cDNA	  (diluted	  
1:10),	  3.7	  μl	  of	  H2O	  milli-­‐Q.	  
The	  thermal	  profile	  was:	  95°C	  for	  5',	  followed	  by	  45	  cycles	  at	  95°C	  for	  15",	  60°C	  for	  1'	  and	  
72°C	  for	  20".	  At	  the	  end	  of	  the	  polymerase	  reaction,	  a	  melting	  cycle	  of	  progressive	  denaturation	  
was	   performed	   to	   confirm	   the	  presence	  of	   specific	   amplicons	   in	   the	   reaction.	  All	   samples	  were	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amplified	  in	  duplicate;	  negative	  controls,	  without	  the	  template	  cDNA,	  were	  used	  in	  each	  assay.	  A	  
sample	   was	   used	   as	   internal	   calibrator	   in	   each	   run.	   The	   analysis	   of	   the	   results	   was	   performed	  
according	   to	   the	  comparative	  method	  with	  evaluation	  of	   the	   threshold	  cycle	   (Ct).	  The	  ΔCt	  value	  
was	  calculated	  by	  subtracting	  the	  Ct	  value	  of	  housekeeping	  gene	  from	  the	  Ct	  value	  of	  the	  target	  
gene,	  for	  a	  sample	  used	  as	  calibrator	  and	  for	  all	  samples.	  The	  ΔΔCt	  value	  was	  then	  calculated	  by	  
subtracting	  the	  ΔCt	  value	  of	  calibrator	  from	  the	  ΔCt	  of	  each	  sample.	  In	  the	  ΔΔCt	  method	  to	  obtain	  
a	  correct	  quantification,	  the	  efficiencies	  of	  PCR	  of	  the	  target	  gene	  and	  the	  reference	  gene	  should	  
be	  close	  to	  2	  (maximum	  efficiency)	  or	  1.8	  (good	  efficiency).	  The	  relative	  expression	  level	  was	  then	  
determined	  by	   calculating	   this	   expression	   [1.8(-­‐ΔΔCt)],	  which	   indicates	   how	  many	   times,	  more	   or	  
less,	  the	  gene	  of	   interest	   is	  expressed	   in	  the	  analyzed	  sample	  compared	  to	  the	  calibrator	  (Pfaffl,	  
2001).	  
	  
3.11	  ELISA	  ASSAY	  
To	  detect	  circulating	  proteasomes	  (c-­‐proteasomes)	   in	  serum	  of	  LLMI	  patients	  and	  healthy	  
subjects	  we	   adopted	   an	   Enzyme-­‐Linked	   Immunosorbent	   Assay	   (ELISA)	   (Mueller	   et	   al.,	   2012).	   In	  
particular,	  we	  performed	   in	  our	   laboratory	  an	  heterogeneous,	  direct	  and	  non-­‐competitive	  ELISA	  
assay	  as	  below	  described.	  
	  
3.11.1	  COATING	  
In	  the	  first	  step,	  the	  antibody	  specific	  for	  the	  analyte	  of	  interest	  was	  linked	  to	  the	  bottom	  
of	  a	  96	  well	  plate,	  the	  plate	  Nunc	  Maxisorp	  (Thermoscientific),	  in	  order	  to	  create	  a	  solid	  phase	  of	  
capture.	  We	  used	  a	  monoclonal	  antibody	  versus	  α6	  protesomes	  subunit	  (Enzo	  Lifesciences)	  diluted	  
1:1500	  in	  sterile	  PBS	  at	  pH	  7.4	  (100ul/well),	  incubated	  overnight	  at	  4°C,	  no	  shaking.	  
	  
3.11.2	  BLOCKING	  
In	  this	  step,	  we	  washed	  the	  plate	  5	  times	  with	  300	  μL	  of	  PBS-­‐T	  0.1%	  and	  we	  added	  300	  µL	  
of	   PBS-­‐T	   0.1%-­‐BSA	   1%	   (blocking	   buffer)	   to	   each	   well	   to	   prevent	   non-­‐specific	   bindings	   of	   the	  
39	  
	  
analyte.	  Then	  we	   incubated	   the	  plate	   for	  6	  h	   in	  shaking	  at	   room	  temperature	  and	  subsequently	  
washed	  the	  plate	  as	  above	  described.	  
	  
3.11.3	  SAMPLES	  AND	  STANDARD	  CURVE	  
To	   determine	   the	   concentration	   of	   c-­‐proteasomes	   in	   sera	   it	   was	   necessary	   to	   set	   up	   a	  
standard	   curve	  with	   20S	  purified	   proteasomes.	  We	  used	  20S	  proteasome,	   purified	   from	  human	  
lymphoblastoid	   cell	   lines	   and	   concentrated	   77	   ug/ml.	   We	   prepared	   serial	   dilutions	   of	   the	   20S	  
proteasome	   from	  0	   to	   100	   ng/ml	   (0,	   6.25,	   12.5,	   25,	   50,	   100	   ng/ml)	   in	   PBS-­‐T	   0.1%-­‐BSA	   1%	   (100	  
μl/well)	   in	   triplicate.	   Serum	   samples	  were	   diluted	   1:15	   and/or	   1:30	   in	   PBS-­‐T	   0.1%-­‐BSA	   1%	   (100	  
µl/well)	   in	   triplicate.	   In	   order	   to	   normalize	   the	   experimental	   variability,	  we	   loaded	   serum	  of	   an	  
healthy	  subject	  as	   internal	  control	   in	  each	  plate.	  The	  plate	  with	  the	  standard	  curve	  and	  samples	  
was	  incubated	  overnight	  at	  4°C,	  in	  shaking.	  
	  
3.11.4	  INCUBATION	  WITH	  ANTI-­‐CORE	  PROTEASOME	  ANTIBODY	  
The	   following	   day	   we	   washed	   the	   plate	   3	   times	   as	   above	   described	   and	   we	   added	  
polyclonal	  anti-­‐core	  proteasomes	  antibody	  (K42	  clone,	  Charité	  ’s	  laboratory	  stock),	  that	  binds	  ,	  α5,	  
α7,	   β7,	   and	  β5i	   proteasomes	   subunits.	  We	  used	   this	   antibody	  diluted	  1:750	   in	   PBS-­‐T	   0.1%	   (100	  
μl/well)	  and	  we	  incubated	  the	  plate	  for	  3h	  at	  4°C,	  in	  shaking.	  
	  
3.11.5	  INCUBATION	  WITH	  SECONDARY	  ANTIBODY	  
In	   the	   last	   step	   we	   washed	   the	   plate	   5	   times	   as	   above	   described	   and	   we	   added	   the	  
peroxidase-­‐conjugated	   anti-­‐rabbit	   IgG	   secondary	   antibody	   for	   the	   detection	   of	   the	   antigen-­‐
antibody	  complex.	  The	  antibody	  was	  diluted	  1:7500	  in	  PBS-­‐T	  0.1%	  (100ul/well)	  and	  we	  incubated	  





The	  detection	  system	  adopted	  entails	  the	  use	  of	  tetramethylbenzidine	  (TMB)	  as	  substrate	  
of	  the	  peroxidase	  enzyme.	  The	  reaction	  leads	  to	  the	  formation	  of	  a	  blue	  colored	  product,	  whose	  
intensity	   is	  proportional	  to	  the	  amount	  of	  analyte	  detected;	  subsequently	  the	  reaction	  has	  to	  be	  
stopped	   with	   an	   acid	   solution,	   that	   turns	   the	   color	   from	   blue	   to	   yellow.	   Finally	   a	   plate	   reader	  
analyzes	  the	  signal	  emitted	  at	  450nm.	  
We	   washed	   the	   plate	   5	   times	   as	   above	   described,	   we	   added	   100uL	   of	   TMB	   and	   we	  
incubated	  the	  plate	  at	  room	  temperature,	  10'	  at	  dark.	  Lastly	  the	  reaction	  was	  stopped	  with	  100	  μl	  
of	  H2SO4	  stopping	  solution	  and	  the	  absorbance	  of	  samples	  was	  measured.	  
	  
3.11.7	  DATA	  ANALYSIS	  
Taking	   into	  account	   that	  we	  used	  a	  non-­‐competitive	  ELISA,	  all	   the	  analyte	  present	   in	   the	  
samples	   is	   captured	  by	   the	  excess	  of	   antibody	  and	   revealed,	   thus	   the	   signal	   analyzed	   is	  directly	  
proportional	  to	  the	  concentration	  of	  analyte	  in	  the	  samples	  and	  the	  dose-­‐response	  curve	  is	  linear.	  
By	  analyzing	  the	  quality	  of	  the	  standard	  curve,	  our	  calibration	  curve	  of	  20S	  proteasome	  reached	  
the	  saturation	  close	  to	  the	  concentration	  of	  100	  ng/ml,	  whereby	  this	  value	  was	  eliminated	  from	  
the	  analysis.	  
We	   calculated	   the	   average	   of	   measures	   in	   triplicate	   and	   the	   analyte	   concentration	   was	  
obtained	  by	  interpolation	  on	  the	  calibration	  curve.	  	  
y=ax	  +	  b	  
where	   x	   is	   the	   concentration	  of	   the	   target	   substance	   in	   the	   sample	   to	  be	  analyzed	  and	  y	   is	   the	  
absorbance.	  
	  
3.12	  STATISTICAL	  ANALYSIS	  
Data	  were	  analyzed	  by	  one-­‐way-­‐ANOVA,	  Kruskal-­‐Wallis,	  Student’s	  t	  or	  Mann-­‐Whitney	  tests	  
to	  assess	  differences	  among	  age	  groups.	  Spearman’s	   test	  was	  applied	   to	  assess	   the	  correlations	  
between	  age	  histological	  parameters	  and	   Immunohistochemistry,	  as	  well	  as	  c-­‐proteasomes	   level	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with	   anthropometric	   parameters	   and	   cytokines	   in	   serum.	   Gender	   of	   donor	  was	   also	   taken	   into	  
consideration	  for	  analyses	  on	  liver	  and	  skeletal	  muscle	  tissue,	  as	  well	  as	  human	  serum.	  All	  values	  
are	   reported	   as	   mean	   of	   three	   independent	   experiments;	   data	   are	   presented	   as	   graphs	   box.	  
Statistical	  comparisons	  were	  performed	  using	  STATA	  software	  version	  9.0	  (Stata	  Corp.	  Texas,	  USA)	  
and	  a	  P-­‐value<0.05	  was	  considered	  as	  statistically	  significant.	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4.	  RESULTS	  ON	  HUMAN	  LIVER	  
4.1	  HISTOLOGICAL	  PROFILE	  OF	  AGED	  HUMAN	  LIVER	  
Human	  liver	  biopsies	  of	  organs	  used	  for	  transplantation	  were	  collected	  in	  the	  framework	  of	  
the	   PRIN08	   project	   “Pretransplant	   liver	   biological	   age	   and	   age-­‐mismatch	   between	   donor	   and	  
recipient	  as	  new	  predictors	  of	  transplant	  outcome”,	  which	  aimed	  to	  identify	  biomarkers	  of	  human	  
liver	   biological	   aging	   and	   not	   of	   chronological	   age	   in	   liver	   donors,	   in	   the	   context	   of	   organ	  
transplant.	  
Before	   investigating	   whether	   aging	   impinges	   upon	   proteasomes	   in	   human	   liver,	   on	   the	  
same	  biopsies	  we	  performed	  histopathological	  analysis.	  The	  main	  parameters	  taken	  into	  account	  
were	  the	  presence	  of	  portal	  inflammation	  and	  lobular	  necrosis.	  Indeed,	  we	  have	  previously	  shown	  
that,	  in	  pathological	  conditions	  such	  as	  cirrhosis	  and	  chronic	  active	  hepatitis,	  the	  levels	  of	  β1i	  and	  
β5i	   i-­‐subunits	   and	   of	   the	   PA28α	   regulatory	   complex	   correlate	   with	   the	   degree	   of	   tissue	  
inflammation	  (Vasuri	  et	  al.,	  2010),	  thus	  all	  samples	  that	  showed	  signs	  of	  active	  inflammation,	  like	  
piecemeal	  necrosis	  or	  lobular	  necrosis,	  with	  a	  score	  ≥1	  in	  one	  or	  more	  parameters	  of	  the	  Ishak’s	  
score	  were	  excluded	   from	  analysis,	   in	   total	   two	   samples	  were	  excluded.	  On	   the	   contrary,	   cases	  
with	  mild	  portal	  lymphocytic	  inflammation	  but	  without	  piecemeal	  necrosis,	  which	  can	  be	  observed	  
even	  in	  the	  absence	  of	  a	  true	  hepatitis,	  were	  included.	  
The	  histological	  analysis	  of	   the	  54	   liver	  biopsies	   (2	  out	  of	  56	  were	  not	  available)	  showed	  
the	  occurrence	  of	  a	  mild	  portal	  chronic	  infiltrate	  in	  17	  (31%)	  cases,	  with	  no	  piecemeal	  necrosis	  or	  
lobular	  necrosis.	  Fibrosis	  was	  scored	  as	  absent	  in	  14	  (26%)	  cases,	  Ishak	  grade	  1	  in	  19	  (35%)	  cases	  
and	   Ishak	   grade	   2	   in	   21	   (39%)	   cases,	   the	  myointimal	   thickening	  was	   present	   in	   33	   (61%)	   cases,	  
biliocytes	  regression	  in	  15	  (37%),	  signs	  of	  mild	  cholestasis	  in	  3	  (5%),	  sinusoid	  dilatation	  in	  8	  (15%)	  
cases.	  Hepatocytes	  polymorphism	  was	  absent	  in	  18	  (33%)	  cases,	  mild	  in	  26	  (48%)	  and	  pronounced	  
in	  10	  (18%)	  cases.	  A	  moderate-­‐to-­‐severe	  lipofuscin	  accumulation	  was	  observed	  in	  20	  (37%)	  cases.	  
Some	  amount	  of	   steatosis	  was	  present	   in	  29	   (54%)	  cases,	  with	  a	  mean	  percentage	  of	  5.42±10.7	  
(range	  0-­‐60%).	  
The	   histological	   parameters	   that	   directly	   correlated	   with	   age	   were	   fibrosis	   (Spearman’s	  
Test	   p<0.001),	   myointimal	   thickening	   (p<0.001),	   biliocytes	   regression	   (p=0.012),	   hepatocytes	  
polymorphism	  (p=0.01)	  and	  lipofuscin	  accumulation	  (p<0.001)	  (table	  8,	  fig.	  4.)	  Remarkably,	  none	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of	   these	   parameters	   correlated	   with	   proteasomes	   composition,	   distribution	   and	   functionality,	  
below	  described.	  
Histological	  parameters	   	   	   	   	  
	   C	   p	   	   	  
Fibrosis	   0.680	   <0.001	   	   	  
Myointimal	  thickening	   0.626	   <0.001	   	   	  
Biliocytes	  regression	   0.344	   	  	  0.012	   	   	  
Hepatocytes	  polymorphism	   0.352	   	  	  0.01	   	   	  
Lipofuscin	  accumulation	   0.595	   <0.001	   	   	  
	  
Table	   8.	  Correlation	   analysis	   of	   age	  with	   histological	   parameters	   in	   all	   liver	   biopsies	   (n=54).	   In	   Table	   are	   shown	  
positive	  correlations	  between	  aging	  and	  different	  histological	  features.	  C=Spearman's	  correlation	  coefficient.	  
	  
	  
Figure	   4.	   Histological	   features	   of	   livers	   from	   representative	   young	   and	   old	   donors.	   Note	   the	   concentric	   portal	  
fibrosis,	  with	  arteriolar	  myointimal	   thickening	  and	   some	  amount	  of	   chronic	   flogistic	   infiltrate	   (asterisks)	   in	   the	   liver	  
from	  old	  donor	  (b),	  compared	  to	  the	  young	  one	  (a).	  pt:	  portal	  tract.	  10x	  magnification.	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4.2	  PROTEASOME	  COMPOSITION	  AND	  CONTENT	  
Starting	   from	   the	   results	   we	   obtained	   in	   the	   liver	   of	   healthy	   adult	   subjects	   and	   under	  
pathological	  conditions	  (Vasuri	  et	  al.,	  2010),	  we	  firstly	  examined	  the	  composition	  and	  content	  of	  
20S	  proteasomes	  subunits,	  as	  well	  as	  of	  the	  PA28αβ	  and	  PA700	  regulators,	  in	  the	  liver	  of	  different	  
age	  donors.	  
Western	  blotting	  analysis	  showed	  that	  the	  constitutive	  (β1,	  β2,	  β5)	  and	  inducible	  (β1i,	  β2i,	  
β5i)	  catalytic	  subunits,	  as	  well	  as	  PA28α	  and	  Rpt2,	  representative	  of	  PA28αβ	  and	  PA700	  regulatory	  
complexes	   respectively,	   were	   expressed	   in	   all	   liver	   biopsies	   (fig.	   5a,	   c).	   Additionally,	   the	  
purification	  of	  20S	  proteasome	  from	  liver	  biopsies	  of	  adult	  (n=4)	  and	  elderly	  (n=3)	  male	  subjects	  
and	  subsequent	  western	  blotting	  analysis,	  confirmed	  that	  both	  constitutive	  and	  inducible	  catalytic	  
subunits	  were	   incorporated	   into	  mature	   and	   proteolitically	   active	   20S	   proteasomes	   (fig.	   5b,	   d).	  
The	  2D-­‐PAGE	  maps	  also	  showed	  that	  most	  of	  the	  proteasome	  subunits	  were	  present	   in	  multiple	  
isoforms,	   likely	  due	  to	  post-­‐translational	  modifications	  (Sixt	  et	  al.,	  2012;	  Schmidt	  et	  al.,	  2006),	   in	  
both	  the	  young	  and	  in	  the	  old	  group	  (fig.	  5e,	  f).	  




Figure	   5.	  Proteasomes	   composition	   of	   different	   age	   human	   livers.	   Example	   of	   western	   blotting	   analysis	   on	   crude	  
protein	  extracts	  from	  human	  liver	  biopsies	  of	  different	  age	  donors	  (1=23	  years,	  2=30	  years,	  3=43	  years,	  4=44	  years,	  
5=58	  years,	  6=58	  years,	  7=70	  years,	  8=84	  years)	  (a),	  and	  on	  20S	  proteasomes	  (b)	  purified	  from	  a	  pool	  of	  human	  liver	  
samples	   from	  adult	   (marked	  as	  1;	  n=4,	  mean	  age	  48±4.5	  years)	  and	  old	   (marked	  as	  2;	  n=3,	  mean	  age	  85±3.5	  years)	  
male	  donors.	  (c,	  d)	  Coomassie	  gel	  staining	  of	  samples	  in	  picture	  (a)	  and	  (b)	  was	  used	  to	  assess	  protein	  isoloading.	  2-­‐D	  
PAGE	  maps	  of	   20S	  purified	  proteasomes	   from	  adult	   (e)	   and	  old	   (f)	   pooled	   liver	   samples	  as	   in	   (b).	  Different	  protein	  
species	  of	  20S	  proteasome	  subunits	  have	  been	  identified.	  
	  
By	   performing	   semi-­‐quantitative	   western	   blotting	   analyses	   we	   found	   no	   age-­‐related	  
variation	  in	  the	  expression	  levels	  of	  α4,	  β1i,	  β2i,	  β5i,	  β5	  subunits	  (fig.	  6A-­‐D,	  G).	  On	  the	  contrary	  an	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age-­‐related	  decrease	  of	  β1	  subunit	   (p=0.0022)	  (fig.	  6E)	  and	  a	  non-­‐monotonic	  change	  of	  β2	  were	  
observed	  in	  the	  whole	  sample	  size	  (p=0.019)	  (fig.	  6F).	  We	  concomitantly	  analyzed	  the	  expression	  
levels	   of	   PA28αβ	   and	   PA700	   proteasome	   regulators,	   represented	   by	   PA28α	   and	   Rpt2	   subunits	  
respectively.	  We	  found	  that	  Rpt2	  content	  was	  not	  affected	  by	  aging	  in	  human	  liver	  (fig.	  6H)	  while	  









Figure	  6.	  Relative	  content	  of	  proteasomes	  subunits	  in	  human	  livers	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  years)	  
and	  elderly	  (≥70	  years)	  subjects.	  Western	  blotting	  analysis	  of	  proteasomes	  subunits	  were	  performed	  on	  crude	  protein	  
extracts	   from	  human	   livers	  of	  young	   (≤40	  years,	  n=7	   ),	  middle	  age	   (41-­‐69	  years,	  n=26)	  and	  elderly	   (≥70	  years,	  n=9)	  
subjects.	  Densitometric	  analysis	  of	  the	  bands	  corresponding	  to	  the	  proteasome	  subunits	  analyzed	  was	  considered	  and	  
data	  were	  normalized	  for	  a	  sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  three	  
independent	  experiments;	  in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  respective	  quartiles.	  The	  relative	  content	  of	  
α4	  (A),	  β1i	  (B),	  β2i	  (C),	  β5i	  (D),	  β5	  (G)	  proteasomes	  subunits	  in	  whole	  sample	  size	  was	  preserved	  during	  aging.	  An	  age-­‐
related	  decrease	  of	  β1	  subunit	  was	  observed	  (one-­‐way	  ANOVA	  p=0.0022;	  age	  group	  1vs2	  *p=0.0012,	  age	  group	  1vs3	  
#p=0.0017,	   age	   group	   2vs3	   p=0.56)	   (E).	   A	   non-­‐monotonic	   age-­‐related	   variation	   of	   β2	   was	   also	   observed	   (one-­‐way	  
ANOVA	  p=0.019;	  age	  group	  1vs2	  *p=0.02,	  age	  group	  1vs3	  p=0.34,	  age	  group	  2vs3	  #p=0.038)	  (F).	  The	  relative	  content	  
of	  Rpt2	  subunit	  of	  PA700	  regulator	  was	  not	  affected	  by	  aging	  (H),	  while	  a	  decrease	  in	  PA28α	  content	  representative	  of	  
PA28αβ	  regulator	  was	  observed	  by	  comparing	  the	  young	  and	  the	  old	  age	  group	  (one	  way	  ANOVA	  p=0.05;	  age	  group	  
1vs2	  p=0.335,	  age	  group	  1vs3	  #p=0.018,	  age	  group	  2vs3	  p=0.06)	  (I). One-­‐way	  ANOVA	  and	  Student’s	  t-­‐test	  were	  applied	  
and	  a	  p	  value	  <0.05	  was	  considered	  statistically	  significant. 
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By	  stratifying	  the	  whole	  sample	  size	  according	  to	  gender,	   the	  β1	  subunit	  showed	  a	   linear	  
decrease	   with	   age	   in	   the	   liver	   of	   male	   donors	   (p=0.008)	   (fig.	   7B),	   but	   not	   in	   female	   subjects	  
(p=0.07)	  (fig.	  7A).	  
We	  also	  calculated	  the	  ratio	  between	  each	  catalytic	  subunit	  and	  α4	  subunit,	  obtaining	  an	  
index	  of	  the	  proportion	  of	  constitutive	  and	  inducible	  subunits	  on	  total	  proteasomes	  (Rodriguez	  et	  
al.,	   2010).	  Remarkably,	   an	   increase	   in	  β5i/α4	   ratio	   in	   the	  whole	   sample	   size	   (p=0.0027)	   (fig.	  7C)	  
and	  in	  biopsies	  of	  female	  (p=0.019)	  (fig.	  7D)	  and	  male	  subjects	  (p=0.039)	  (fig.	  7E)	  was	  observed.	  
Regarding	  PA28αβ	  proteasomes	  regulators	  we	  confirmed	  that	  PA28α	  subunit	  decreased	  with	  age	  








Figure	   7.	   Relative	   content	   of	   proteasomes	   subunits	   in	   human	   liver	   of	   female	   and	   male	   subjects.	   Densitometric	  
analysis	   of	   the	   expression	   levels	   of	   proteasomes	   subunits	   in	   crude	   protein	   extracts	   from	   human	   liver	   biopsies	   of	  
females	  (F)	  and	  males	  (M)	  belonging	  to	  young	  (≤40	  years,	  F	  n=0,	  M	  n=7	  ),	  middle	  age	  (41-­‐69	  years,	  F	  n=16,	  M	  n=10),	  
and	  elderly	  (≥70	  years,	  F	  n=3,	  M	  n=6)	  subjects.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  in	  graph	  
box	   data	   are	   expressed	   as	   median	   and	   respective	   quartiles.	   An	   age-­‐related	   decrease	   of	   β1	   subunit	   was	   observed	  
considering	   samples	   from	   male	   donors	   (one-­‐way	   ANOVA	   •p=0.008;	   age	   group	   1vs2	   *p=0.027,	   age	   group	   1vs3	  
#p=0.0021,	   age	   group	   2vs3	   p=0.24)	   (B)	   but	   not	   in	   those	   from	   females	   (Student’s	   t-­‐test	   p=0.07)	   (A).	   β5i/α4	   ratio	  
increased	   during	   aging	   in	   the	   whole	   cohort	   (Kruskal-­‐Wallis	   test	   p=0.0027;	   Mann-­‐Whitney	   U	   test	   age	   group	   1vs2	  
p=0.26,	  age	  group	  1v3	  #p=0.045,	  age	  group	  2vs3	  *p=0.025)	  (C)	  and	  in	  both	  male	  (Kruskal-­‐Wallis	  test	  p=0.039;	  Mann-­‐
Whitney	  U	   test	   age	   group	  1vs2	  p=0.38,	   age	   group	  1v3	   #p=0.013,	   age	   group	  2vs3	   *p=0.0017)	   (E)	   and	   female	  donors	  
(Student’s	   t-­‐test	   *p=0.019)	   (D).	   A	   decreased	   PA28α	   content	  was	   observed	   in	  male	   donors	   subset	   (one	  way	  ANOVA	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p=0.048;	   age	   group	   1vs2	   p=0.69,	   age	   group	   1vs3	   *p=0.030,	   age	   group	   2vs3	   p=0.05)	   (G)	   but	   not	   in	   female	   donors	  
(Student’s	  t-­‐test	  p=0.32)	  (F).	  One-­‐way	  ANOVA,	  Kruskal-­‐Wallis,	  Mann-­‐Whitney	  and	  Student’s	  t-­‐test	  were	  applied.	  
	  
4.3	  PROTEASOME	  SUBCELLULAR	  LOCALIZATION	  	  
We	  also	  performed	  immunohistochemical	  analysis	  to	  assess	  which	  cell	  types	  undergo	  the	  
above	   mentioned	   age-­‐related	   modifications	   and	   we	   extended	   our	   previous	   observations	   on	  
subcellular	  distribution	  of	  proteasomes	  in	  human	  liver.	  As	  previously	  described	  (Vasuri	  et	  al.,	  2010;	  
Gohlke	   et	   al.,	   2013),	   β1	   and	   PA28α	   subunits	   were	   variably	   expressed	   both	   at	   nuclear	   and	  
cytoplasmic	   level,	   in	   all	   cell	   types,	   including	   biliocytes;	  while	   β1i	   and	   β5i	   showed	   a	   cytoplasmic	  
positivity	   in	  all	   cell	   types,	   in	  particular	   in	   lymphocytes	  and	  Kupffer	  cells.	   In	   the	  current	  work	  we	  
focused	   on	   hepatocytes,	   which	   represent	   the	   main	   cell	   population	   of	   the	   liver.	   A	   strong	   (2+)	  
nuclear	  positivity	  for	  β5i	  was	  recorded	  in	  8	  (15%)	  cases	  and	  for	  β1i	  just	  in	  1	  (2%)	  case,	  whereas	  a	  
mild-­‐to-­‐moderate	  cytoplasmic	  positivity	  for	  both	  the	  subunits	  was	  observed	  in	  all	  cases.	  A	  strong	  
nuclear	  immune-­‐reactivity	  for	  β1	  was	  seen	  in	  47	  (87%)	  cases,	  while	  cytoplasm	  was	  positive	  (2+)	  to	  
β1	   in	   26	   (48%)	   cases.	   The	   same	   distribution	   was	   observed	   in	   biopsies	   from	   female	   and	   male	  
donors	  (data	  not	  shown).	  Notably,	  no	  changes	   in	  expression	  level	  and	  localization	  of	  β1,	  β1i,	  β5i	  
subunits	   were	   observed	   in	   human	   hepatocytes	   during	   aging	   (fig.	   8a-­‐f).	   As	   far	   as	   it	   concerns	  
PA28αβ	  proteasomes	   regulator,	   the	  PA28α	   subunit	   showed	  a	  nuclear	  and	   cytoplasmic	  positivity	  
(2+)	  in	  38	  (70%)	  and	  23	  (43%)	  cases	  respectively	  (table	  9).	  Remarkably,	  this	  positivity	  significantly	  
decreased	  with	  aging	  (C=-­‐0.343,	  p=0.011)	  (fig.	  8g,	  h),	  confirming	  at	  least	  the	  loss	  of	  PA28α	  subunit	  
recorded	  in	  crude	  protein	  extracts	  from	  male	  donors.	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Immunohistochemical	  analysis	   	   	   	   	  
Compartment	  positivity	   cytoplasm	   nucleus	   	   	  
β1	   (2+)	  48%	   (2+)	  87%	   	   	  
β1i	   	  	  	  (+)	  99%	  	   (2+)	  2%	  	   	   	  
β5i	   (+)	  99%	  	   (2+)	  15%	  	   	   	  
PA28α	   (2+)	  43%	   (2+)	  70%	   	   	  
	  
Table	  9.	  Immunohistochemical	  analysis	  of	  proteasomes	  in	  human	  hepatocytes	  of	  liver	  biopsies	  (n=54).	  In	  Table	  are	  
shown	  proteasomes	  subunits	  representative	  of	  proteasomes	  subcellular	  distribution	  at	  cytoplsmic	  and	  nuclear	   level.	  
The	  positivity	  to	  each	  subunit	  is	  reported	  as	  strong	  (2+)	  or	  mild-­‐to-­‐moderate	  (+)	  and	  also	  the	  percentage	  frequency	  in	  
all	  liver	  biopsies	  analyzed	  is	  shown.	  




Figure	   8.	   Immunohistochemical	   analysis	   of	   proteasomes	   distribution	   showed	   an	   age-­‐related	   decrease	   of	   PA28α	  
subunit	  in	  the	  citosol	  of	  hepatocytes.	  A	  young	  (on	  the	  left)	  and	  an	  old	  (on	  the	  right)	  liver	  donors	  are	  represented.	  β1	  
subunit	  (a,	  b)	  showed	  the	  same	  strong	  nuclear	  and	  cytoplasmic	  positivity,	  while	  β1i	  (c,	  d)	  and	  β5i	  (e,	  f)	  were	  always	  
negative	  or	  weakly	  expressed	   in	  the	  nucleus.	  Note	  the	  decreased	  cytoplasmic	  positivity	  of	  PA28α	   in	  older	   livers	   (h),	  
compared	  to	  younger	  (g)	  (Spearman	  test	  •p=0.011).	  20x	  magnification.	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4.4	  PROTEASOME	  FUNCTIONALITY	  
4.4.1	  OXIDIZED	  PROTEIN	  CONTENT	  
An	  increased	  level	  of	  oxidized	  proteins	  has	  been	  described	  in	  the	  liver	  of	  aged	  mice	  and	  it	  
was	   directly	   correlated	   to	   an	   impairment	   in	   proteasomes	   activities	   (Breusing	   et	   al.,	   2009).	  We	  
investigated	  whether	  these	  age-­‐related	  modifications	  occur	  also	  in	  human	  liver.	  We	  measured	  the	  
content	  of	  oxidized	  proteins	  in	  biotic	  samples	  from	  donors	  with	  different	  age	  by	  oxyblot	  detection	  
kit	  (fig.	  9).	  
	  
Figure	  9.	  Analysis	  of	  oxidized	  proteins	  by	  oxyblot	  detection	  in	  crude	  protein	  extracts	  from	  human	  liver	  biopsies	  of	  
different	   age.	   Equal	   amounts	   of	   crude	   protein	   extracts	   were	   analyzed	   by	   immunoblotting	   for	   oxidized	   proteins	  
content.	   The	   picture	   shows	   a	   representative	   blot	   from	   liver	   samples	   with	   the	   characteristic	   smear	   of	   modified	  
proteins.	  Protein	  isoloading	  was	  assessed	  by	  Coomassie	  gel	  staining	  (data	  not	  shown).	  
	  
The	  densitometric	  quantification	  of	  the	  smears	  of	  oxyblots	  showed	  that	  no	  changes	  were	  





Figure	  10.	  Relative	  content	  of	  oxidized	  proteins	  in	  human	  liver	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  years)	  and	  
elderly	  (≥70	  years)	  subjects.	  Western	  blotting	  analysis	  of	  oxidized	  proteins	  was	  performed	  on	  crude	  protein	  extracts	  
from	   different	   age	   human	   livers	   (young	   n=7;	   middle	   age	   n=26;	   old	   n=9).	   Densitometric	   measure	   of	   the	   bands	  
corresponding	   to	  oxidized	  proteins	  was	  considered	  and	  data	  were	  normalized	   for	  a	  sample	  used	  as	   internal	  control	  
and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  in	  graph	  box	  data	  are	  expressed	  
as	  median	  and	  respective	  quartiles.	  Difference	  among	  age	  groups	  was	  analyzed	  using	  one-­‐way	  ANOVA	  test	  and	  a	  p	  
value<0.05	   was	   considered	   statistically	   significant.	   The	   relative	   content	   of	   oxidized	   proteins	   in	   human	   liver	   was	  
preserved	  during	  aging	  (p=0.70).	  
	  
4.4.2	  POLY-­‐UBIQUITIN	  CONJUGATED	  PROTEIN	  CONTENT	  
We	   also	   analyzed	   the	   amount	   of	   poly-­‐ubiquitin	   conjugated	   proteins,	   which	   represent	  
another	  indirect	  index	  of	  proteasomes	  functionality	  (fig.	  11),	  and	  even	  in	  this	  case	  no	  statistically	  
significant	  differences	  among	  age	  groups	  emerged	  (p=0.19)	  (fig.	  12).	  




Figure	  11.	  Content	  of	  mono-­‐	  and	  poli-­‐ubiquitin	  conjugated	  proteins	  in	  crude	  protein	  extracts	  of	  human	  liver	  from	  
donors	  of	  different	  age.	  Representative	   immunobloting	  of	   liver	  crude	  protein	  extracts	  by	  using	  an	  antibody	  specific	  
for	  K48-­‐,	  K63-­‐	  and	  K29-­‐	   linked	  conjugates,	   that	   recognizes	  mono-­‐	  and	  poly-­‐ubiquitin	  conjugated	  proteins,	  but	  not	   free	  
ubiquitin	  molecules.	  A	  characteristic	  smear	  of	  modified	  proteins	  was	  observed	  and	  quantified.	  Protein	  isoloading	  was	  
assessed	  by	  Coomassie	  gel	  staining	  (data	  not	  shown).	  
	  
	  
Figure	  12.	  Relative	  content	  of	  poly-­‐ubiquitinylated	  proteins	  in	  human	  liver	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  
years)	   and	   elderly	   (≥70	   years)	   subjects.	  Western	   blotting	   analysis	   of	   poly-­‐ubiquitin	   conjugates	   was	   performed	   on	  
crude	  protein	  extracts	  from	  different	  age	  human	  livers	  (young	  n=7;	  middle	  age	  n=26;	  old	  n=9).	  Densitometric	  measure	  
of	  the	  bands	  corresponding	  to	  poly-­‐ubiquitinylated	  proteins	  was	  considered	  and	  data	  were	  normalized	  for	  a	  sample	  
used	  as	  internal	  control	  and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  in	  graph	  
box	  data	  are	  expressed	  as	  median	  and	  respective	  quartiles.	  Difference	  among	  age	  groups	  was	  analyzed	  using	  one-­‐way	  
ANOVA	   test	   and	   a	   p	   value<0.05	   was	   considered	   statistically	   significant.	   The	   relative	   content	   of	   poly-­‐ubiquitin	  




In	   our	   study,	   gender	   does	   not	   seem	   to	   affect	   the	   levels	   of	   oxidized	   and	   poly-­‐ubiquitin	  
conjugated	  proteins	  (data	  not	  shown).	  
	  
4.4.3	  PROTEASOME	  ACTIVITY	  	  
The	  analysis	  of	  proteasomes	  activities,	  measured	  by	  short	  fluorogenic	  peptides	  assay	  and	  
reported	   as	   specific	   activity	   for	   total	   protein	   (Rodriguez	   et	   al.	   2010),	   showed	   that	   the	   CT-­‐like	  
(p=0.64)	  (fig.	  13A)	  and	  the	  C-­‐like	  (p=0.40)	  (fig.	  13C)	  specific	  activities	  were	  preserved	  during	  aging,	  
while	  a	  trend	  to	  increase	  was	  observed	  for	  the	  T-­‐like	  specific	  activity	  (p=0.07)	  (fig.	  13B).	  However,	  
normalizing	   the	   three	  proteolytic	   activities	   for	  α4	   subunit,	   a	   non-­‐replaceable	   component	   of	   the	  
catalytic	  core	  and	  thus	  representative	  of	  total	  proteasomes	  content,	  any	  difference	  emerged	  (fig.	  
13D-­‐F).	  




Figure	  13.	  Proteasome	  functionality	  in	  human	  livers	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  years)	  and	  elderly	  (≥70	  
years)	   subjects.	   Proteasomes	   specific	   activities	  were	  measured	   in	   crude	  protein	  extracts	   from	  human	   liver	  biopsies	  
(young	  n=7;	  middle	  age	  n=26;	  old	  n=9).	  Hydrolysis	  of	  the	  fluorogenic	  peptides	  LLVY-­‐AMC	  (A),	  VGR-­‐AMC	  (B)	  and	  LLE-­‐
AMC	  (C)	  measured	  the	  chymotripsin-­‐like	  (CT-­‐L),	  the	  trypsin-­‐like	  (T-­‐L)	  and	  the	  caspase-­‐like	  (C-­‐L)	  activities,	  respectively.	  
We	   considered	   the	   mean	   of	   three	   independent	   experiments;	   in	   graph	   box	   data	   are	   expressed	   as	   median	   and	  
respective	  quartiles.	  Difference	  among	  age	  groups	  was	  analyzed	  by	  using	  one-­‐way	  ANOVA	  and	  Student’s	  t-­‐test	  and	  a	  p	  
value<0.05	   was	   considered	   statistically	   significant.	   None	   of	   the	   three	   proteasome	   activities	   (expressed	   as	  
nmol/mg*min)	   was	   affected	   by	   aging,	   even	   if	   a	   trend	   to	   increase	   was	   observed	   for	   T-­‐L	   activity (one-­‐way	   ANOVA	  
p=0.07;	  Student’s	  t-­‐test	  age	  group	  1vs2	  p=0.91,	  age	  group	  1vs3	  p=	  0.16,	  age	  group	  2vs3	  *p=0.04)	  (B).	  The	  same	  results	  
emerged	  dividing	  specific	  activities	  by	  α4	  relative	  content:	  CT-­‐L/	  α4	  p=	  0.49	  (D),	  T-­‐L/	  α4	  p=	  0.11	  (E),	  C-­‐L/	  α4	  p=0.40	  (F).	  
	  
Of	   note,	   by	   stratifying	   our	   data	   according	   to	   gender	   we	   observed	   that	   proteasomes	  
activities	  were	  differently	  affected	  by	  aging,	  in	  the	  liver	  of	  men	  and	  women.	  
In	  fact,	  only	  in	  liver	  from	  male	  donors,	  the	  T-­‐like	  activity/α4	  relative	  content	  was	  increased	  
in	   the	   old	   group	   compared	   to	   the	   middle-­‐age	   group	   (p=0.014),	   with	   no	   statistically	   significant	  




Figure	   14.	  Proteasome	   trypsin-­‐like/α4	   specific	   activity	   in	   human	   livers	  of	   female	   and	  male	   subjects.	   Proteasome	  
trypsin-­‐like	   specific	   activity	   was	  measured	   by	   using	   VGR-­‐AMC	   substrate	   in	   crude	   protein	   extracts	   from	   biopsies	   of	  
females	  (F)	  and	  males	  (M)	  belonging	  to	  young	  (≤40	  years,	  F	  n=0,	  M	  n=7	  ),	  middle	  age	  (41-­‐69	  years,	  F	  n=16,	  M	  n=10),	  
and	  elderly	  (≥70	  years,	  F	  n=3,	  M	  n=6)	  subjects	  and	  normalized	  for	  α4	  relative	  content,	  measured	  by	  western	  blotting.	  
We	   considered	   the	   mean	   of	   three	   independent	   experiments;	   in	   graph	   box	   data	   are	   expressed	   as	   median	   and	  
respective	  quartiles.	  Difference	  among	  age	  groups	  was	  analyzed	  using	  one-­‐way	  ANOVA	  test	  and	  Student’s	  t-­‐test	  and	  a	  
p	  value<0.05	  was	  considered	  statistically	  significant.	  Only	   in	  males	  (B),	  but	  not	   in	  females	  (A)	  a	  non-­‐monotonic	  age-­‐
related	  modification	  of	  the	  trypsin-­‐like	  activity	  per	  amount	  of	  α4	  relative	  content	  was	  observed.	  In	  particular	  in	  male	  
group	  the	  comparison	  between	  the	  middle-­‐age	  and	  the	  elderly	  subjects	  (*p=0.014)	  was	  statistically	  significant.	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Similarly,	  a	  decline	  in	  the	  C-­‐like	  activity/α4	  relative	  content	   in	  the	  male	  middle-­‐age	  group	  
was	   recorded,	  along	  with	  no	  differences	  between	   the	  younger	  and	   the	  older	   subjects	   (p=0.026)	  
(fig.	  15).	  
	  
Figure	  15.	  Proteasome	  caspasic-­‐like/α4	  specific	  activity	   in	  human	   livers	  of	   female	  and	  male	  subjects.	  Proteasome	  
caspasic-­‐like	  specific	  activity/α4	  relative	  content	  was	  measured	  by	  using	  LLE-­‐AMC	  substrate	  in	  crude	  protein	  extracts	  
from	  biopsies	  of	  females	  (F)	  and	  males	  (M)	  belonging	  to	  young	  (≤40	  years,	  F	  n=0,	  M=7	  ),	  middle	  age	  (41-­‐69	  years,	  F	  
n=16,	  M	  n=10),	  and	  elderly	  (≥70	  years,	  F	  n=3,	  M	  n=6)	  subjects	  and	  normalized	  for	  α4	  relative	  content,	  measured	  by	  
western	   blotting.	  We	   considered	   the	  mean	  of	   three	   independent	   experiments;	   in	   graph	  box	   data	   are	   expressed	   as	  
median	   and	   respective	   quartiles.	   Difference	   among	   age	   groups	   was	   analyzed	   by	   using	   one-­‐way	   ANOVA	   test	   and	  
Student’s	  t-­‐test	  and	  a	  p	  value<0.05	  was	  considered	  statistically	  significant.	  Only	  in	  males	  (B),	  but	  not	  in	  females	  (A)	  a	  
non-­‐monotonic	  age-­‐related	  modification	  of	  the	  caspasic-­‐like	  activity	  per	  amount	  of	  α4	  relative	  content	  was	  observed	  
(one-­‐way	   ANOVA	   •p=0.026;	   Student’s	   t-­‐test	   age	   group	   1vs2	   #p=0.034,	   age	   group	   1vs3	   p=0.38,	   age	   group	   2vs3	  
*p=0.014).	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4.A/B	  RESULTS	  ON	  HUMAN	  SKELETAL	  MUSCLE	  
4.A	  ANALYSES	  ON	  BIOPSIES	  OF	  VASTUS	  LATERALIS	  SKELETAL	  MUSCLE	  FROM	  
HEALTHY	  SUBJECTS	  AND	  PATIENTS	  WITH	  LOWER	  LIMB	  MOBILITY	  
IMPAIRMENT	  (LLMI)	  
	  
4.A1	  EXPRESSION	  LEVELS	  OF	  PROTEASOME	  SUBUNITS	  
Many	  efforts	  have	  been	  done	  to	  understand	  the	  contribution	  of	  the	  UPS,	  one	  of	  the	  major	  
pathways	   for	   protein	   degradation,	   to	   the	   loss	   of	  muscle	  mass	   that	   occurs	   during	   aging	   in	   both	  
human	   and	   rodents.	   To	   date,	  most	   of	   the	   studies	  were	   performed	   in	   animal	  models	   and	  were	  
mainly	  focused	  on	  ubiquitin	  pathway	  rather	  than	  proteasomes.	  Indeed,	  few	  data	  are	  available	  on	  
the	  contribution	  and	  involvement	  of	  proteasomes,	  and	  in	  particular	  of	  i-­‐proteasome,	  in	  the	  aging	  
of	  human	  skeletal	  muscle.	  
In	   the	   framework	  of	   the	  European	  project	  MYOAGE	   ‘’Understanding	  and	  Combating	  Age-­‐
related	  Muscle	  weakness”,	  we	  collected	  biopsies	  of	  v.	   lateralis	   skeletal	  muscle	   from	  hospitalized	  
patients	   (Rizzoli	   Hospital,	   Bologna)	  with	   limited	   lower	   limb	  mobility	   impairment	   (LLMI	   patients)	  
undergoing	  surgery	  for	  hip	  replacement,	  and	  healthy	  physically	  and	  cognitively	  active	  subjects.	  
We	   firstly	   analyzed	  proteasomes	   composition	   and	   content,	  at	  mRNA	   level,	   in	  v.	   lateralis	  
muscle	   biopsies	   obtained	   from	   female	   healthy	   subjects	   and	   LLMI	   patients,	   both	   belonging	   to	  
different	   age.	   In	   particular	  we	   focused	   our	   attention	   on	   α6	   subunit,	  which	   is	   a	   not-­‐replaceable	  
component	   of	   the	   catalytic	   core	   and	   thus	   representative	   of	   total	   proteasomes	   content,	   on	   β1	  
catalytic	   subunit	   of	   constitutive	   proteasomes,	   β1i	   and	   β5i	   catalytic	   inducible	   subunits	   of	   i-­‐
proteasomes	   as	   well	   as	   the	   inducible	   subunit	   PA28β,	   representative	   of	   PA28αβ	   proteasomes	  
regulator.	  
Quantitative	   PCR	   (qPCR)	   analysis	   showed	   that	   all	   the	   constitutive	   and	   inducible	  
components	  of	  proteasomes	  were	  present	  at	  transcriptional	  level	  in	  v.	  lateralis	  muscle	  of	  healthy	  
subjects	  and	  LLMI	  patients.	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Additionally,	  in	  healthy	  subjects	  we	  found	  a	  statistically	  significant	  age-­‐related	  increase	  in	  
the	  expression	  level	  of	  the	  inducible	  subunits	  β1i	  (p=0.009)	  (fig.	  16D)	  and	  β5i	  (p=0.009)	  (fig.	  16E),	  
as	  well	  as	  PA28β	  (p=0.036)	  (fig.	  16C),	  while	  the	  constitutive	  subunits	  α6	  and	  β1	  were	  not	  affected	  
by	  aging	  (p=0.173	  and	  p=0.072	  respectively)	  (fig.	  16A-­‐B).	  
	  
Figure	   16.	   Quantitative	   PCR	   analysis	   of	   mRNAs	   encoding	   proteasomes	   subunits	   in	   human	   v.	   lateralis	   muscle	   of	  
young	  (≤40	  years,	  n=5)	  and	  elderly	  (≥70	  years,	  n=5)	  female	  healthy	  subjects.	  Relative	  expression	  of	  mRNA	  levels	  was	  
measured	  by	  using	  specific	  primers	  for	  α6	  and	  β1	  constitutive	  subunits	  (A,	  B),	  PA28β	  inducible	  subunit	  (C),	  β1i	  and	  β5i	  
i-­‐proteasome	   subunits	   (D,	   E).	  We	   considered	   the	  mean	   of	   three	   independent	   experiments;	   in	   graph	   box	   data	   are	  
expressed	   as	  median	   and	   respective	   quartiles.	   Difference	   between	   the	   two	   age	   groups	  was	   analyzed	   using	  Mann-­‐
Whitney	   test	   and	   a	  p	   value<0.05	  was	   considered	   statistically	   significant.	   An	   age-­‐related	   increase	   in	   the	   expression	  
levels	  of	  inducible	  subunits	  PA28β	  (C,	  *p=0.036),	  β1i	  (D,	  *p=0.009)	  and	  β5i	  (E,	  *p=0.009)	  was	  observed,	  while	  the	  α6	  
and	  β1	  constitutive	  subunits	  were	  not	  affected	  by	  aging	  (A,	  p=0.173	  and	  B	  p=0.072	  respectively).	  
	  
On	  the	  contrary,	  when	  we	  analyzed	  the	  expression	  levels	  of	  these	  proteasomes	  subunits	  in	  
LLMI	  patients,	  no	  statistically	  significant	  differences	  were	  observed	  between	  age	  groups,	  even	  if	  a	  
general	  trend	  to	  increase	  was	  present	  (fig.	  17A-­‐E).	  




Figure	   17.	   Quantitative	   PCR	   analysis	   of	   mRNAs	   encoding	   proteasomes	   subunits	   in	   human	   v.	   lateralis	   muscle	   of	  
young	  (≤40	  years,	  n=6)	  and	  elderly	   (≥70	  years,	  n=6)	   female	  LLMI	  patients.	  Relative	  expression	  of	  mRNA	   levels	  was	  
measured	  by	  using	  specific	  primers	  for	  α6	  and	  β1	  constitutive	  subunits	  (A,	  B),	  inducible	  subunit	  PA28β	  (C),	  as	  well	  as	  
β1i	  and	  β5i	   i-­‐proteasome	  subunits	  (D,	  E).	  We	  considered	  the	  mean	  of	  three	   independent	  experiments;	   in	  graph	  box	  
data	  are	  expressed	  as	  median	  and	  respective	  quartiles.	  Difference	  between	  the	  two	  age	  groups	  was	  analyzed	  by	  using	  
Student’s	  t	  (for	  β1,	  α6,	  PA28β,	  β5i)	  and	  Mann-­‐Whitney	  (for	  β1i)	  tests	  and	  a	  p	  value<0.05	  was	  considered	  statistically	  
significant.	  No	  age-­‐related	  modification	  in	  the	  expression	  levels	  of	  these	  proteasomes	  subunits	   in	  LLMI	  patients	  was	  
observed. 
	  
4.A2	  PROTEASOME	  COMPOSITION	  AND	  CONTENT	  
We	   analyzed	   by	   western	   blotting	   proteasomes	   composition	   and	   content	   at	   the	   protein	  
level.	   Experiments	  performed	  on	   crude	  protein	  extracts,	   from	  healthy	   female	   subjects,	   showed	  
that	   the	   constitutive	  proteasome	   represents	   the	  major	  population	   in	  human	  v.	   lateralis	   skeletal	  
muscle,	  while	  the	   inducible	  components	  of	   i-­‐proteasome,	  β1i	  and	  β5i,	  as	  well	  as	  PA28β	  subunit,	  




Figure	   18.	  Western	   blotting	   analysis	   of	   crude	   protein	   extracts	   from	  human	   v.	   lateralis	  muscle	   of	   female	   healthy	  
subjects.	  α4,	  β1	  and	  β5	  constitutive	  subunits	  are	  expressed	  in	  both	  young	  and	  elderly	  healthy	  subjects,	  while	  β1i,	  β5i	  
and	  PA28β	  inducible	  subunits	  are	  almost	  undetectable	  compared	  to	  a	   liver	  sample,	  used	  as	   internal	  positive	  control	  
for	  proteasomes	  subunits	  (a).	  Protein	  isoloading	  was	  assessed	  by	  Coomassie	  gel	  staining	  (b).	  
	  
This	  suggests	  that	  post-­‐transcriptional	  mechanisms	  might	  impinge	  upon	  protein	  synthesis,	  
assembly	  and/or	  maturation	  of	  inducible	  proteasomes	  components	  in	  healthy	  subjects.	  
We	  next	  performed	  a	  densitometric	  analysis	  of	   the	  bands	  corresponding	   to	  proteasomes	  
subunits	   obtained	   by	   western	   blotting,	   in	   order	   to	   assess	   possible	   age-­‐related	   modification	   in	  
human	   v.	   lateralis	   muscle	   of	   healthy	   subjects.	   Thus,	   taking	   into	   account	   that	   the	   signal	   of	   the	  
bands	   corresponding	   to	   inducible	   components	   of	   proteasomes	   was	   weak	   for	   a	   reliable	  
quantitative	  estimation,	  we	  performed	  a	  densitometric	  analysis	  only	  on	  constitutive	  components	  
of	  proteasomes,	  in	  particular	  on	  α4,	  β1	  and	  β5.	  Additionally,	  since	  some	  free	  α	  subunits	  might	  be	  
found	  in	  cells,	  in	  particular	  during	  senescence	  (Chondrogianni	  et	  al.,	  2005)	  we	  also	  have	  calculated	  
the	   ratio	  between	  each	  catalytic	   subunit	   and	  α4	   (β1/α4	  and	  β5/α4	   ratio),	  obtaining	  an	   index	  of	  
assembled	  proteasomes	  (Rodriguez	  et	  al.,	  2010).	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In	  healthy	   female	   subjects	  we	   found	   that	   the	   content	  of	  α4	  and	  β1	   subunits	   and	  of	   the	  
ratio	  β1/α4	  were	  unchanged	  during	  aging	  (p=0.81,	  p=0.82	  and	  p=0.78	  respectively)	  (fig.	  19A,	  B,	  D),	  
while	  the	  level	  of	  β5	  catalytic	  subunit	  and	  the	  ratio	  β5/α4	  were	  increased	  (p=0.037	  and	  p=0.047,	  
respectively)	  (fig.	  19C,	  E).	  
	  
Figure	  19.	  Relative	  content	  of	  proteasomes	  constitutive	  subunits	  in	  crude	  protein	  extracts	  from	  human	  v.	  lateralis	  
muscle	  of	  young	  (≤40	  years,	  n=5)	  and	  elderly	  (≥70	  years,	  n=9)	  healthy	  subjects.	  Densitometric	  analysis	  of	  the	  bands	  
corresponding	   to	   α4	   (A),	   β1	   (B)	   and	   β5	   (C)	   constitutive	   subunits	   was	   performed	   and	   data	   were	   normalized	   for	   a	  
sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  
in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  respective	  quartiles.	  The	  ratio	  between	  each	  catalytic	  subunit	  and	  α4	  
(β1/α4,	  β5/α4),	  was	  also	  calculated	  (D,	  E).	  Difference	  between	  the	  two	  age	  groups	  was	  analyzed	  using	  Student’s	  t-­‐test	  
and	  a	  p	  value<0.05	  was	  considered	  statistically	  significant.	  An	  age-­‐related	  increase	  of	  β5	  relative	  content	  (C,	  *p=0.037)	  
and	  of	  β5/α4	  ratio	  (E,	  *p=0.047)	  was	  observed.	  
	  
Of	   note,	   these	   findings	   also	   emerged	   when	   we	   investigated	   proteasomes	   protein	  
composition	   of	   human	   v.	   lateralis	   muscle	   of	   female	   and	   male	   LLMI	   patients.	   Indeed	   inducible	  





Figure	  20.	  Western	  blotting	  analysis	  of	  crude	  protein	  extracts	  from	  human	  v.	  lateralis	  muscle	  of	  LLMI	  patients.	  α4,	  
β1	  and	  β5	  constitutive	  subunits	  are	  expressed	   in	  LLMI	  patients	  of	  different	  age,	  while	  β1i,	  β5i	  and	  PA28β	   inducible	  
subunits	  are	  almost	  undetectable	  compared	   to	  a	   liver	   sample	   (L),	  used	  as	   internal	  positive	  control	   for	  proteasomes	  
subunits	  (a).	  Protein	  isoloading	  was	  assessed	  by	  Coomassie	  gel	  staining	  (b).	  
	  
In	   LLMI	   patients,	   the	   same	   analysis	   showed	   that	   proteasomes	   content	   was	   largely	  
preserved	   during	   aging	   (fig.	   21A-­‐D),	   indeed	   only	   a	   borderline	   non-­‐monotonic	   variation	   in	   the	  
β5/α4	  ratio	  (p=0.06)	  (fig.	  21E)	  was	  observed.	  In	  particular,	  an	  age-­‐related	  decrease	  in	  elderly	  (≥70	  
years)	   respect	   to	  middle-­‐age	   (41-­‐69	  years)	  patients	  was	   found	  (p=0.039),	  while	   the	  young	  group	  




Figure	  21.	  Relative	  content	  of	  proteasomes	  constitutive	  subunits	  in	  crude	  protein	  extracts	  from	  human	  v.	  lateralis	  
muscle	   of	   young	   (≤40	   years,	   n=14),	  middle	   age	   (41-­‐69	   years,	   n=18)	   and	   elderly	   (≥70	   years,	   n=17)	   LLMI	   patients.	  
Densitometric	  analysis	  of	  the	  bands	  corresponding	  to	  α4	  (A),	  β1	  (B)	  and	  β5	  (C)	  constitutive	  subunits	  was	  performed	  
and	  data	  were	  normalized	  for	  a	  sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  
three	   independent	   experiments;	   in	   graph	   box	   data	   are	   expressed	   as	   median	   and	   respective	   quartiles.	   The	   ratio	  
between	  each	   catalytic	   subunit	   and	  α4	   (β1/α4,	  β5/α4)	  was	  also	   calculated	   (D,	   E).	  Differences	  among	   the	   three	  age	  
groups	  were	  analyzed	  by	  using	  Kruskal-­‐Wallis	  test	  and	  a	  p	  value<0.05	  was	  considered	  statistically	  significant.	  Only	  an	  
age-­‐related	   decrease	   of	   β5/α4	   relative	   content	   was	   observed,	   comparing	   the	   group	   of	   middle-­‐age	   to	   the	   elderly	  
subjects	  (E,	  *p=0.039).	  
	  
This	   latter	   result	   also	   emerged	   when	   muscle	   samples	   from	   female	   LLMI	   patients	   were	  
considered	   (fig	   22A,	   B);	   in	   particular	   a	   decrease	   of	   β5/α4	   ratio	   was	   observed	   in	   the	   old	   group	  
compared	   to	   the	   middle-­‐age	   patients	   (p=0.022)	   (fig.	   22A).	   Remarkably,	   no	   age-­‐related	  




Figure	  22.	  Relative	  content	  of	  β5/α4	  ratio	   in	  crude	  protein	  extracts	  from	  human	  v.	   lateralis	  muscle	  of	  young	  (≤40	  
years),	  middle	  age	   (41-­‐69	  years)	  and	  elderly	   (≥70	  years)	   female	  and	  male	  LLMI	  patients.	  Densitometric	  analysis	  of	  
β5/α4	   relative	   content	   in	   crude	   protein	   extracts	   from	   human	   v.	   lateralis	   biopsies	   of	   females	   (F)	   and	   males	   (M)	  
belonging	   to	  young	   (≤40	  years,	   F	  n=5,	  M	  n=9	   ),	  middle	  age	   (41-­‐69	  years,	   F	  n=12,	  M	  n=6),	   and	  elderly	   (≥70	  years,	   F	  
n=11,	   M	   n=6)	   LLMI	   patients.	   We	   considered	   the	   mean	   of	   three	   independent	   experiments;	   in	   graph	   box	   data	   are	  
expressed	   as	   median	   and	   respective	   quartiles.	   Differences	   among	   the	   three	   age	   groups	   were	   analyzed	   by	   using	  
Kruskal-­‐Wallis	   test	  and	  a	  p	   value<0.05	  was	  considered	  statistically	   significant.	  The	  comparison	  between	   the	  middle-­‐
age	   subjects	   and	   the	   elderly	   in	   female	   patients	   was	   statistically	   significant	   (A,	   *p=0.022),	   while	   no	   age-­‐related	  
modification	  was	  observed	  in	  male	  patients	  (B).	  
	  
Finally,	  we	  investigated	  whether	  muscle	  inactivity	  affected	  proteasomes	  content	  in	  human	  
skeletal	  muscle,	  by	  comparing	  healthy	  subjects	  and	  LLMI	  patients.	  This	  analysis	  was	  possible	  only	  
for	  female	  subjects	  because	  muscle	  biopsies	  from	  healthy	  male	  donors	  were	  not	  available	  (fig.	  23).	  




Figure	   23.	  Western	   blotting	   analysis	   of	   crude	   protein	   extracts	   from	  human	   v.	   lateralis	  muscle	   of	   female	   healthy	  
subjects	  and	  LLMI	  patients.	  No	  difference	  in	  proteasomes	  composition	  was	  observed	  between	  healthy	  subjects	  and	  
LLMI	   patients.	   Indeed,	   the	   constitutive	   subunits	   α4,	   β1	   and	   β5	  were	   expressed	   in	   both	   young	   and	   elderly	   healthy	  
subjects	  and	  LLMI	  patients,	  while	  the	  inducible	  subunits	  β1i,	  β5i	  and	  PA28β	  were	  almost	  undetectable,	  compared	  to	  a	  
liver	   sample	   (L),	   used	   as	   internal	   positive	   control	   for	   proteasomes	   subunits.	   Protein	   isoloading	   was	   assessed	   by	  
Coomassie	  gel	  staining	  (data	  not	  shown).	  
	  
Remarkably,	   semi-­‐quantitative	   densitometric	   analyses	   showed	   that	   independently	   of	   the	  
age	  of	  subjects,	  all	  the	  proteasomes	  subunits	  considered	  were	  present	  at	  significant	  higher	  levels	  
in	   LLMI	   patients	   that	   in	   healthy	   subjects	   (α4	   p=0.0002;	   β1	   p=0.0001;	   β5	   p=0.0001;	   β1/α4	  
p=0.0073;	  β5/α4	  p=0.0001)	  (fig.	  24A-­‐E).	  




Figure	  24.	  Comparison	  of	  the	  relative	  content	  of	  proteasomes	  constitutive	  subunits	  in	  human	  v.	  lateralis	  muscle	  of	  
young	   (≤40	   years)	   and	   elderly	   (≥70	   years)	   healthy	   donors	   and	   LLMI	   patients.	   Densitometric	   analysis	   of	   the	   bands	  
corresponding	   to	   the	   constitutive	   subunits	  α4	   (A),	   β1	   (B)	   and	  β5	   (C)	  was	  performed	   in	   crude	  protein	  extracts	   from	  
human	  v.	  lateralis	  muscle	  biopsies	  of	  young	  (≤40	  years,	  healthy	  n=5,	  LLMI	  n=14)	  and	  elderly	  (≥70	  years,	  healthy	  n=14,	  
LLMI	   n=17)	   subjects.	   Data	   were	   normalized	   for	   a	   sample	   used	   as	   internal	   control	   and	   loaded	   in	   every	   gel.	   We	  
considered	  the	  mean	  of	  three	   independent	  experiments;	   in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  respective	  
quartiles.	   The	   ratio	   between	   each	   catalytic	   subunit	   and	   α4	   (β1/α4,	   β5/α4)	   was	   also	   calculated	   (D,	   E).	   Differences	  
between	  groups	  were	  analyzed	  by	  using	  Kruskal-­‐Wallis	  test	  and	  a	  p	  value<0.05	  was	  considered	  statistically	  significant.	  
Independently	   from	  age,	   all	   the	   proteasomes	   subunits	   considered	  were	   present	   at	   significant	   higher	   levels	   in	   LLMI	  
patients	   than	   in	  healthy	  subjects	   (A,	  α4	  •p=0.0002;	  B,	  β1	  •p=0.0001;	  C,	  β5	  •p=0.0001;	  D,	  β1/α4	  •p=0.0073;	  E,	  β5/α4	  
•p=0.0001).	  
	  
4.A3	  PROTEASOME	  SUBCELLULAR	  LOCALIZATION	  	  
Considering	  that	  the	  results	  on	  proteasomes	  composition	  seem	  to	  be	  almost	  the	  same	  in	  
healthy	  subjects	  and	  LLMI	  patients,	  we	  took	  advantage	  of	  the	  larger	  amount	  of	  biopsies	  available	  
from	  LLMI	  patients	  to	  deeply	  examine	  the	  subcellular	  distribution	  of	  proteasomes.	  Different	  cells	  
constitute	   the	   mature	   skeletal	   muscle,	   such	   as	   myofibers	   (multinucleated	   syncytia	   of	  
rhabdomyocytes	  which	   derive	   from	  mononuclear	   precursor	   cells),	   blood	   vessel	   endothelial	   cells	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(whose	  proportion	  is	  different	  in	  type	  I	  and	  type	  II	  fibers),	  satellite	  cells	  (the	  stem	  cells	  reservoir	  of	  
mature	   skeletal	  muscle)	   and	   cells	   of	   immune	   system	   (fig.	   25A).	   Immunohistochemical	   analyses	  
were	  performed	  by	  using	  antibodies	  specific	   for	  the	  constitutive	  (β1)	  and	   inducible	  (β1i	  and	  β5i)	  
catalytic	  subunits.	  
As	   far	   as	   the	   β1	   constitutive	   subunit,	   it	   was	   present	   in	   all	   cell	   types	   as	   expected	   and	  
focusing	   on	   rhabdomyocytes	   we	   observed	   that	   it	   was	   mainly	   localized	   at	   cytosolic	   level	   in	  
correspondence	  of	  the	  Z	  disc	  and	  of	  the	  A	  band	  of	  sarcomere	  (fig.	  25B).	  
On	   the	   contrary,	   the	   inducible	   subunits	   β5i	   (fig.	   25C)	   and	   β1i	   (fig.	   25D)	   gave	   a	  weak	   or	  
absent	  immune-­‐staining	  in	  rhabdomyocytes	  at	  cytosolic	  level,	  while	  nuclei	  were	  almost	  negative.	  
As	  reported	  in	  literature	  the	  endothelial	  cells,	  the	  white	  blood	  cells	  within	  vessels,	  and	  the	  tissue	  
lymphocytes	  were	  always	  positive	  for	  i-­‐proteasome	  (fig.	  25E).	  
No	   difference	   on	   proteasomes	   staining	   was	   observed	   between	   young	   and	   elderly	   LLMI	  
patients.	  




Figure	  25.	  Proteasomes	  subcellular	  distribution	  in	  human	  v.	  lateralis	  muscle	  of	  LLMI	  patients.	  Immunohistochemical	  
analyses	  on	  3µm	  thick	  sections	  obtained	  from	  human	  v.	  lateralis	  muscle	  of	  LLMI	  patients	  of	  different	  age	  (young	  n=8	  
and	  old	  n=7	  LLMI	  patients),	  were	  performed	  by	  using	  specific	  antibodies	  against	  the	  constitutive	  subunit	  β1	  (B)	  and	  
the	  inducible	  subunits	  β5i	  (C),	  β1i	  (D).	  Representative	  sections	  from	  one	  young	  LLMI	  patient	  (25	  years)	  are	  shown.	  The	  
β1	  subunit	  showed	  strong	  positivity	  in	  the	  cytosol	  of	  rhabdomyocytes	  (B).	  On	  the	  contrary,	  the	  inducible	  subunits	  gave	  
a	  weak	   (β5i,	  C)	   or	   absent	   (β1i,	  D)	   immune-­‐staining	   in	   rhabdomyocytes	   at	   cytosolic	   level,	  while	   nuclei	  were	   almost	  
negative.	   As	   expected	   the	   endothelial	   cells,	   the	  white	   blood	   cells	  within	   vessels,	   and	   the	   tissue	   lymphocytes	  were	  
always	   positive	   for	   i-­‐proteasome	   (E).	   Hematoxylin-­‐eosin	   staining	   was	   also	   performed	   in	   order	   to	   highlight	   cellular	  
compartment	  (A).	  
	  
4.A4	  PROTEASOME	  COMPOSITION	  AND	  CONTENT	  IN	  HUMAN	  MYOBLAST	  
CELLS	  
Satellite	   cells	   are	   a	   population	   of	   mononuclear	   muscle	   stem	   cells	   that	   reside	   at	   the	  
periphery	  of	  muscle	  fibers,	  between	  the	  basal	  lamina	  and	  the	  sarcolemma	  and	  play	  a	  pivotal	  role	  
in	  muscle	   repair	   and	   regeneration.	  Actually,	   satellite	   cells	   are	   activated	   in	   response	   to	  different	  
physiological	  and	  pathological	  stimuli	  to	  generate	  a	  committed	  population	  of	  myoblasts,	  that	  are	  
capable	  of	  differentiate	  (Carosio	  et	  al.,	  2011).	  
72	  
	  
Satellite	  cells	  were	   isolated	   from	  human	  v.	   lateralis	  muscle	  biopsies	  of	  young	  and	  elderly	  
healthy	  subjects	   in	   the	   framework	  of	   the	  European	  project	  MYOAGE,	  and	  myoblast	  cell	   cultures	  
were	  propagated	  at	  different	  oxygen	  tensions.	  We	  performed	  western	  blotting	  analysis	  on	  crude	  
protein	  extracts,	  in	  order	  to	  assess	  whether	  proteasomes	  composition	  in	  muscle	  cell	  precursors	  is	  
different	  from	  that	  observed	  ex	  vivo	  in	  mature	  and	  differentiated	  muscle	  cells.	  From	  this	  analysis	  
we	   found	   that	   myoblasts	   expressed	   high	   level	   of	   i-­‐proteasome	   subunits	   as	   well	   as	   PA28αβ	  
regulator,	   concomitantly	   with	   constitutive	   proteasomes.	   Additionally,	   in	   our	   experimental	  
conditions,	  despite	  variability	  among	  subjects,	  oxygen	  tension	  and	  age	  of	  the	  donor	  did	  not	  affect	  
proteasomes	  composition	  and	  content	  (fig.	  26).	  
	  
	  
Figure	   26.	   Representative	   immunoblotting	   of	   myoblast	   cell	   cultures	   isolated	   from	   human	   v.	   lateralis	   muscle	   of	  
young	  and	  elderly	  healthy	  donors.	  Western	  blotting	  analysis	  was	  performed	  on	  crude	  protein	  extracts	  of	  myoblast	  
cell	   cultures	   obtained	   from	   young	   (Y,	   n=3)	   and	   old	   (O,	   n=5)	   healthy	   subjects	   and	   propagated	   at	   different	   oxygen	  
tensions	   (5%	   and	   21%).	  Myoblasts	   expressed	   high	   level	   of	   the	   i-­‐proteasome	   subunits	   β1i,	   β5i	   as	  well	   as	   PA28β	   of	  
PA28αβ	  regulator,	  concomitantly	  with	  the	  constitutive	  subunits	  α4,	  β1	  and	  β5.	  Oxygen	  tension	  and	  age	  of	  the	  donor	  
did	   not	   affect	   proteasomes	   composition	   and	   content.	   A	   liver	   sample	   (L)	   was	   used	   as	   internal	   positive	   control	   for	  
proteasomes	  subunits.	  
	  
4.A5	  PROTEASOME	  FUNCTIONALITY	  
Taking	  into	  account	  the	  subtle	  age-­‐related	  modifications	  of	  proteasomes	  content	  observed	  
in	   both	   healthy	   subjects	   and	   LLMI	   patients,	   we	   performed	   additional	   investigations	   to	   test	  
whether	  aging	  impinged	  upon	  proteasomes	  functionality.	  Accordingly,	  we	  measured	  proteasomes	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activity	  indirectly	  by	  the	  quantification	  of	  oxidized	  proteins	  and	  poly-­‐ubiquitin	  conjugated	  content	  
and	   directly	   by	   short	   fluorogenic	   peptides	   assay.	   All	   the	   analyses	   were	   performed	   in	   the	   LLMI	  
patients	  of	  different	  age	  and	  gender,	  because	  no	  sufficient	  bioptic	  muscle	  samples	   from	  healthy	  
donors	  were	  available.	  
4.A5.1	  OXIDIZED	  PROTEIN	  CONTENT	  
As	   indirect	   marker	   of	   proteasomes	   functionality,	   we	   examined	   the	   content	   of	   oxidized	  
proteins	   in	  human	  skeletal	  muscle	  of	  LLMI	  patients	  of	  different	  age	  by	  oxyblot	  detection	  kit	   (fig.	  
27).	  
	  
Figure	   27.	   Analysis	   of	   oxidized	   proteins	   by	   oxyblot	   detection	   in	   crude	   protein	   extracts	   from	   human	   v.	   lateralis	  
biopsies	  of	  LLMI	  patients	  of	  different	  age.	  Equal	  amounts	  of	  crude	  protein	  extracts	  were	  analyzed	  by	  immunoblotting	  
for	   oxidized	   proteins	   content.	   The	   picture	   shows	   a	   representative	   blot	   from	   male	   muscle	   samples	   with	   the	  
characteristic	   smear	   of	   modified	   proteins.	   Protein	   isoloading	   was	   assessed	   by	   Coomassie	   gel	   staining	   (data	   not	  
shown).	  
	  
The	   densitometric	   quantification	   of	   the	   smears	   of	   oxyblots	   showed	   that	   the	   levels	   of	  
oxidized	  proteins	  were	  not	  modified	  during	  aging	  in	  whole	  samples	  size	  (p=0.11)	  (fig.	  28A);	  on	  the	  
contrary	   stratifying	   the	   results	   by	   gender,	   we	   found	   a	   slight	   age-­‐related	   increase	   in	   oxidized	  




Figure	  28.	  Relative	  content	  of	  oxidized	  proteins	  in	  human	  v.	  lateralis	  muscle	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  
years),	  and	  elderly	  (≥70	  years)	  LLMI	  patients.	  Densitometric	  analysis	  of	  the	  bands	  corresponding	  to	  oxidized	  proteins	  
was	   performed	   and	   data	   were	   normalized	   for	   a	   sample	   used	   as	   internal	   control	   and	   loaded	   in	   every	   gel.	   We	  
considered	  the	  mean	  of	  three	   independent	  experiments;	   in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  respective	  
quartiles.	  Differences	  among	  age	  groups	  were	  analyzed	  by	  using	  ANOVA	  and	  Student’s	  t	  tests	  and	  a	  p	  value<0.05	  was	  
considered	  statistically	  significant.	  The	  relative	  content	  of	  oxidized	  proteins	  in	  whole	  sample	  size	  (young	  n=15;	  middle-­‐
age	   n=25;	   old	   n=15)	  was	   preserved	   during	   aging	   (A,	   p=0.11).	   By	   stratifying	   data	   according	   to	   gender	   only	   in	  males	  
(young	  n=9;	  middle-­‐age	  n=12;	  old	  n=6)	  (C,	  p=0.033),	  but	  not	  in	  female	  subjects	  (young	  n=6;	  middle	  age	  n=13;	  old	  n=9)	  
(B,	  p=0.78)	  an	  age-­‐related	  increase	  of	  oxidized	  proteins	  content	  was	  observed.	  In	  particular,	  in	  males	  the	  comparisons	  
between	  the	  young	  group	  and	  the	  middle-­‐age	  one,	  and	  between	  young	  and	  elderly	  subjects	  were	  statically	  significant	  
(C,	  *p=0.014,	  #p=0.035,	  respectively).	  
	  
4.A5.2	  POLY-­‐UBIQUITIN	  CONJUGATED	  PROTEIN	  CONTENT	  
Proteins	   targeted	   to	   proteasome	   degradation	   are	   in	   general	   tagged	   by	   poly-­‐ubiquitin	  
chains	   that	   allow	   their	   recognition	   by	   19S	   regulator	   of	   26	   proteasome.	   Thus,	   levels	   of	   poly-­‐
ubiquitin	  conjugated	  proteins	  may	  represent	  an	  indirect	  index	  of	  proteasomes	  functionality.	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By	  using	  an	  antibody	  specific	  for	  K29-­‐,	  K48-­‐	  and	  K63-­‐	  linked	  conjugates	  (fig.	  29),	  we	  found	  no	  
age-­‐related	  modification	  in	  the	  content	  of	  poly-­‐ubiquitin	  conjugated	  proteins	  in	  the	  whole	  sample	  
size	  (p=0.99)	  (fig.	  30A),	  nor	  in	  females	  (p=0.33)	  (fig.	  30B)	  nor	  in	  male	  patients	  (p=0.31)	  (fig.	  30C). 
	  
Figure	  29.	  Content	  of	  mono-­‐	  and	  poli-­‐ubiquitin	  conjugated	  proteins	  in	  crude	  protein	  extracts	  of	  human	  v.	  lateralis	  
muscle	  derived	  from	  LLMI	  patients	  of	  different	  age.	  Representative	  immunobloting	  of	  muscle	  crude	  protein	  extracts	  
by	   using	   an	   antibody	   specific	   for	   K48-­‐,	   K63-­‐	   and	   K29-­‐	   linked	   conjugates,	   that	   recognizes	   mono-­‐	   and	   poly-­‐ubiquitin	  
conjugated	  proteins,	  but	  not	  free	  ubiquitin	  molecules.	  A	  characteristic	  smear	  of	  modified	  proteins	  was	  observed	  and	  
quantified.	  Protein	  isoloading	  was	  assessed	  by	  Coomassie	  gel	  staining	  (data	  not	  shown).	  




Figure	   30.	   Relative	   content	   of	   poly-­‐ubiquitin	   conjugated	   proteins	   in	   crude	   protein	   extracts	   of	   human	   v.	   lateralis	  
muscle	  of	  young	  (≤40	  years),	  middle	  age	  (41-­‐69	  years),	  and	  elderly	  (≥70	  years)	  LLMI	  patients.	  Densitometric	  analysis	  
of	   the	   bands	   corresponding	   to	   poly-­‐ubiquitin	   conjugated	   proteins	  was	   performed	   and	   data	  were	   normalized	   for	   a	  
sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  gel.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  
in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  respective	  quartiles.	  Differences	  among	  age	  groups	  were	  analyzed	  by	  
using	  ANOVA	   test	   and	   a	  p	   value<0.05	  was	   considered	   statistically	   significant.	   The	   relative	   content	  of	   poly-­‐ubiquitin	  
conjugated	  proteins	  in	  LLMI	  subjects	  (young	  n=16;	  middle-­‐age	  n=22;	  old	  n=15)	  was	  not	  affected	  by	  aging	  (A,	  p=0.99).	  
The	  same	  result	  emerged	  when	  females	  (young	  n=6;	  middle-­‐age	  n=12;	  old	  n=9)	  (B,	  p=0.33)	  and	  male	  patients	  (young	  
n=10;	  middle-­‐age	  n=10;	  old	  n=6)	  (C,	  p=0.31)	  were	  analyzed	  separately.	  
	  
4.A5.3	  PROTEASOME	  ACTIVITY	  
Analyzing	  proteasomes	   functionality	  by	   short	   fluorogenic	  peptides	  assay	   in	   crude	  protein	  
extracts	  of	  human	  skeletal	  muscle	  biopsies	  of	  LLMI	  patients,	  we	  found	  that	  the	  chymotrypsin-­‐like	  
(CT-­‐L),	  trypsin-­‐	  like	  (T-­‐L)	  and	  caspase-­‐like	  (C-­‐L)	  specific	  activities	  were	  similar	  among	  the	  three	  age	  
groups	  (p=0.85,	  p=0.37,	  p=0.78	  respectively)	  (fig.	  31A-­‐C).	  
The	   same	   result	   emerged	  normalizing	   the	   three	   specific	   activities	   for	  α4	   subunit	   relative	  




Figure	  31.	  Proteasomes	  functionality	   in	  human	  v.	   lateralis	  muscle	  of	  LLMI	  patients.	  Proteasomes	  specific	  activities	  
were	  analyzed	  in	  crude	  protein	  extracts	  from	  human	  v.	  lateralis	  muscle	  of	  young	  (≤40	  years,	  n=12),	  middle-­‐age	  (41-­‐69	  
years,	  n=24)	  and	  elderly	  (≥70	  years,	  n=13)	  LLMI	  patients.	  Hydrolysis	  of	  the	  fluorogenic	  peptides	  LLVY-­‐AMC	  (A),	  VGR-­‐
AMC	   (B)	   and	   LLE-­‐AMC	   (C)	   measured	   the	   chymotripsin-­‐like	   (CT-­‐L),	   the	   trypsin-­‐like	   (T-­‐L)	   and	   the	   caspase-­‐like	   (C-­‐L)	  
specific	   activities,	   respectively.	  We	   considered	   the	  mean	  of	   three	   independent	   experiments;	   in	   graph	   box	   data	   are	  
expressed	  as	  median	  and	  respective	  quartiles.	  Differences	  among	  age	  groups	  were	  analyzed	  by	  using	  ANOVA	  test	  and	  
a	   p	   value<0.05	   was	   considered	   statistically	   significant.	   None	   of	   the	   three	   proteasomes	   activities	   (expressed	   as	  
nmol/mg*min)	  was	  affected	  by	  aging	  (A,	  p=0.85;	  B,	  p=0.37;	  C,	  p=0.78).	  Same	  result	  emerged	  dividing	  specific	  activities	  
by	  α4	  relative	  content	  :	  CT-­‐L/α4,	  p=0.63	  (D);	  T-­‐L/α4,	  p=0.51	  (E);	  C-­‐L/α4,	  p=0.78	  (F).	  
	  
Stratifying	  our	  data	  by	   gender,	   in	  order	   to	   test	  whether	  proteasomes	  activities	  might	  be	  
differently	  affected	  by	  aging	  in	  male	  and	  female	  LLMI	  patients.	  We	  found	  an	  age-­‐related	  increase	  
in	  the	  T-­‐L/α4	  ratio	  in	  male	  subjects	  (p=0.026)	  (fig.	  32B),	  but	  not	  in	  females	  (p=0.66)	  (fig.	  32A).	  




Figure	   32.	   Proteasome	   trypsin-­‐like	   activity/α4	   relative	   content	   in	   human	   v.	   lateralis	  muscle	   of	   female	   and	  male	  
LLMI	  patients.	  Proteasome	  trypsin-­‐like	  specific	  activity	  was	  measured	  by	  using	  VGR-­‐AMC	  substrate	   in	  crude	  protein	  
extracts	  from	  v.	  lateralis	  biopsies	  of	  females	  (F)	  and	  males	  (M)	  belonging	  to	  young	  (≤40	  years,	  F	  n=5,	  M	  n=7	  ),	  middle-­‐
age	  (41-­‐69	  years,	  F	  n=11,	  M	  n=13),	  and	  elderly	  (≥70	  years,	  F	  n=10,	  M	  n=3)	  LLMI	  patients	  and	  normalized	  for	  α4	  relative	  
content.	  We	  considered	  the	  mean	  of	  three	  independent	  experiments;	  in	  graph	  box	  data	  are	  expressed	  as	  median	  and	  
respective	   quartiles.	   Differences	   among	   age	   groups	   were	   analyzed	   by	   using	   ANOVA	   and	   Student’s	   t	   tests	   and	   a	   p	  
value<0.05	  was	  considered	  statistically	  significant.	  Only	  in	  males	  (B,	  •p=0.026),	  but	  not	  in	  females	  (A,	  p=0.66)	  a	  slight	  
age-­‐related	   increase	   in	   trypsin-­‐like	   activity/α4	   relative	   content	   was	   observed.	   In	   particular	   in	   male	   patients	   the	  
comparisons	  between	  the	  young	  group	  and	  the	  middle-­‐age	  one	  (B,	  *p=0.018),	  and	  between	  the	  young	  and	  the	  elderly	  
(B,	  #p=0.023)	  were	  statistically	  significant.	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4.B	  ANALYSIS	  OF	  PROTEASOME	  IN	  SERUM	  OF	  HEALTHY	  SUBJECTS	  AND	  LLMI	  
PATIENTS	  
Although	  proteasomes	  are	  mainly	   linked	  to	   intracellular	  protein	  degradation,	  several	  studies	  
have	  reported	  their	  presence	  in	  extracellular	  spaces	  and	  fluids,	  as	  intact	  and	  proteolitically	  active	  
enzymes,	   named	   circulating	   proteasomes	   (c-­‐proteasomes).	   The	   incidence	   and	   relevance	   of	   c-­‐
proteasomes	  have	  been	  investigated	  in	  different	  pathological	  conditions,	  where	  their	  levels	  often	  
correlated	  with	   disease	   activity	   and	   clinical	   outcome	   (Sixt	   et	   al.,	   2008).	  However,	   at	   present	   no	  
data	  are	  available	  concerning	  c-­‐proteasome	   levels	   in	  patients	  with	  restricted	  mobility,	  as	  well	  as	  
during	  healthy	  aging.	  
	  
4.B1	  CIRCULATING	  PROTEASOME	  CONCENTRATION	  IN	  HEALTHY	  SUBJECTS	  
Firstly	  we	  measured	  c-­‐proteasomes	  levels	  in	  serum	  from	  young	  (≤40	  years)	  and	  old	  healthy	  
subjects	  (≥70	  years),	  by	  ELISA	  immune-­‐assay.	  
A	   statistically	   significant	   decrease	   of	   c-­‐proteasomes	   levels	   in	   elderly	   subjects	   was	   observed	  
(p=0.0002)	  (fig.	  33A);	  this	  result	  also	  emerged	  by	  stratifying	  according	  to	  gender,	  both	  in	  females	  
(p=0.0001)	  (fig.	  33B)	  and	  male	  subjects	  (p=0.014)	  (fig.	  33C).	  




Figure	  33.	  Serum	  levels	  of	  c-­‐proteasome	  in	  healthy	  donors	  of	  different	  age.	  Circulating	  proteasomes	  concentration	  
was	  detected	  by	  a	  home-­‐made	  ELISA	  assay	   in	   serum	  samples	   from	  young	   (≤40	  years,	  n=33)	  and	  elderly	   (≥70	  years,	  
n=67)	   healthy	   subjects.	   Data	   were	   normalized	   for	   a	   sample	   used	   as	   internal	   control	   and	   loaded	   in	   every	   plate.	  
Comparison	  between	  the	  two	  age	  groups	  was	  calculated	  by	  using	  Student’	  t-­‐test	  and	  a	  p	  value<0.05	  was	  considered	  
statistically	  significant.	  A	  decrease	  of	  c-­‐proteasomes	  levels,	  expressed	  as	  ng/ml,	  was	  observed	  in	  elderly	  respect	  young	  
subjects	  (A,	  *p=0.0002).	  Stratifying	  by	  gender,	  this	  result	  was	  confirmed	  also	  in	  old	  females	  (B,	  *p=0.0001)	  and	  in	  old	  
male	  donors	  (C,	  *p=0.014).	  
	  
Additionally,	  we	  tested	  whether	  gender	  impinges	  upon	  c-­‐proteasomes	  levels,	  by	  comparing	  
female	  and	  male	  donors	  of	  the	  same	  age	  group.	  From	  this	  analysis	  we	  found	  that	  c-­‐proteasomes	  
levels	  were	  higher	   in	  elderly	  male	   than	  old	   females	   (p<0.0001)	   (fig.	   34B),	   but	   similar	  within	   the	  
young	  group	  (p=0.20)	  (fig.	  34A).	  




Figure	   34.	   Serum	   levels	   of	   c-­‐proteasomes	   in	   healthy	   male	   and	   female	   donors	   of	   different	   age.	   Circulating	  
proteasomes	   in	   serum	  samples	   from	  young	   (≤40	  years,	   F	  n=19,	  M	  n=14	   )	   and	  elderly	   (≥70	  years,	   F	  n=31,	  M	  n=36	   )	  
healthy	  subjects.	  Data	  were	  normalized	  for	  a	  sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  plate.	  Comparison	  
between	   female	   and	   male	   donors	   of	   the	   same	   age	   group	   was	   calculated	   by	   using	   Mann-­‐Whitney	   test	   and	   a	   p	  
value<0.05	   was	   considered	   statistically	   significant.	   The	   analysis	   showed	   that	   c-­‐proteasomes	   levels	   were	   higher	   in	  
elderly	  male	  subjects	  than	  old	  females	  (B,	  *p<0.001),	  with	  no	  gender	  difference	  within	  the	  young	  group	  (A,	  p=0.20).	  
	  
4.B2	  CIRCULATING	  PROTEASOME	  CONCENTRATION	  IN	  LLMI	  PATIENTS	  
Secondly,	  we	  measured	  c-­‐proteasomes	  levels	  in	  serum	  of	  LLMI	  patients	  of	  different	  age.	  
Remarkably	   also	   in	   this	   case,	   a	   significant	   decrease	   of	   c-­‐proteasomes	   levels	   during	   aging	   was	  
observed	  in	  whole	  samples	  size	  (p=0.04)	  (fig.	  35A),	  but	  not	  when	  females	  (p=0.13)	  (fig.	  35B)	  and	  
male	  subjects	  (p=0.25)	  (fig.	  35C)	  were	  analyzed	  separately.	  




Figure	  35.	  Serum	  levels	  of	  c-­‐proteasomes	   in	  LLMI	  patients	  of	  different	  age.	  Circulating	  proteasomes	  concentration	  
was	  measured	  in	  serum	  samples	  from	  young	  (≤40	  years,	  n=11),	  middle-­‐age	  (41-­‐69	  years,	  n=15)	  and	  elderly	  (≥70	  years,	  
n=20)	   LLMI	   patients.	   Data	   were	   normalized	   for	   a	   sample	   used	   as	   internal	   control	   and	   loaded	   in	   every	   plate.	  
Comparison	   among	   the	   three	   age	   groups	   was	   performed	   by	   using	   Kruskal-­‐Wallis	   test	   and	   a	   p	   value<0.05	   was	  
considered	   statistically	   significant.	   The	   analysis	   showed	   that	   c-­‐proteasomes	   levels	   (ng/ml)	   decrease	   with	   aging	   (A,	  
•p=0.04);	  in	  particular	  the	  comparisons	  between	  the	  young	  and	  the	  elderly	  (A,	  *p=0.028)	  and	  between	  the	  middle-­‐age	  
group	  and	  the	  old	  one	  (A,	  #p=0.045)	  were	  statistically	  significant.	  Stratifying	  by	  gender,	  no	  age-­‐related	  modifications	  
were	  observed	  in	  females	  (B,	  p=0.13)	  and	  males	  (C,	  p=0.25)	  LLMI	  patients.	  
	  
Additionally,	   analyzing	   the	   three	   different	   age	   groups	   separately,	   in	   contrast	   to	   healthy	  
subjects,	  no	  difference	  according	  to	  gender	  was	  found	  for	  c-­‐proteasomes	   levels	   in	  LLMI	  patients	  
(fig.	  36A-­‐C).	  




Figure	  36.	  Serum	  levels	  of	  c-­‐proteasomes	  in	  male	  and	  female	  LLMI	  patients	  of	  different	  age.	  Circulating	  proteasomes	  
in	  serum	  samples	  from	  young	  (≤40	  years,	  F	  n=5,	  M	  n=6	  ),	  middle-­‐age	  (41-­‐69	  years,	  F	  n=5,	  M	  n=10)	  and	  elderly	  (≥70	  
years,	  F	  n=14,	  M	  n=6)	  LLMI	  patients.	  Data	  were	  normalized	  for	  a	  sample	  used	  as	  internal	  control	  and	  loaded	  in	  every	  
plate.	   Comparison	   between	   female	   and	  male	   patients	   within	   the	   same	   age	   group	  was	   performed	   by	   using	  Mann-­‐
Whitney	   test	   and	   a	   p	   value<0.05	   was	   considered	   statistically	   significant.	   No	   difference	   according	   to	   gender	   was	  
observed	  for	  all	  three	  age	  groups	  (A,	  the	  young	  group;	  B,	  the	  middle-­‐age	  group;	  C,	  the	  elderly	  group).	  
	  
4.B3	  COMPARISON	  OF	  CIRCULATING	  PROTEASOME	  LEVELS	  BETWEEN	  
HEALTHY	  SUBJECTS	  AND	  LLMI	  PATIENTS	  
Taking	   into	  account	  that	   in	  several	  pathological	  conditions,	  such	  as	  cancer,	  autoimmunity	  
and	  inflammatory	  diseases,	  c-­‐proteasomes	  levels	  were	  higher	  than	  those	  of	  healthy	  controls,	  we	  
investigated	  whether	  this	  phenomenon	  was	  also	  present	   in	  LLMI	  patients.	  Thus	  we	  compared	  c-­‐
proteasomes	  levels	  between	  LLMI	  patients	  and	  healthy	  subjects,	  within	  the	  same	  age	  group.	  
In	  young	  subjects	  c-­‐proteasomes	   levels	  were	  higher	   in	  LLMI	  patients	  than	  healthy	  donors	  
(p=0.0096)	  (fig.	  37A);	  while	  only	  a	  trend	  was	  observed	  for	  the	  same	  comparison	  between	  patients	  
and	  healthy	  within	  the	  elderly	  group	  (p=0.06)	  (fig.	  37A).	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Stratifying	  by	  gender,	  in	  order	  to	  test	  whether	  LLMI	  pathology	  differently	  affected	  levels	  of	  
c-­‐proteasomes	   in	   male	   and	   female	   subjects,	   in	   the	   same	   age	   groups.	   Higher	   levels	   of	   c-­‐
proteasomes	  were	  observed	  in	  LLMI	  patients	  respect	  to	  healthy	  donors	  within	  the	  female	  elderly	  
group	  (p=0.0065)	  (fig.	  37B)	  with	  no	  modification	  in	  the	  female	  young	  group	  (p=0.19)	  (fig.	  37B).	  On	  
the	  contrary,	  c-­‐proteasomes	  levels	  were	  higher	  in	  young	  male	  patients	  than	  in	  young	  male	  healthy	  
donors	  (p=0.017)	  (fig.	  37C),	  but	  similar	  levels	  were	  reported	  in	  the	  elderly	  (p=0.18)	  (fig.	  37C).	  




Figure	   37.	   Comparison	   of	   c-­‐proteasomes	   serum	   levels	   between	   healthy	   subjects	   and	   LLMI	   patients.	   Circulating	  
proteasomes	  concentration	  in	  serum	  samples	  from	  young	  (≤40	  years,	  healthy	  n=33,	  LLMI	  n=11)	  and	  elderly	  (≥70	  years,	  
healthy	  n=67,	   LLMI	  n=20)	  donors.	  Data	  were	  normalized	   for	   a	   sample	  used	  as	   internal	   control	   and	   loaded	   in	  every	  
plate.	  Differences	  between	   groups	  were	   calculated	  by	  using	  Kruskal-­‐Wallis	   test	   and	   a	  p	   value<0.05	  was	   considered	  
statistically	   significant.	  We	   observed	   higher	   c-­‐proteasomes	   levels	   in	   LLMI	   patients	   than	   in	   healthy	   subjects	   for	   the	  
young	   (A,	   *p=0.0096),	   whereas	   only	   a	   trend	  was	   observed	   in	   the	   old	   group	   (A,	   p=0.06).	   Stratifying	   by	   gender	   the	  
young	  (≤40	  years,	  healthy	  F	  n=19,	  healthy	  M	  n=14;	  LLMI	  F	  n=5,	  LLMI	  M=	  6)	  and	  the	  elderly	  (≥70	  years,	  healthy	  F	  n=31,	  
healthy	  M	  n=36;	   LLMI	  F	  n=14,	   LLMI	  M	  n=6)	   subjects,	  we	   found	  significant	  higher	   levels	  of	   c-­‐proteasomes	   in	   female	  
patients	  respect	  to	   female	  healthy	  subjects	  within	  the	  elderly	  group	  (B,	  *p=0.0065),	  but	  similar	   levels	   in	   the	   female	  
young	  donors	  (B,	  p=0.19).	  On	  the	  contrary,	  c-­‐proteasomes	  levels	  were	  higher	  in	  young	  male	  patients	  respect	  to	  young	  
male	  healthy	  subjects	  (C,	  *p=0.017),	  with	  no	  difference	  in	  the	  male	  elderly	  group	  in	  the	  comparison	  between	  patients	  
and	  healthy	  (C,	  p=0.19).	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4.B4	  CORRELATION	  BETWEEN	  C-­‐PROTEASOMES	  LEVEL,	  ANTHROPOMETRIC	  
PARAMETERS	  AND	  CYTOKINES	  IN	  HEALTHY	  SUBJECTS	  
At	   last,	   we	   performed	   correlation	   analyses	   between	   c-­‐proteasomes	   level	   and	   additional	  
variables	  included	  in	  the	  MYOAGE	  database,	  described	  by	  McPhee	  and	  co-­‐workers	  (McPhee	  et	  al.,	  
2013).	  In	  particular,	  informations	  on	  anthropometric	  and	  body	  composition	  parameters,	  as	  well	  as	  
muscle	  function	  (handgrip	  strength	  and	  quadriceps	  torque	  best	  effort)	  were	  used.	  Additionally,	  we	  
performed	   the	   same	   correlation	   analyses	   between	   c-­‐proteasomes	   level	   and	   the	   level	   of	   some	  
adipokines	   (leptin,	   adiponectin	   and	   resistin)	   as	   well	   as	   IGF-­‐1,	   measured	   in	   serum	   of	   healthy	  
subjects,	  by	  co-­‐workers	  in	  the	  laboratory	  (Bucci	  et	  al.,	  2013).	  As	  shown	  in	  table	  10,	   in	  the	  whole	  
sample	  size	  of	  healthy	  subjects,	  we	  observed	  a	  positive	  correlation	  between	  c-­‐proteasomes	  level	  
with	  handgrip	  and	  quadriceps	   strength	  as	  well	   as	   IGF-­‐1.	  On	   the	   contrary,	   a	  negative	   correlation	  
was	  found	  between	  c-­‐proteasomes	  level	  and	  total	  fat	  mass,	  both	  in	  weight	  (kg)	  than	  in	  percentage	  
(%),	  as	  well	  as	  for	  leptin,	  and	  resistin/IGF-­‐1	  ratio.	  
	  
	  
Table	  10.	  Correlation	  analysis	  of	  c-­‐proteasomes	  levels	  with	  anthropometric	  measurements	  and	  cytokines	  levels	   in	  
all	   healthy	   subjects	   (n=99).	   In	   Table	   are	   shown	   positive	   and	   negative	   correlations	   between	   c-­‐proteasomes	  
concentration	  and	  different	  anthropometric	  variables,	  as	  well	  as	  cytokine	  levels.	  C=Spearman's	  correlation	  coefficient.	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Stratifying	  by	  age,	  we	  observed	  no	  significant	  correlation	  between	  c-­‐proteasomes	  level	  and	  
the	  above	  described	  variables	   in	  the	  young	  healthy	  subjects.	  On	  the	  contrary,	   in	  the	  old	  healthy	  
donors	   we	   found	   a	   significant	   positive	   correlation	   between	   c-­‐proteasomes	   level	   and	   weight,	  
handgrip,	   quadriceps	   strength;	   while	   total	   fat	   mass	   (%),	   leptin	   and	   leptin/adiponectin	   ratio	  
correlated	  negatively	  with	  c-­‐proteasomes	  level	  (table	  11).	  
	  
	   	  	  	  	  	  Young	   	   	   	  	  	  	  	  Old	   	  
	   	  	  	  	  C	   	  	  	  	  p	   	   	  	  	  	  C	   	  	  	  	  	  	  p	  
Weight	  (kg)	   	  0.113	   0.531	   	   0.269	   	  	  	  0.029	  
Handgrip	  (kg)	   	  0.208	   0.253	   	   0.447	   	  <0.0001	  
Quadriceps	  strength	  (N/m)	   	  0.295	   0.095	   	   0.376	   	  	  	  0.002	  
Total	  fat	  mass	  (%)	   -­‐0.113	   0.0538	   	   -­‐0.45	   	  <0.001	  
Leptin	  (ng/ml)	   -­‐0.091	   0.615	   	   -­‐0.359	   	  	  	  0.003	  
Leptin/adiponectin	  ratio	   -­‐0.092	   0.611	   	   -­‐0.293	   	  	  	  0.017	  
	  
Table	  11.	  Correlation	  analysis	  of	  c-­‐proteasomes	  levels	  with	  anthropometric	  measurements	  and	  cytokines	  levels	   in	  
young	  (n=33)	  and	  elderly	  (n=66)	  healthy	  subjects.	  In	  Table	  are	  shown	  positive	  and	  negative	  correlations	  between	  c-­‐
proteasomes	   concentration	   and	   different	   anthropometric	   variables,	   as	  well	   as	   cytokines.	   C=Spearman's	   correlation	  
coefficient.	  
	  
We	  did	  not	  further	   investigated	  possible	  gender-­‐related	  differences,	  because	  the	  number	  




Human	  aging	  and	  longevity	  are	  complex	  and	  multifactorial	  traits,	  that	  are	  the	  result	  of	  the	  
interaction	  between	  environmental,	  genetic,	  epigenetic	  and	  stochastic	   factors,	  each	  contributing	  
to	  the	  overall	  phenotype	  (Salvioli	  et	  al.,	  2013;	  Rattan	  2007;	  D’Aquila	  et	  al.,	  2013).	  These	  complex	  
processes	   act	   differently	   in	   each	   organ	   system,	   tissue	   and	   even	   in	   single	   cells	   of	   the	   body,	  
determining	  a	  different	  aging	  rate	  for	  each	  of	  them.	  Thus,	  the	  aged	  body	  could	  be	  considered	  as	  a	  
mosaic	  of	  tissues	  and	  organs	  displaying	  different	  level	  of	  senescence,	  a	  situation	  we	  proposed	  to	  
indicate	   as	   a	   dynamic	   “aging	   mosaic”	   (Cevenini	   et	   al.,	   2010).	   An	   example	   is	   the	   brain,	   where	  
different	   regions	   such	   as	   cortex,	   hippocampus	   and	   cerebellum	   show	   different	   levels	   of	  
neurodegeneration	  and	  inflammation	  (Mishto	  et	  al.,	  2006a).	  
Despite	   some	   structural	   changes	   in	   its	  morphology	   and	   a	   reduced	   regenerative	   capacity,	  
human	  liver	  seems	  to	  be	  marginally	  affected	  by	  aging	  (Schmucker,	  2005;	  Schmucker	  et	  al.,	  2011;	  
Tajiri	   et	   al.,	   2013).	   Accordingly,	   orthotopic	   liver	   transplants	   where	   the	   age	   of	   the	   donor	   is	  
considerably	  higher	  than	  that	  of	  the	  recipient,	  have	  notably	   increased	  in	  the	  last	  years,	  and	  liver	  
graft	   from	  aged	   subjects	   has,	   in	   specific	   conditions,	   function	   and	  duration	   comparable	   to	   those	  
achievable	  with	  liver	  grafts	  from	  young	  donors	  (Cescon	  et	  al.,	  2003;	  Gastaca	  et	  al.,	  2005;	  Cescon	  et	  
al.,	  2008;	  Schmeding	  et	  al.,	  2010).	  This	  evidence	   seems	   to	   indicate	   for	   the	   liver	  a	  peculiar	  aging	  
pattern	   where	   the	   biological	   age	   does	   not	   correspond	   to	   the	   chronological	   age	   of	   the	  
organ/donor,	   and	   indirectly	   confirms	   its	   capacity	   to	   rejuvenate	   when	   in	   presence	   of	   the	  
appropriate	  microenvironment	  (Conboy	  et	  al.,	  2005).	  
On	   the	   contrary,	   a	   decrease	   in	   mass,	   strength	   and	   power	   in	   human	   skeletal	   muscle	   (a	  
phenomenon	  defined	  as	  sarcopenia)	  occurs	  during	  human	  aging,	   leading	  to	  a	  progressive	   loss	  of	  
mobility	   and	   increased	   risk	   of	   falls	   and	   invalidity.	   Different	   factors	   are	   involved	   in	   the	   onset	   of	  
skeletal	   muscle	   wasting,	   including	   denervation,	   inactivity,	   hormonal	   and	   nutritional	   changes,	  
inflammation	  and	   imbalance	  between	  protein	  synthesis	  and	  degradation,	  among	  others	  (Lang	  et	  
al.,	   2010;	   Sipilä	   et	   al.,	   2013).	   In	   fact,	   alterations	   in	   proteolysis	  may	   contribute	   to	   the	  onset	   and	  
progression	  of	  several	  age-­‐related	  pathological	  conditions,	   including	  skeletal	  muscle	  wasting	  and	  
sarcopenia	  (Ciechanover,	  2013),	  as	  well	  as	  to	  the	  aging	  phenotypes	  (López-­‐Otín	  et	  al.,	  2013).	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The	  ubiquitin-­‐proteasome	  system	  (UPS)	  is	  one	  of	  the	  most	  important	  cellular	  pathways	  for	  
intracellular	   degradation	   of	   short-­‐lived	   as	   well	   as	   damaged	   proteins,	   thus	   contributing	   to	   the	  
maintenance	   of	   cellular	   homeostasis	   (Chondrogianni	   et	   al.,	   2010;	   Koga	   et	   al.,	   2011).	   Several	  
studies	  reported	  that	  the	  content	  and	  the	  activity	  of	  proteasomes,	  the	  catalytic	  core	  of	  UPS,	  are	  
variably	   affected	  by	   aging	   in	  different	   cell	   types	   and	  organs,	   both	   in	  human	  and	  animal	  models	  
(Baraibar	  et	  al.,	  2012).	  To	  date,	  studies	  of	  liver	  proteasomes	  composition	  and	  functionality	  during	  
aging	  produced	  controversial	  results	  in	  rodents	  (Baraibar	  et	  al.,	  2012)	  and	  no	  data	  are	  available	  on	  
the	  age-­‐related	  modifications	  of	  proteasomes	  in	  human	  liver.	  However,	  our	  previous	  observations	  
on	  proteasome	  dynamic	  in	  normal	  fetal	  and	  adult	  human	  livers	  demonstrated	  that	  i-­‐proteasome	  is	  
absent	   in	   hepatocytes	   during	   fetal	   life,	   but	   it	   is	   detectable	   at	   cytoplasmic	   level	   from	   the	   third	  
month	  of	  extrauterine	  life	  (Vasuri	  et	  al.,	  2010).	  
Regarding	   skeletal	   muscle,	   most	   of	   the	   studies	   present	   in	   the	   literature	   have	   been	  
performed	  in	  animal	  models	  and	  they	  were	  mainly	  focused	  on	  ubiquitin	  pathway,	  rather	  than	  on	  
proteasomes	  (Vinciguerra	  et	  al.,	  2010).	  In	  rat,	  an	  age-­‐related	  increase	  of	  constitutive	  proteasomes	  
and	  i-­‐proteasomes	  content	  in	  type	  I	  and	  II	  fibers	  of	  skeletal	  muscle	  (Husom	  et	  al.,	  2004;	  Ferrington	  
et	  al.,	  2005),	  as	  well	  as	  in	  gastrocnemius	  and	  soleus	  muscles	  of	  aged	  sarcopenic	  animals	  (Altun	  et	  
al.,	  2010)	  has	  been	  reported.	  However,	  despite	  the	  age-­‐related	  induction	  of	  the	  i-­‐proteasome,	  this	  
isoform	   seems	   to	   represent	   a	   minor	   fraction	   of	   total	   proteasomes	   in	   rat	   skeletal	   muscle	  
(Dahlmann	   et	   al.,	   2001).	   Only	   one	   study	   examined	   proteasomes	   functions	   in	   human	   rectus	  
abdominis	  muscle	  and	  no	  age-­‐related	  changes	  emerged	  (Bossola	  et	  al.,	  2008).	  
On	   these	   premises,	   we	   aimed	   at	   analyzing	   proteasomes	   changes	   in	   human	   liver	   and	  
skeletal	  muscle	  during	  aging,	  taking	  advantage	  of	  two	  research	  projects	   in	  which	  our	  group	  was	  
involved:	   the	   Italian	   Ministry	   of	   University	   and	   Research	   Grant	   PRIN2008	   ‘’Pretransplant	   liver	  
biological	   age	   and	   age-­‐mismatch	   between	   donor	   and	   recipient	   as	   new	   predictors	   of	   transplant	  
outcome’’	   to	   Dr.	   Gianluca	   Grazi,	   Regina	   Elena	   Hospital,	   Rome,	   and	   the	   FP7	   European	   project	  
“MYOAGE	   -­‐	   Understanding	   and	   Combating	   Age-­‐related	   Muscle	   weakness”,	   coordinator	   Prof.	  
Gillian	  Butler-­‐Browne,	  INSERM,	  Paris,	  France.	  Additionally,	  we	  studied	  for	  the	  first	  time	  the	  levels	  
of	   circulating	   proteasomes,	   the	   extracellular	   proteasome	   isoforms,	   in	   sera	   of	   young	   and	   aged	  
healthy	  subjects	  as	  well	  as	  patients	  with	  lower	  limb	  mobility	  impairment	  (LLMI).	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5.1	  LIVER	  STUDY	  
The	   analyses	   of	   proteasomes	   composition	   at	   protein	   level	   showed	   that	   i-­‐proteasome	  
catalytic	  subunits,	  concomitantly	  to	  their	  homologous	  of	  constitutive	  proteasome,	  were	  expressed	  
in	   different	   cell	   types	   of	   human	   liver,	   including	   hepatocytes,	   and	   incorporated	   into	   active	   20S	  
proteasomes.	  The	  histological	  analysis	  of	  these	  liver	  biopsies	  showed	  no	  signs	  of	  necrotic	  damage	  
or	   morphologically	   evident	   inflammation;	   thus	   the	   presence	   of	   i-­‐proteasomes	   even	   in	   young	  
subjects	   suggests	   that,	   at	   variance	  with	  other	  organs	   such	  as	  brain,	   in	   liver	  a	  basal	   level	  of	  pro-­‐
inflammatory	  cytokines	  is	  warranted,	  probably	  sustained	  by	  the	  continuous	  exposure	  to	  antigenic	  
stimuli	  coming	  from	  the	  gut	  microbiota	  via	  the	  portal	  vein.	  In	  fact	  hepatocytes	  express	  a	  number	  
of	   pattern	   recognition	   receptors	   (PRR),	   such	   as	   TLR3,	   RIG-­‐I	   and	   MDA5	   that	   can	   trigger	   the	  
production	   of	   inflammatory	   cytokines	   (Broering	   et	   al.,	   2011).	   At	   the	   same	   time	   a	   permanent	  
activation	  of	  intracellular	  signaling	  pathways	  could	  be	  also	  possible	  (Ebstein	  et	  al.,	  2012;	  Grimm	  et	  
al.,	  2012)	  although	  such	  notions	  remain	  to	  be	  formally	  addressed.	  	  
As	   far	   as	   age-­‐related	   changes	   of	   proteasomes	   content,	   we	   detected	   an	   age-­‐related	  
decrease	  of	  β1	  and	  a	  non-­‐monotonic	  variation	  of	  β2	  catalytic	  constitutive	  subunits.	  By	  stratifying	  
the	   sample	   size	   according	   to	   gender,	   the	  β1	   subunit	   decreased	  with	   aging	  only	   in	  male	  donors,	  
while	  an	   increase	   in	  β5i/α4	  ratio	   in	   the	  whole	  sample	  set	  and	  both	   in	   female	  and	  male	  subjects	  
was	   observed.	   This	   suggests	   that	   during	   aging	   a	   shift	   toward	   proteasomes	   containing	  
immunosubunits	   occurs,	   as	   recently	   described	   also	   in	   aged	   rat	   liver	   (Gohlke	   et	   al.,	   2014).	  
Concomitantly,	   PA28α	   subunit	   representative	   of	   PA28αβ	   proteasome	   regulator	   decreased	   with	  
age	   in	  whole	  sample	  size	  and	   in	  male	  elderly	  biopsies.	   Interestingly,	   IHC	  analyses	  suggested	  that	  
this	  age-­‐related	  modifications	  occurred	  mainly	  in	  the	  cytosol	  of	  hepatocytes.	  As	  no	  variation	  in	  the	  
amount	  of	  PA700	  regulator	  occurred,	  it	  is	  possible	  that	  liver	  aging	  is	  accomplished	  by	  a	  variation	  in	  
the	  amount	  of	  hybrid	  PA700-­‐20S-­‐PA28	  and	  PA28-­‐20S-­‐PA28	  proteasomes.	  Taking	  into	  account	  that	  
intermediate	   type	   proteasomes	   as	   well	   hybrid	   proteasomes	   might	   have	   different	   substrate	  
preferences	  and	   increase	  antigenic	  diversity	   (Gohlke	  et	   al.,	   2014;	  Vigneron	  et	   al.,	   2012),	   further	  
investigations	   on	   changes	   in	   proteome	   repertoire	   during	   liver	   aging	   should	   be	   addressed.	  
Moreover,	  at	  present,	  no	  data	  are	  available	  on	  gender	  contribution	  to	  proteasomes	  content,	  and	  
considering	  that	  biopsies	  from	  young	  female	  donors	  were	  not	  available,	  additional	  studies	  on	  this	  
issue	  should	  be	  performed.	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Regarding	   the	   analysis	   of	   proteasomes	   functionality,	   the	   major	   finding	   of	   our	   study	   in	  
human	  liver	  is	  that	  we	  did	  not	  observe	  any	  accumulation	  of	  oxidized	  proteins,	  a	  classical	  hallmark	  
of	  normal	  aging	  and	  age-­‐related	  diseases.	  At	  the	  same	  time,	  we	  did	  not	  observe	  any	  age-­‐related	  
changes	   in	   the	  amount	  of	  poly-­‐ubiquitin	  conjugates,	   including	   those	  on	  Lys48,	  which	   represents	  
the	  main	  signal	  for	  proteasome	  degradation,	  suggestive	  of	  a	  preserved	  functionality.	  Indeed,	  only	  
a	   drop	   of	   the	   T-­‐like	   and	   C-­‐like	   activities	   normalized	   for	   proteasomes	   content	  were	   observed	   in	  
male	  donors	  of	  middle-­‐age	  group,	  with	  not	  statistically	  significant	  differences	  between	  the	  young	  
and	  the	  old	  groups.	  Taking	  into	  account	  that	  our	  investigations	  were	  performed	  on	  crude	  protein	  
extracts	   of	   liver	   biopsies,	  we	  were	   not	   able	   to	   discriminate	   between	   20S	   and	   26S	   proteasomes	  
activity,	  as	  well	  as	   to	  assess	   the	   role	  of	  others	  possible	  mechanisms	  of	   regulation.	  Thus,	   further	  
tests	  on	  purified	  proteasomes	  are	  needed	  to	  assess	  whether	  aging	  might	  impinge	  upon	  these	  two	  
isoforms	   at	   different	   extent.	   Additionally,	   our	   data	   also	   suggest	   that	   gender	   could	   affect	  
proteasomes	   functionality	   and	   oxidative	   stress	   response,	   thus	   this	   issue	   has	   to	   be	   considered	  
when	  performing	  studies	  in	  humans	  (Baumgartner	  et	  al.,	  1999;	  Fanò	  et	  al.,	  2001).	  
	  
5.2	  MUSCLE	  STUDY	  
The	  analyses	  of	  proteasomes	  composition	  showed	  at	  the	  level	  of	  gene	  expression	  an	  age-­‐
related	   increase	  of	   the	   inducible	  components,	   such	  as	  β1i	  and	  β5i	  catalytic	  subunits,	  and	  PA28β	  
subunit	  of	  PA28αβ	  regulatory	  complex,	   in	  healthy	  subjects,	  along	  with	  no	  change	  of	  constitutive	  
components,	  represented	  by	  α6	  and	  β1.	  The	  same	  trend,	  even	  if	  not	  significant,	  was	  also	  detected	  
in	  LLMI	  patients,	   suggesting	   that	   the	  expression	  of	   inducible	  components	  of	  proteasome	  can	  be	  
up-­‐regulated	  during	  physiological	  aging	  as	  well	  as	  physical	  inactivity,	  likely	  due	  to	  the	  presence	  of	  
pro-­‐inflammatory	   cytokines,	   such	   as	   TNF-­‐α	   that	   may	   activate	   the	   NF-­‐kB	   pathway,	   as	   recently	  
demonstrated	   (Barberi	  et	  al.,	  2013).	  However,	  we	  observed	   that	   i-­‐proteasomes	  were	  present	  at	  
very	  low	  protein	  levels	  in	  human	  v.lateralis	  skeletal	  muscle.	  In	  particular,	  β1i	  and	  PA28β	  subunits	  
were	   barely	   detectable	   in	   biopsies	   of	   LLMI	   patients	   and	   all	   the	   three	   inducible	   components,	  
including	   β5i,	   were	   absent	   in	   both	   young	   and	   elder	   healthy	   donors.	   These	   data	   were	   also	  
confirmed	  by	  IHC	  in	  LLMI	  subjects;	  indeed,	  in	  the	  rhabdomyocytes,	  the	  staining	  for	  the	  constitutive	  
component	  of	  proteasomes,	   represented	  by	  β1,	  was	  strong	  at	  cytosolic	   level,	  while	   in	   the	  same	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cell	  type	  the	  signals	  corresponding	  to	  β1i	  and	  β5i	  were	  absent	  or	  barely	  detectable.	  Therefore,	  it	  is	  
to	   suppose	   that	   post-­‐transcriptional	   and/or	   post-­‐translational	   mechanisms	   may	   impinge	   upon	  
protein	  synthesis,	  assembly	  and	  maturation	  of	  inducible	  proteasomes,	  in	  terminally	  differentiated	  
rhabdomyocytes.	   The	   same	   phenomenon	   has	   been	   observed	   in	   the	   brain	   of	   lymphocytic	  
choriomeningitis	  virus-­‐infected	  mice	   (Kremer	  et	  al.,	  2010),	  where	  an	  accumulation	  of	  precursors	  
but	   not	   mature	   i-­‐proteasomes	   was	   shown	   in	   microglia	   cells.	   Thus,	   it	   is	   possible	   that	   in	  
rhabdomyocytes,	   despite	   be	   present	   at	   transcriptional	   level,	   the	   presence	   of	   mature	   20S	   i-­‐
proteasome	  might	  be	  deleterious	  or	  not	  necessary	  for	  muscle	  cell	  metabolism.	  Moreover,	  as	  Altun	  
and	  co-­‐workers	  showed,	  immunoblotting	  analysis	  performed	  by	  using	  antibody	  directed	  against	  i-­‐
proteasome	   subunits	   in	   crude	   protein	   extracts	   has	   low	   sensitivity,	   thus	   a	   more	   sensitive	   assay	  
involving	  specific	  probes	  for	  active	  β	  subunits	  (Kessler	  et	  al.,	  2001)	  may	  help	  to	  further	  investigate	  
the	  contribution	  of	  i-­‐proteasome	  in	  human	  skeletal	  muscle	  cells.	  	  
Remarkably,	   a	   different	   scenario	   was	   observed	   when	   we	   studied	   myoblast	   cell	   cultures	  
obtained	   from	   v.	   lateralis	   muscle	   biopsies	   of	   young	   and	   old	   donors	   and	   propagated	   in	   vitro.	  
Indeed,	  by	  performing	  western	  blotting	  analysis	  on	  crude	  protein	  extracts	  of	  myoblast	  cell	  cultures	  
from	  young	  and	  elderly	  subjects,	  we	  found	  that	  these	  muscle	  precursors	  expressed	  high	   level	  of	  
inducible	   components	   (β1i,	   β5i,	   PA28β),	   concomitantly	   with	   constitutive	   proteasomes.	   Our	  
findings	   thus	   indirectly	   provide	   new	   evidence	   supporting	   the	   notion	   that	   i-­‐proteasome	  may	   be	  
required	   for	   the	   maintenance	   of	   proliferative	   capacity	   of	   muscle	   cells.	   Indeed,	   an	   enhanced	  
expression	  of	   genes	  encoding	   subunits	  of	   the	  20S	   i-­‐proteasome	   in	  human	  embryonic	   stem	  cells	  
coupled	   to	   their	   down-­‐regulation	   as	   the	   cells	   progress	   into	   differentiation	   has	   been	   reported,	  
suggesting	   a	   role	   in	   the	   degradation	   of	   cell	   cycle	   regulatory	   components	   and/or	   differentiation	  
inducing	   factors	   (Atkinson	   et	   al.,	   2012).	   Furthermore,	   an	   involvement	   of	   i-­‐proteasome	   in	   the	  
protection	  against	  oxidative	  stress,	  through	  its	  ability	  to	  remove	  more	  efficiently	  than	  constitutive	  
proteasomes,	  oxidized	  and	  damaged	  proteins,	  has	  been	  observed	  (Seifert	  et	  al.,	  2010;	  Pickering	  et	  
al.,	  2012a).	  This	  propriety	  seems	  to	  be	  particularly	  required	  in	  embryonic	  stem	  cells	  where	  these	  
proteins	   are	   present	   at	   high	   levels	   and	   their	   elimination	   is	   necessary	   for	   normal	   embryonic	  
development	   in	   vivo	   (Hernebring	   et	   al.,	   2006;	   Hernebring	   et	   al.,	   2013).	   Finally,	   Ziyou	   and	   co-­‐
workers	   reported	   for	   the	   first	   time	   that	   i-­‐proteasomes,	   independently	   of	   constitutive	  
proteasomes,	   play	   an	   important	   role	   in	   proper	   skeletal	   muscle	   development.	   Indeed,	   down-­‐
regulation	  of	  i-­‐proteasomes	  increased	  oxidized	  protein	  levels	  and	  induced	  apoptosis,	  resulting	  an	  
impaired	   C2C12	   skeletal	   muscle	   differentiation	   (Cui	   et	   al.,	   2014).	   We	   also	   observed	   that	   the	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content	   of	   inducible	   components	   in	   myoblast	   was	   not	   affected	   by	   aging,	   as	   well	   as	   culture	  
conditions	  (e.g.	  different	  oxygen	  tension).	  This	  fact	   is	   in	  agreement	  with	  recent	  findings	  showing	  
that	  muscle	  progenitors	  from	  young	  and	  old	  donors	  display	  similar	  characteristic	   in	  vitro,	  such	  as	  
proliferative,	   differentiation	   and	   senescent	   profile	   (Asharidah	   et	   al.,	   2013),	   and	   the	   reduced	  
regenerative	  capacity	  of	   stem	  cells	  during	  aging	  may	  be	   related	   to	  an	  hostile	  microenvironment	  
(Lepperdinger	   et	   al.,	   2013;	   Barberi	   et	   al.,	   2013),	   probably	   arising	   from	   systemic	   chronic	  
inflammation	  which	  is	  typical	  of	  elderly	  subjects	  (Franceschi	  et	  al.,	  2007).	  It	  is	  however	  to	  note	  that	  
the	  myoblasts	   that	  we	   could	   analyze	  were	   at	   quite	   advanced	   culture	   passage,	   so	   that	   all	   these	  
results	  should	  be	  further	  confirmed	  with	  more	  early-­‐passages	  cultures.	  
As	  far	  as	  proteasome	  content,	   in	  biopsies	  from	  healthy	  subjects	  we	  found	  an	  age-­‐related	  
increase	  in	  β5	  protein	  level	  and	  in	  the	  β5/α4	  ratio,	  suggesting	  an	  increased	  content	  of	  constitutive	  
proteasomes,	  as	  also	  reported	  in	  animal	  models	  (Husom	  et	  al.,	  2004;	  Ferrington	  et	  al.,	  2005;	  Altun	  
et	  al	  2010),	  which	  could	  be	  mediated	  by	  an	  enhanced	  subunit	  translation,	  more	  efficient	  assembly	  
or	  slower	  degradation	  of	  proteasomes	  during	  aging.	  However,	  as	  the	  amount	  of	  muscle	  biopsies	  
from	  young	  and	  elderly	  healthy	  subjects	  was	  not	  sufficient	  to	  measure	  proteasomes	  functionality,	  
further	  investigations	  were	  not	  possible.	  It	  would	  be	  of	  interest	  to	  assess	  whether	  this	   increased	  
proteasomes	   content	   is	   paralleled	   by	   an	   enhanced	   proteolytic	   activity	   (thus	   the	   proteasomes	  
activity	   per	   unit	   of	   proteasomes	   would	   be	   maintained)	   or	   it	   represents	   a	   compensatory	  
mechanism	  to	  counteract	  the	  age-­‐related	  decline	  in	  proteasomes	  activity	  during	  aging,	  as	  reported	  
in	   several	   studies	   in	   human	  and	   rodents	   (Baraibar	   et	   al.,	   2012).	  Moreover,	   considering	   that	   the	  
healthy	   donors	   were	   only	   females,	   further	   investigations	   are	   needed	   to	   assess	   whether	   males	  
undergo	  the	  same	  age-­‐related	  changes	  (Baumgartner	  et	  al.,	  1999).	  Of	  note,	  by	  comparing	  healthy	  
subjects	  and	  LLMI	  patients,	  independently	  of	  their	  age,	  we	  observed,	  in	  the	  latter	  group,	  a	  marked	  
increase	  of	   constitutive	  proteasomes	   content,	  possibly	   contributing	   to	  muscle	  wasting	  occurring	  
during	  physical	   inactivity.	  A	  similar	  increase	  of	  proteasomes	  content	  has	  been	  described	  in	  other	  
pathological	  situations,	  such	  as	  neurodegeneration	  (Mishto	  et	  al.,	  2006a;	  Bellavista	  et	  al.,	  2013).	  
Moreover,	   in	  physically	   inactive	  patients,	  at	  variance	  with	  what	  observed	   in	  healthy	  subjects,	  no	  
age-­‐related	  differences	   in	  proteasomes	  content	  were	  found	  when	  the	  young	  and	  the	  old	  groups	  
were	  compared.	  In	  fact,	  only	  a	  non-­‐monotonic	  variation	  in	  β5/α4	  ratio,	  in	  whole	  sample	  size	  and	  
in	  female	  donors,	  was	  observed.	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Regarding	   proteasome	   functionality,	   it	   appears	   preserved	   during	   aging	   in	   female	   LLMI	  
patients,	  and	  only	  a	  slight	  increase	  in	  the	  trypsin	  like	  activity/α4	  relative	  content	  in	  male	  subjects	  
emerged.	  This	  latter	  phenomenon	  might	  represent	  a	  compensatory	  mechanism	  to	  counteract	  the	  
increased	   levels	   of	   oxidized	   proteins	   found	   in	   male,	   but	   not	   in	   female,	   LLMI	   patients.	   On	   the	  
contrary,	  no	  age-­‐related	  modifications	  of	  poly-­‐ubiquitinylated	  protein	  content	  were	  observed,	  nor	  
in	   male	   nor	   in	   female.	   This	   fact	   suggests	   a	   maintained	   balance	   between	   ubiquitynilation	   and	  
protein	  degradation	  by	  26S	  proteasomes.	  
	  
5.3	  CIRCULATING	  PROTEASOMES	  STUDY	  
A	   third	   part	   of	   my	   study	   focused	   on	   the	   detection	   of	   circulating	   proteasomes	   (c-­‐
proteasomes)	  in	  sera	  of	  healthy	  subjects	  as	  well	  as	  LLMI	  patients	  recruited	  in	  the	  framework	  of	  
the	   MYOAGE	   European	   project.	   We	   also	   correlated	   circulating-­‐proteasomes	   levels	   with	  
anthropometric	  measurements	  and	  parameters	  of	  body	  composition,	  muscle	   function	  as	  well	  as	  
cytokines.	  	  
Although	   proteasomes	   are	   mainly	   linked	   to	   intracellular	   protein	   degradation,	   several	  
studies	  have	  reported	  their	  presence	  in	  extracellular	  spaces	  and	  fluids,	  as	  intact	  and	  proteolytically	  
active	  enzymes.	  The	  incidence	  and	  relevance	  of	  c-­‐proteasomes	  have	  been	  investigated	  in	  different	  
pathological	   conditions,	   where	   their	   levels	   often	   correlated	   with	   disease	   activity	   and	   clinical	  
outcome	   (Sixt	   et	   al.,	   2008).	   However,	   at	   present,	   no	   data	   are	   available	   concerning	   possible	  
correlation	  between	  c-­‐proteasomes	  levels	  and	  muscle	  function	  during	  aging.	  
We	  found	  for	  the	  first	  time	  that,	  in	  healthy	  subjects,	  levels	  of	  c-­‐proteasomes	  decreased	  in	  
elderly	  subjects	  (≥70	  years)	  and	  this	  phenomenon	  was	  present	  in	  both	  men	  and	  women.	  Secondly,	  
we	  observed	  that	  c-­‐proteasomes	  levels	  were	  higher	  in	  elderly	  male	  than	  females,	  thus	  suggesting	  
that	  gender-­‐related	  factors,	  such	  as	  hormones,	  might	  impinge	  upon	  c-­‐proteasomes	  levels	  only	  in	  
the	  late	  adulthood.	  In	  LLMI	  patients	  c-­‐proteasomes	  levels	  followed	  the	  same	  trend,	  as	  a	  decrease	  
was	  observed	  in	  the	  group	  of	  elderly	  patients,	  with	  not	  clear	  gender	  difference.	  This	  fact	  might	  be	  
related	  to	  the	  number	  of	  subjects	  analyzed	  as	  well	  as	  to	  the	  variability	  among	  LLMI	  patients.	  	  
Additionally,	  gender	  of	  donor	  does	  not	  seem	  to	  affect	  c-­‐proteasome	  levels	  in	  the	  three	  age	  
groups	  considered	  separately,	  suggesting	  that	  LLMI	  condition	  might	  mask	  the	  gender	  issue.	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Moreover,	   we	   found	   that	   LLMI	   patients	   had	   an	   increased	   levels	   of	   c-­‐proteasomes	  
compared	  to	  healthy	  donors.	  Similarly,	   increased	  levels	  of	  c-­‐proteasomes	  have	  been	  observed	  in	  
some	  pathologies,	  such	  as	  malignancy,	  autoimmune	  diseases,	  trauma	  and	  sepsis	  (Sixt	  et	  al.,	  2008).	  
Specifically	   this	   effect	   emerged	   within	   the	   young	   group,	   in	   all	   the	   samples	   and	   in	   male	   LLMI	  
patients;	   on	   the	   contrary	   in	   female	   patients	   the	   difference	   emerged	   in	   the	   elderly	   group.	   The	  
discrepancy	  might	  be	  in	  part	  related	  to	  the	  gender	  contribution	  we	  found	  in	  healthy	  subjects.	  At	  
present,	  the	  origin	  and	  the	  role	  of	  c-­‐proteasomes	  in	  blood	  have	  not	  been	  fully	  elucidated.	  Recent	  
findings	   suggested	   that	   proteasomes	   might	   be	   released	   by	   active	   mechanisms,	   such	   those	  
observed	  in	  choroid	  plexus	  cells	  (Muller	  et	  al.,	  2012)	  and	  in	  mice	  mesenchimal	  stem	  cells	  (Lai	  et	  al.	  
2012).	  The	   latter	   study	  showed	  that	  both	  constitutive	  and	   inducible	  proteasomes	  subunits	  were	  
present	   in	  exosomes	  vesicles	  and	  might	  have	  a	  potential	  therapeutic	  effect	   in	  a	  mouse	  model	  of	  
myocardial	   infarction	   by	   degrading	   oligomers	   (Lai	   et	   al.,	   2012).	   Correlation	   analysis	   in	   healthy	  
subjects	   showed	  that	   levels	  of	  c-­‐proteasomes	  were	  positively	  correlated	   to	  muscle	  strength	  and	  
negatively	   to	   total	   fat	  mass,	   in	   the	  whole	   sample	   size	   and	   in	   particular	   in	   the	   elderly	   subjects.	  
Further	  investigations	  are	  needed	  to	  assess	  mechanisms	  underlying	  these	  relationships,	  however	  
the	   significant	   positive	   association	   between	   c-­‐proteasomes	   and	   muscle	   strength	   suggests	   an	  
important	  role	  of	  c-­‐proteasomes	  in	  the	  maintenance	  of	  muscle	  function.	  




This	   study	   was	   aimed	   at	   identifying	   possible	   age-­‐related	   modifications	   of	   proteasome	  
composition,	  content	  and	   functionality	  of	   two	  different	  human	  tissues	  such	  as	   liver	  and	  skeletal	  
muscle.	  To	  our	  knowledge,	   this	   is	   the	   first	   time	  that	  such	  an	  ambitious	   task	   is	   tackled	   in	  human	  
aging	  studies.	  We	  could	  reveal	  that:	  
i)	   proteasomes	   composition	   and	   functionality	   does	   not	   seem	   to	   be	   affected	   by	   aging	   in	   human	  
liver	   and	   skeletal	   muscle,	   except	   minor	   changes/remodeling	   occurring	   especially	   in	   the	  
middle-­‐age	  subjects	  
ii)	  while	   i-­‐proteasomes	  are	   induced	   in	   liver	  as	  soon	  as	   the	   third	  month	  of	  extrauterine	   life,	   they	  
play	  a	  marginal	   role	   in	   the	  aging	  of	   skeletal	  muscle,	  both	   in	  healthy	  condition	  and	   in	  LLMI	  
patients,	   suggesting	   that	   these	   two	   tissues	   might	   have	   different	   request	   in	   term	   of	  
proteasomes	  composition	  and	  substrate	  specificity	  
iii)	   further	   investigations	   are	   needed	   to	   elucidate	   the	   contribution	   of	   i-­‐proteasomes	   to	   cell	  
proliferation	  and	  differentiation	  of	  muscle	  cell	  precursors	  
iv)	   as	   in	   LLMI	  patients	  we	  observed	  an	   increase	  of	   constitutive	  proteasomes	  content,	  additional	  
studies	   should	   be	   performed	   to	   understand	   if	   this	   phenomenon	   is	   the	   cause	   or	   the	  
consequence	  of	  LLMI	  pathological	  condition	  
v)	  some	  proteasomes-­‐related	  parameters	  seem	  to	  be	  affected	  by	  gender	  ,	  which	  is	  an	  important	  
issue	  to	  take	  into	  account	  when	  performing	  studies	  in	  humans	  
vi)	  we	  measured	  c-­‐proteasomes	  levels	  in	  serum	  of	  subjects	  participating	  to	  the	  MYOAGE	  study	  and	  
we	  could	  observe	  that	  such	  levels	  decrease	  during	  aging,	  in	  both	  healthy	  subjects	  and	  LLMI	  
patients,	  but	  their	  function	  and	  origin	  have	  yet	  to	  be	  fully	  understood	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